var title_f27_15_27888="TM perforation";
var content_f27_15_27888=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64202&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tympanic membrane perforation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 417px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tympanic membrane perforation with surrounding myringosclerosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nikolas H Blevins, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_15_27888=[""].join("\n");
var outline_f27_15_27888=null;
var title_f27_15_27889="Patient information: Granulomatosis with polyangiitis (Wegenerâ€™s) (The Basics)";
var content_f27_15_27889=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?27/35/28212\">",
"         Patient information: Chronic kidney disease (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/5/13398\">",
"         Patient information: Chronic kidney disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/14/30944\">",
"         Patient information: Renal (kidney) biopsy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Granulomatosis with polyangiitis (Wegener&rsquo;s) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/granulomatosis-with-polyangiitis-wegeners-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H7060075\">",
"      <span class=\"h1\">",
"       What is granulomatosis with polyangiitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Granulomatosis with polyangiitis is a rare disease that causes pain and swelling of blood vessels and other tissues. It can affect organs or structures anywhere in the body. In most cases, granulomatosis with polyangiitis affects the nose, mouth, ears, lungs, and kidneys.",
"     </p>",
"     <p>",
"      Granulomatosis with polyangiitis used to be called &ldquo;Wegener&rsquo;s granulomatosis.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7060090\">",
"      <span class=\"h1\">",
"       What are the symptoms of granulomatosis with polyangiitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Runny nose &ndash; The discharge from the nose can include pus or blood and does not go away",
"       </li>",
"       <li>",
"        Small sores in the nose or mouth",
"       </li>",
"       <li>",
"        Sinus infections &ndash;The sinuses are hollow areas in the bones of the face",
"       </li>",
"       <li>",
"        Ear problems, including fluid leaking from the ear, ear pain, ear infections, and hearing loss &nbsp;",
"       </li>",
"       <li>",
"        Inflammation and break down of &ldquo;cartilage&rdquo; &ndash; Cartilage is the tough, elastic tissue found in the ears, the windpipe, and the spaces between bones.",
"       </li>",
"       <li>",
"        A hoarse voice",
"       </li>",
"       <li>",
"        Cough",
"       </li>",
"       <li>",
"        Wheezing and breathing problems",
"       </li>",
"       <li>",
"        Chest pain",
"       </li>",
"       <li>",
"        Blood in the urine",
"       </li>",
"       <li>",
"        Red or purple spots on the skin, most often on the lower legs",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7060105\">",
"      <span class=\"h1\">",
"       Is there a test for granulomatosis with polyangiitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will ask about your symptoms and do an exam. Other tests include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"       <li>",
"        A X-ray or CT scan (a special type of X-ray) of the chest",
"       </li>",
"       <li>",
"        A biopsy &ndash; This is a test that involves taking a small sample of tissue. A doctor examines the sample in a lab. The tissue is usually taken from the skin or the kidney. Sometimes, the sample is taken from inside the nose or the lungs.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7060120\">",
"      <span class=\"h1\">",
"       How is granulomatosis with polyangiitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The treatment happens in 2 parts, 1 after the other. It involves medicines that suppress the body&rsquo;s infection-fighting system, called the &ldquo;immune system.&rdquo;",
"     </p>",
"     <p>",
"      The first part of treatment is called &ldquo;induction.&rdquo; You will need to take strong medicines that are given as pills or into a vein through a small tube called an &ldquo;IV.&rdquo; You will need to see your doctor at least once a month during this part of treatment. That&rsquo;s because the medicines can have serious side effects. This part lasts until your symptoms get better, which usually takes about 6 months.",
"     </p>",
"     <p>",
"      The second part of treatment is called &ldquo;maintenance.&rdquo; For this part, your doctor will switch you to a lower dose of the medicines you are taking. Or you might take different medicines that have less serious side effects. The maintenance part lasts at least 1 year.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7060135\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=see_link\">",
"       Patient information: Chronic kidney disease (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=see_link\">",
"       Patient information: Chronic kidney disease (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/14/30944?source=see_link\">",
"       Patient information: Renal (kidney) biopsy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?27/15/27889?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83998 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-AA596B28AF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_15_27889=[""].join("\n");
var outline_f27_15_27889=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7060075\">",
"      What is granulomatosis with polyangiitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7060090\">",
"      What are the symptoms of granulomatosis with polyangiitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7060105\">",
"      Is there a test for granulomatosis with polyangiitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7060120\">",
"      How is granulomatosis with polyangiitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7060135\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/5/13398?source=related_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/35/28212?source=related_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/14/30944?source=related_link\">",
"      Patient information: Renal (kidney) biopsy (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_15_27890="Pseudomembranous colitis US";
var content_f27_15_27890=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51120&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudomembranous colitis on ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transabdominal ultrasound of the colon in a patient with pseudomembranous colitis. A characteristic feature is the asymmetric hypoechoic bowel wall thickening (BW) with loss of wall layer structure and \"cobblestone-like\" or pseudopolypous picture of the mucosa and the absence of a visible lumen. Depending upon the degree of inflammation, a hyperechogenic reaction of the mesentery may be seen. Ultrasonography of lymphomatous infiltration of the intestinal wall may display a similar image.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christoph F Dietrich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_15_27890=[""].join("\n");
var outline_f27_15_27890=null;
var title_f27_15_27891="Atherosclerosis PI";
var content_f27_15_27891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83222&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Atherosclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 441px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAG5AckDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvPNS0HQNZ+JuvTeJNJ0vUIrTRNPdGvraOYQgzXxYjeDjO0Zx6D0r0OvMfGsdrJ4n8T2Grx+IIdP1jQrKzF1pWm3FyfllvPMUNHFIqnbInDDo1AHnfwd1Xw1408W3um618O/CVjZ3du9/ojppMSvPbrM8Z35BBbgdAv3WOMEV6Nod8fCfwd8SX2j21tH/AGTPrc1rb+XiFfKvLkom1SMKNoGBjjpiuf03w78PtJ1Tw1qOjaV4o0290JSkc1p4avY2uwUCH7QfsuZCQDzwfmPrXY+FtHTX/htq2l6jFfWltq11qysJIWt5xDPeXBVtki5UlHDDcvccUAed+Dvjlqesah4S0vVLLT7HVL24canGyOAtu0HnQzRZfhWUjO7d0PTIrttO+MXh6+NlILTVYLHUEuX068mhRYr3yATII/nLA8HG9Vz2qw/wl8NPrPhbVCLr7Z4ftFsYW3Ji5iWPYomG35sDPTb1PbAFfTvg74esTZRi71Wex09LlNOs5pkaKy88ESGP5AxPJxvZsdqAKVn8b9Eu9GstUTQfE8dle3lvY20k1kkazyzeZjYxfawUxkMQTjcvXPFmy+M2hXFzawy6brNr52rnQpZJ44dtteZOI5Csh64PzLuHqRWj/wAKu0X/AIRDw14c+1aj9h0C9iv7V/MTzHkjLFQ52YK/Oc4APTmqcnwe0B/Mzear+88Q/wDCSnEsf/Hzz8n3P9Xz06/7VAE8vxW0S28cWvhW+t7q21C6uGtYX8+1mUuOm5YpmkjDcY3ovXnHOIvgN4l1XxR8LLDWdeuDe6jJJcB5BGkZcJK6qMKFUcADt71BYfBnQrHWLG+g1LWRFZam+rQWhkiMSzvjdk+XvIOBwWOMcEZOeh8K+A9K8N+BH8JWkt5PpbpNGzTyKZSspYsNyqo/iOMCgDm7b41+G5bzVrOa3vYbvTbCbUZIlltbjfHECXVWgmdQ4wflYrXP638bryVfClx4a8L6v9i1bU4LRn1K0WH7RHIAcW5Mqguc4DH5Mjk4wTt2PwP0C1jWNtW1yeOPSZ9FiWSSACK3l3bgNsQywLsQTnk85rc1H4Z6Te+GfDOjC81K3HhyWCfT7uJ4zMjxDCltyFG9SCuOKAMfU/jh4T0zxE2j3Rulmiuo7K4kDQEQTN1Vk8zzGCnhmRGUHjNQt8cNE+y61dReH/FM1lo8ssN3dR2KGFWjdUYB/M2k/OGxnO0EkDjO9bfDi0stW1G+0rXdc046nKlxfw2ssKpcyjq5zGWRm/i8tlz7VNo/gKw8PeFfEukaUZLtdZmuruSO/kGxpJkClCUUEJwOxIyetAF3wz400zxLrmr6dpC3Ey6YITLebV8hzKm9VQ7skhevAxXTVwnwW8Cn4feBLXR7iSGbUWdp7yaIkrJI3HBIBIChVGR2ru6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBp60UHrRWD3YwooopAFFFFABRRRQAUUUUAFFFFABRRRQAUVHPPDAm6eWOJfV2AH61i3vjHw1ZZF1r+lREfwm6TP5ZzQNRb2N6iuMk+KHgxG2/2/auf+mau/8gahb4qeE/8Alne3Uv8A1zsJz/7JRctUpv7LO5org/8AhaWhH/VWuty/7mmy/wBRSf8ACz9LP3dJ8Qkev9nsP5mgfsKn8p3tFcGPibpx/wCYN4g/Gyx/7NTh8StP76Nr4Hr9i/8AsqLh7Cp2O6rF8b6rPoXgzX9XtFie50/T7i7iWUEozxxswDAEHGQM4IrBHxJ0v+PTNdT66e5/lmsfx3400zW/AfijTbOHU1vLnSbyOJJrGVA7mB8KCVxknAA7kgDmhbidKa3R6hRXJ3HxE8LW9xNDNqmx4mKMTby7cg44bbgj3BwafB8QfCM7bV8RaarZxiScRn/x7FAvZz7HU0VQtNZ0y8x9j1Kynz08qdX/AJGr9BLVgooooEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUDrRQOtNbgOooorcQUUUUAFFFFABRRRQAUUUUANPWig9aKwe7GFFFFIAoopCcDJOAKAFork9Z+IPhzS52tjffbb0HH2WxQ3EmfQhcgfiRXN3/xB1q5XGlaPbaeD0k1Sfc4/7ZRZP5sKVzaGHqVPhR6hWfq2taXpEZk1XUbSzTGczzKmfpk8143d32taic6t4j1GRT1hsQtnGPbK5cj6mqEWmadDL5sWn23nd5ZV86Qn1LPk1Lmjthlk38TsekS/FLw87MmkjUNXkHaxtHcZ/wB4gL+tZF98RNelyNN8OW9qvaTUb5QR9Y48n9a5x5pHUK8jlR0XPA/ComIRcsQqjueBSczrhllNfFqaFz4j8X3gPn+IbGwB6pp9hvI/4FKf6VnXAu7sY1DX/EF2O6/bPIU/8BjA/nUJvbbJVZVc+kYLn9M017zaMiCbH95wEH/jxFTzM6Y4WjHZED6Bozvvl0yOd/71xLJM35s1WbfT9PtsfZ9NsI8f3bZP6iqE+uW0Q+e4skb0a4DH8lBqlJ4ntV/5e4T/ANc4JH/U4FK7NlCC2R1CTPGuIyEHogC/ypTcTHrNJ/30a41/FUP8Mt23+5Ai/wDoRNRnxMrH5YdRb/gaD+QoKsux2Zdz1Zj+NJmuLPiNv4bO+P1uSP5CmnxHL2sLn8bt/wDCkM7aiuJHiOXPOnXH4Xb/AOFKPEbDlrO9H0umP9KA1O1pQzDoSPxri/8AhJ4weYdQX/tshx+YqRPFUGRl79PrHE3/ANegNex2XnS4/wBY/wD30aY58wYkCyD0dQ3865iLxPanre7fQS2jD9VNXbfXbaU/Leae3p+9MZ/IinqS0nui5caPplz/AK/TbJz6+QoP5gUsGm29tj7E13ZY6G1u5Ysfk2KWO8dxlIPMX1hlVx/MU83sSj96s0X/AF0jYfr0ouyXTg90W4r/AF+2INl4o1WPH8NwI7gf+PLn9a0bXxt4xsx+9Ojaog/vxvbSH8QWX9Kx4p4Zv9VLG/srA1LT5mYywdGX2Tr7P4obB/xOfDupWw/iktGW7jH124b/AMdro9C8d+Gdck8rT9XtjcdPImJilz/uPg/lXloyOhrmfiEkU9lpsc8aSO8sjlmALbVVRjPXGWqlM5Z5ZB/C7H09RXyt4U8a+IPCksf2G7kvdPXhrC6kLLt9EY8of0r6H8E+LdN8X6V9s012WRDtntpOJIX9GH8j0NVGSex52JwdTD/Ft3OioooqjkCiiigAooooAKKKKACiiigAooooAKB1ooHWmtwHUUUVuIKKKKACiiigAooooAKKKKAGnrRQetFYPdjCsLxH4t0Pw6ANW1CGKZh8luvzyv8ARFyx/Kq3xMkvIfAGvTabPLb3cVo8iSxHDLtGTg9jgGvH9ItLS1t1lsoVVp1DtKTukfIzlnPJ/OolKx24TCfWLu9kjtNR+ImrXoZdE0pLCI/dudTbL/hChz/30w+lcrei61Ri+v6nfaoT1heTybcewiTAP/AiaJZY4lzK6oD3Y4zVK61WKAdgDyGlOwEewPzH8BWbk2exTwdKl0NCBUtofJtY44IumyFAi/kKbJIka5kdUHqxxXPT6xNKStuszj/ZXyh+Zy35AVXK6hKdy7LYHqyr83/fbZP8qk6krbI6F7+ILuQPIvZgNq/99NgVm3PiC3j4E0O7+7HumP8A47gfrWPcWVsrebf3Qd/70jFz+ZqS3hWYgWOn3N0T3WMsPz6UwbS3YsviGSRiI4buX6usQP4KCf1qrJeapMf3VtbQ89Wj3t+bk/yrcg0DXrjG21t7Nf8AprIMj8FzVxPA9zKB9s1XHqIosj8yf6U+VmbrU1uzkJzqLj/StVdV/urJtH5LgVRkt7QHM88kx9cZ/nXpMHgPSkwZ5Lu4P+1LtB/75ArQh8K6JD9zTLZj6yKXP/j2afIzN4qC2R5Es9hGcJCW+r1KlxniCwDfSMt/SvaYbK3gAENtDGP9iMD+VS4I4BNP2ZLxfkeNRxavJ/qdKuPwtmH86sLp3iN+mnXK/VFH8zXrZX3JpNlP2aJeKl2R5SuheJnP/HlIPrJGP61IPDfic/8ALrz/ANd4/wDGvUNpxSbSO1Hs0T9an5fceeQeE9cbTp5ppRDeKw8m3LowkUDnkZwc4xn0P1rl2vbuN2R2ZXQ7WVlAKkdjXtePyrmfFvhlNYX7TabY79V69FlHo3v6GlKGmhdLE2fv7M87GpXA6lT/AMBpRqDH78MTfhVORJIpXimRo5ozteNhgqfQ0lY3Z6CUXqi6buBvv2if8BOKQtYSfejkj+hzVOii4+VFtbWzLZhufLb3GD/SrkP9pQ82epSkeglJH5HIrIop3E4G/wD2vq0Z/wBKt7e6A7yQjP5rViHxNArfvrS6tvUwTbh/3y1c6lxMn3ZXA+tTfb5iAJBHIP8AaWi5PIdnZa7bTsFj1CBm6bLlDE359D+VZHjO7Ml9ZxumPKtySUbeMs57j2Udq5ud1lORGqDGCB0qEIFbdGSjeqnH6UXDkd0y+hDLlSCD3FaHh7W73wvrcOsaXzIny3EOcC4i7offuD2NYsUjeYA2BIeA3QP7H0PvWnYxrcyxqZY4EP3pJm2rGB1LfT/9VC0ehVSMKkHGex9Y6JqdtrWkWmpWD77a6jWWM+xHQ+46H3FXsV4Z8ONG0HVtVGia5aC6gtbdrqx0q/iDogdvmmljbI85s5C4/doQPvF69Mh+H3gyGVJYfCHh2OVGDK66ZACpHIIO3g11adT46pHllZbDfiH4rfwno0Nxaac+q6jczeTbWKS+W0xCs7/Ng42ojt07AcZzVPW/iRoWm6VLcwSXF7c/2YurRW1vbTSl4HD7GLIjBVJQgseF4zjIzqeIfB+jeI9Wsr3XrSPUY7OKSOKzuo0ltwzlSZCjKcuAmAc8AnjnNZuj/DrR9Ki1CGCa9e3vLA6YYXddsVv5k0gRMKCNvnsoyThVUdsk0IEi+JXh5dOs7q+lvbRp7dbl45NPucwRk43yfu/kj3AgSNtU4JBwKvjxz4fOo/YheSmYXf2BmFpN5S3G7b5TSbNisT0BIzkYzkVzeo/CDRdSksp9Rv7y8vLW2WzFxd2ljcM8KsSiFZLdkGNxG5VDEHknirF/oOm6x4L1/R/Cep2V3c6k/wDaMcrXKuLd5pN6TKYwSAChZOOSmM9SDQDs9H1Wy1m0a602bzrdZZIfMCMoLxuUbGQMgMpGRwccE1eqjoWl22iaNZaZYKVtbSFYYweThRjJPcnqT3NXqQBRRRQAUUUUAFA60UDrTW4DqKKK3EFFFFABRRRQAUUUUAFFFFADT1ooPWisHuxlTVrUXulXlqRkTwvER/vKR/WvljSvFMEWk2VnJcxpdxxeW0a8FSvHzM3C/QA19XyyJEheV1RB1ZjgD8azHKyxPFp+mxyI5JZplEUZJ6kgjLfgMH1qXHmOzC4p4e9le589RW9zOomknjhVv442yxH++ct+WKakNhbz+XEGnum/hQFnb69WNen6j8K7ETXGoWhYXEh3PY27GG3f1CrkkH8cewo0q1srW2C2FtHbp0ZVTacj19/rU+zfU9WGPhNe6tThbTR9YuwPs1hHZxnPz3J2n/vkZP54rVh8Gq4B1HULidj1WECNf6n9a7EgE8ikKiqUERLETl1sYlj4f0mxIa3sIPMH/LR13t+bZNanYDsOlTbffNJs9s1VjJtvcg2igoKl2emf8/5/WoLu5trQE3NzDCOv7xwv8zSEBSkKHtWXN4o0SIkf2jFKR2hVpP8A0EGqsnjDTh/qor6X0xBtz/30RSui1Tk9kbu00mPauXl8aD/ljpVww9ZJkX+WafpHia71DWtPs2sIIYri5jhdvPLMFZgDj5Rzg0uZFOhUSvY6TaPSk2CuHPi3VpLHTJ44rBDdafaXT5Rzh5YI5GA+boGc4HPAHJqu3ijW2582zT/dtyf5saHJJ2HDD1JxUktGd8UpNhrz1vEuuc/6XAO3/Huv+NOtPFepQahbHUbjzbUs3mJHbLuYBScD0ycDPbNLnRTwtRK9jvJSkUbSSsqRqCWZjgKPUntXB+IvF7y77fRCVj6NdMOT/uD/ANmP4DvVDW9UvNab/S2EdsGylsh+Ue7H+I/p6Csww88iplPsdFHCdZ/cZTQksWYszMckk5JPqTTDEa1Gh9sUww/hWR3WsZmw0mD6VomH2pjQ+1AFCirhhz2qMwe1AyvRUphNNMZFADKKUqRSYPpQAjKGUg9DVqxcseT8x+Vv94d/xH8qrU+1+W4PoQrH8Dj+TUCejudZ4K1F9L8f+H71nOJbr7LKzHqso28/jg19S18fag7W8Mdwv3oJopR7bXBr7Bram9DwM3glVUu6CvL/ABL4i8baLrPiOPT9Hm1bT7ZVu7Z1tyXaN0RBBFtwGdZBJI2cnZgfxAj1CitDyDxka545tvHWjaeU1qe1juLe11B5bRWt5kMI8ydGjtQqrvOcmfIII8sLjFj4DaTqOmbv7S0+7s/+Ke0iH/SIWj/eJ9p3pyB8y7lyOo3DPWvXqKdwOC8S3XjTw/oV5q02r+HruGzTzZIE0aaNnQEbgGN2QDjOODXe1zPxPg+0/DbxXCMAvpN0ASOh8psH8Dg10FnOLm0guAABLGsgAOcZGetD1VwJqKKKQBRRRQAUDrRQOtNbgOooorcQUUUUAFFFFABRRRQAUUUUANPWmP5hOEwo/vHn9KeetLWNrtjIVt4w4dwZJB0Z+SPp2H4VNRSEgAknAFWAtcb4nsvsepJdxDEF0dkgHRZMcH8R+orcbW4JGKadFNqDjj/RwCg+shwn4Zz7Vg+OoNfvPCuqPbPZ2ckMLTwoimaQsg3D5jgA8Y+6frUto1pNxkmUCQFJJwB1JrHu/E+kW5Ki7WeQdUtlMp/8d4H4muDt5hqmnwXl5NLciVFkJuJCyjI7A/KMfSqlxrml2zeSLmN3HAigBc/ktYOp2PoI4RJXnI7O58XueLLTXOf4riQIB+A3H+VZVxr2tXH/AC9QWw9IIcn83z/KsW3uNRvebHRLsoeklwVhX9eadJaaooBvdR0nTl7gHew/76IFTzSNVToR8yzcSXdyALq+vZl7hpyo/JcCqYsreL5vJiU9dxUZ/M0zyNM/5etdvrs91t1IX/xwf1pwOgpjZpd5ckd5j/i39KT8zWLS+CI17q2ThrmEH03A1Gb63OQrM5H91GP9K0E1S0iXFvokKezMo/kDS/2/dLkQ2FlGPTcT/ICp0LvVe0TOFxvOEtrh/on/ANetfwoJ28UaOfsVwo+2Q5LLwBvXmq7eINUI4+xp/wBs2P8A7NWj4X1jUpvE+kJJNB5b3kKsqw4yC47kmnFq5FSNXkenQwrWG7fRPD5hspZUOjadhl6H/Q4fal+x6gRj+zZfzI/9lp1nqOoQaF4fit7oRxLo2nYXylJH+iRHqaedW1TH/H8R9IU/wpza5mRhoVfYwttZfkRfYtSPTT5B/wAC/wDrU06fqX/QOcf8C6fpU/8Aa2qZ/wCP5vxhj/wpRrOqj/l8U/WBP8Km6NuSsVm07UTz/Z8nPuT/AEpp06/72Eo9OD/hV4a5qo/5eID9bcf0NSL4h1IdRZN9YWH8nouhctbt+RkvZXag5s5sD/ZzVeRJU+/bTD8B/jXRjxLegHdaWTfRnX+pqePxO3/LWwx/1zuM/wA0p6C/fLociSMndHKD/uEn9M0wvD3cL/vZX+ddmfEFlKf39hPj3VH/AKinf2hoUq4kCx+oe3YfyBH60WF7Sot1+DOLCK4GxlYe1NMPtiuzOm+HbpGeKeyAAyStwoIH0Y8Vzmp/2LbCQ2Fze3TKpIEWFj/76fqPop+tHKEa93axmmGmGHnpU+nNJcW7NNs3qxXKjAPTH6GrBj46UjdMzDD7UwwitMxe1NMY7UrAZZgpiRFZOBwUIz75WtUw/SmyxbZLdB1b5z+LZH6IfzpifYr66udLmABO4qAB1yWA4r7Br5KuLFdRvdL010WRLy9jidHGVZM5bI7jANevN4E8IEkjwroIGf8AoHQ//E104enzps8LOpfvIryPV6K8n/4QTwh/0Kugf+C6H/4mj/hBPCH/AEKugf8Aguh/+Jrf2HmeNzHrFFeQXng/wPYwmW98PeGraL+/NZQIPzK1hyw/DFCRHoeh3BH/AD76Oso/NYyKTpJbsqKlL4Vc9t1y3N3omoW43Zmt5IxtGTypHFUPAVx9s8C+HLkFT52m20mV6fNEp4/OvKNDf4fRa1YyWfhuzt7qOdGilGh7CjhgVYMI+CDgg1B4d0rwVcaFocOt6foEurLYwQOb23hMreWgiUFmHzYCAdTwKSgnpcbhOO6Pe6K8nHgTwgVBHhbQCDyCNOh5/wDHaP8AhBPCH/Qq6B/4Lof/AImq9h5kXPWKK8n/AOEE8If9CroH/guh/wDiaP8AhBPCH/Qq6B/4Lof/AImj2HmHMesUDrXhHxA8F+FrXwF4luLXw1okNxFplzJHLHYRKyMImIYELkEHkEV7uOtRKHI0F7jqKKK0AKKKKACiiigAooooAKKKKAE7mmSyJEheV1RB1LHApsjSFtsYAPdm6D8O9UdUvdP0Wyk1HV7qOCCIZaedsBfYe59ByfesnJIpK5N9ouJ+LWEIh/5azgj8k6n8dtVriytIozc6xciZUGS1ywWJP+A8KPqcn3rzDXvivfXMjReH7KOyhI4ub9C8rD1SBTkexYge1cHftd6xdrc6xLPqMqnKtqL7lT/chTCL+JNZSqHfQy+rV8j13VvipoVs7W2hQ3OuXKjAWxT90v1kPy4+ma4rXPiF4j1FHgN1puhxOCDFbL9tuSD2P8I/KuZeFpUVLiWSWMdI/uxj2CLhf0pyRhFCooVR2AwBWbqPoerRyqnHWWpkWukabBFHH9jvL8J9039xsQfSNc/ka1Yrq5gQJZLa2EY6La26qfzOf5U/aaQqahyZ6MaEF0K0yyTnNzPcz/8AXSViPy6UxLeND8sSqR3C1c2mjbzUmijFbIr4pCtWNvtQVoKuV9tG2pyvrRtFAXK+2tXwmv8AxVOjf9fsP/oYqjsFanhVQPE+jn/p8h/9DFOO6Iqv93L0ZhwLnRtAP/UG07/0jhpdpqS0UHRPD5/6g2nf+kcNO2U5/EzPCP8AcQ9F+RBtNGDU+yjZUnRcgwaTHtU+yjYaAuQYNLg1LsNBQ+lAXIcUVLtOaNp9KB3M7VlBsmYgfIyvk9sEf0zVbZkEHvxWvNAJoXiYfK6lT+PFZVtlol3H5h8rexBwaDOW5LoZyZkPVgrj6j5T/IfnWoYqxUL2t2sqAnkttH8QP3l/qPpXQx7ZY1kiYOjDKkdCKozWmhWMXJ+tMMXaruwnHGabsyenNAypHbebKqAhd3c9AO5P0GarRkXF9LMmfLHCZ64wAv8A46Af+BVc1JxEjWqDdLJ8soz0/wCmf1P8XoOOpqMBLW1eSZgERS7tjGe5ND7Ew9583Q1vAlkL/wAeQyYHlaZbtMf99/lUflk169XF/CvSXsdAfUbpCt5qj/aXBHKR9I1/755/4FXQeI9btdA01ru7JZidkMKcvNIeiKPU/p1r0qMeSnqfKY6q8RiG4+iJ9X1Sy0exe71K4SCBeMtyWP8AdUdSfYV5v4g8d39yrR2gbS4G6DAa6cepz8sX/jx+lczresXl9qJu76VJNQxhRGcx2Y/uRerer9T2rGJABJPuSa5quJb0iepg8rjFc9XV9i3NfSSTGUD96essrGWU/V2yfyxUDzzSfflkb6sTVRp+nlrnJwCxwD9O5/CrEdlqE33IZQPXywo/8eNc2rPVXJTVloS2cxguoZdzDy3V+PY5rV126XzIo7WdXjja5jKqdyYF3PsPPBBTYR/skVkHTNTUZ8uQj2CH+tV5PtNuwFxERk4G5ShP58H86aulYhqnOam+l/xNvSNbvdLlDWFxJacgssXMT/70R+X/AL52n3r0fwz48tr+eOz1dYrS6kIWKZGzBMfQE8o3+y34E15FFIkmQuQwGSrDBH4U+WJJY2SRQ6N1UjrWlOvKBjiMuo11daM+kKK8q+HfjCWzuLfRNalMls5EdpeSNllPaJyf0b8K9Vr0ITU1dHzFehOhPkmc38Sv+Sc+Kv8AsFXf/olq9YHWvJ/iV/yTnxV/2Crv/wBEtXrA61nV3Rmh1FFFABRRRQAUUUUAFFFFABRRRQA1s84GTXzFqd7qni/Umv8AxHdNutZpIo7CH5YrZlbBHqW4+91r6dPWvC/iXow8P+Nft0a7dN1w5J7R3Sjkf8DHP1BrlqX1sellkoKraa32Odit44l2xoFHU47+596fsqfZR5dYH1K0K+yjZU+yjYaQXK+ygoasbDmkKHtQFyDYc9KNpFTlSKTbQFyDafSjbU+0+lGw+lFguV9uO1G2p2woyxCgepxUD3Vqn3riAfWQf40WDmSE2+1afhcD/hJtI/6/If8A0MVknULIdbqE/Rs/yq94Z1fTj4p0aNbuMyPewqqjOSS4wOlVFamVWceSWvQoWIB0Lw//ANgbTv8A0khp+2s+LXNMs9H0CC6u1jmTRtOypBOM2cJ7D3FM/wCEn0X/AJ/V/wC+G/wpzT5mZYWpBUIJvovyNPbRsrNXxJpDYCXJb6ROf6U4a/ppAIkmP0t5Of0qbM39rD+ZF/ZRtqgde04HBef/AMB5P8KYfEelA4aaVc8cwOP6UcrD20P5kaWyjbWeviHR2H/H/EM+oI/pU8GrabOWEN7C5VHkbDfdRVLMx9AFBJPYAmlZj9pHuWNpo20TXNtDcSwTXMMc8TFJI3cKyMDggg8gg05Xif7ksbfRgaLFKSezGbTWXdQ/Z7zd/wAs5z+T4/qB+hrb8snpUdxbLcQtFKuUb0OCD6j0NAMx3iEq4OeuQR1B9c02CWayZtpRATkhh+7Y+vqpqcB7eVYbrG88JJ0En+B9vyqyF7AUbCspDk1BWALW7g/7Dow/PIph1CR8raLtbGMo25h/wLov4ZPpSi1hzzDGT/uirCR4AwAFHYU7i9nfdlW1tRFhmAMmMYHRR6D/AB71LoenR+LPEraTknT7AR3GoMDjdktsi/Eoc+wq3oOl6j4tv2sPD42wo2261ErmKAdwp/jf2H413Oi+HrDwt441PS9LRhAmj2Ds7nLyMbi+JZj3P9AB2rahT5pJs8rMscqcPZU3r1OmJVEJJVEUZPYKB/IV4f4o1+TWdSOpdI8NHp6nrHCeDLj+8/OPQV6F8T78waFFp8chSTUpDC7DqsKjdKf++Rt/4FXkFxKZ53kxtB4VR0VRwAPoMCtsVUt7qOTKMMpN1ZfIgdljQsxwo61Jpun3Gq3IVV2op5J5C/4t+gqGGJ72/jgiPRsA+hxy34D9TXf2sEWmWSQwLtcjj1Ge59/61ywjfc9itVtoiCy0ux0xc4Mlxjlicsfxq19q2/6uFF/CqxySSeSefrTgK19DltfcnN07cFEP4VHshlV0njDI3bAIH4GkCjAFOC0DsjndV0BVG/T8tt5EeeR/uE9PoeKybeQudj439iP4h9OxHcV3iqRXO+JdN2sLy3UKCw8zH8L/AML/AI9D9RUSj1RtSq2dmZUsCTwvFIMqw5/xr1v4Z+IX1jSHs7592p2BEcrHrKh+5J+I4PuPevKIG82IMBj1HoehH51q+Fr/APsbxbpl6WKwTN9juMdCr8KT9HwadCpyS9TLMsOq1FyW61PT/iV/yTnxV/2Crv8A9EtXrA615P8AEsY+HXirP/QKu/8A0S1esDrXZV3R8sh1FFFABRRRQAUUUUAFFFFABRRRQA09ayPFegWfibQrnS9QU+VKMq6/eicfddfcGtc9aKwe7KTad0fOHlXml6nLomuoI9SgGVcfduY+0ieue47GrWz3r2bxh4U03xXp4t9RRlmjy0F1EdssDeqt/Toa8l1fwt4q8O8S2R12zXpdWIAlx/txHv8A7uaxlDsfRYTMozSjUdmU9nvSbKzm1qJWKSWepxyg4Mb2Uob8sVq6ZpnibWcHS/D1xFCelxqLi3X67eWP4Cp5Wd0sTSgruSI9hpGUhcjH1NdRZ/C3Xboq2reI4bROpi0+2yf+/jn/ANlresPhL4Ygw1+l9qjjve3TsCf91cL+lUoM4qma0Y/DqeS3mrWVpxPqNpGfTO4/kDTbW5utQIGl2etX4PQ2tidv/fTCvobTfDWh6WF/s7R9PtivRordFP5gZrXpqmjknm8n8MT54tvCPi6+GYtBu4lP8V5fpEP++UJNaUfws8VXK5uLjRLbP+3NOR+eBXutFVyI5ZZlXl1seMWvwVnbm+8QoDnlbbT0X9WJrXtfgxoiD/SdU1mdj1xOsY/8dUfzr1Cuf+IWoXWkeAfEupafL5N7Z6Zc3EEm0NskSJmU4IIOCBwRinyoxli60t5GHb/CfwhFzLp89yfWe7lb9N2K1dP8BeFdPuobm00KxjuIXEkcnl7mVhyCCecivK9G+KevaZrkmneIw11c6Zor3E8axpEl673FsttcBtvyArMQwHCkOccCu1HxC1L+1otFOg2ra22ovpzxx6lut1YWrXKv5vlBiMABhsBHJAbgGuWxk6s5btmn4A8L2Nv4H8Mpq2jWY1SHS7SG4M1ujSK6QopVjjORtx+FdRFptjDgRWVqmP7sSj+led23xE8QXmpw2dn4X09/tF/e6dbu+sMoaS1Zg7MPs52qQjEYyc8EDrVOb4yRi00O9t9JSe0vobKS6VJp2lszcuFUNtgMQHII3yoWwcDOMlmyLs9YEaDoij6CnYHtXI/Cq7ub7wcJ724muJv7Q1BPMmcu21b2dVGT2CgADsABXX0hCYFIVU9VB/CnUUAQSWltJ/rLeF/95Aa5H4paZYQ/DTxfNFZWyTLo17tkWJQwzbuDg49K7WuV+K//ACS3xl/2Bb3/ANEPTW6Hcv33hLw7fyySXmhaXPJIxd3e0jLMxOSScZJrNm+G/g6XO7w5pwz/AHYtv8qefiN4I/6HLw3/AODSD/4qj/hY3gj/AKHLw3/4NIP/AIqhxfYanJbMzp/hP4Ol5TTJYG9YbuZMfhuxVGf4P6GwP2bUtctvTZebgP8AvpTW/wD8LG8Ef9Dl4b/8GkH/AMVR/wALG8Ef9Dl4b/8ABpB/8VS5fI0WIqx2k/vOMu/g3I8ZS38U3hQ/wXVtHMD/ACrI/wCFR+KLQsLXXdNu488LcQvHj8Rk16V/wsbwR/0OXhv/AMGkH/xVH/CxvBH/AEOXhv8A8GkH/wAVS5L9DaOPxEdpHmifDbxkX2ltBjX+/wCdK36bK3dF+EKySLJ4q1aS/TvZ2q+TCfZj95h+Irrv+FjeCP8AocvDf/g0g/8AiqhvPiR4PSzna08XeGJblY2MSPq0Cqz44BO7gE45oVO3QdTMMRUVnI6fTrC00yyitNOtora1iGEiiUKq/gK4PUv+Sp6z/wBgbT//AEfe1heAv2hPBnihora/uG0PUXIXyb0jymb/AGZR8uPdtufSt3Uv+Sp6z/2BtO/9H3tbUk1I4mzzn4qXnmeIRbg8W1kqj2aVyT/47GPzrgmO1Cx6AZrqfiKSfGGq57fZ1H08s/4muVuxi2lx/dNctZ3mz6vLoqOGjY2fBVsN7zyD5hhCT9NzfzH5V0MrmWRnPU9P8Ky/DA2adJxy0sg/XH8hWqBVLYmXxMbt9aeAT9KcF5qQKKZNxipTwozgU4KTUqpimS2MVckUlxbJc20sD/dkUofbNWFTsKlRMYp2IbOBdPLvpEwFEkaTADsSMMP++lNQ6nEZdOuFThwhZT6MOR+oq/qyga0oH92VTj2l4/maaUyjZ9DmuaWjPTpe/TVz0nxfef2j8H9avf8An50KeX8Wt2Jr2Uda8HuCT+z/AHmc5/4R6f8A9ENXvA616FR35T4pqzaHUUUUxBRRRQAUUUUAFFFFABRRRQA09aKD1orB7sYUUUUgCiiigAooooAKKKKACiiigCvf3SWNjc3cwYxwRtKwXqQoyce/FYWqeItKk8KabfX9pLcabrTWtqLeSJH3C6ZUUSKTgr+8G4c8Z61sazavfaPf2kRUSTwSRKWOACykDPtzXkOhfCvV7MWLeRoWl/Zm0oSwWEzul0bW4EslxIxiT96yggDB68t6NAetTaHpM8zTTaXYSStbGyLvboWNuTkxZI+5nnb09qZp3h7RdMitotO0jTrSK1kaaBILVIxE7KVZkAHykqSCRyQSK8mX4Ua2ba5hjk0ezmNrNBNfQSyGbV2eZJAbr5BtG1WU4Mh+c4wODa/4VrqmxJDpXhprD+0muz4aM8n9nKhgEYIbycFw4L48oLlj3+aj5gdlba34cj8Fr4vTTVgsYUmv0AtkEyu5beVC/wAbknJB5Lcnk1U8OWPhTxHeXSS+DLOyv9DeG0Md7Y2xeD92k0ao0ZcBQHUjB4NVH8BXU3wVTwdcjTpL1bZYucm3DB9wIyucDHHy1lar8Mbn+2Ly4sNO0C70dtRS6i0S6LRWrxiyjgG4LGyqyOhZRsYYPY9DQD1WztLaxg8iyt4beHcz+XCgRdzMWY4HcsSSe5JNT15Fp/w68T6X9mfStdgtpF02JZQrybZLyAyeSp7mDEu1gTkiNOOteheCtFbw94U0vSpZFlntoFE8idJJT80jj/ecsfxpAbdFFFABRRRQAZozRRQAZozRRQAZozRRQAZqG8ie4s54Y55IHkjZFljxujJGAwzxkdeamoouBw3gX4VeEPBQSTR9Jie+Xk311++nJ9Qx+7/wEAVT1L/kqes/9gbTv/R97Xoted6l/wAlT1n/ALA2nf8Ao+9rWk7zE9jy74m2xj8W3Mn8M9tBKP8AgJdD/wCy1yEyboXX1BFeofFmxZoNN1BR8sbtayn0WTBQ/wDfaqP+BV5qF9a5sRG02fU5XUU8Ol2NfwpIJLSZOuHEg+jAf1BrfVfWuM0e5/s7VB5hAhPDeyE5z/wFv0NdwqU4O6HVXLJjFX8qlVKcq4qVUqrGLYxV54FSKnrUir6VKsfrTIbI1WpdojUsxwF5J9BjrUqJ6Cs7xDdx2djIsh+8u5+eiDr+Z4H19jRsTu7I46b97q0jEY2RjPszsXI/IikvXEFhcS9AkbN+lSWqyFWknH76VjI49Ce34Dj8Knhsf7U1PTtLxkXc6iT2iT53P5DH41zL3pWR67ao0W30R23iG1Nj8E9UtWGGh8PzIR7/AGds17YOteT/ABL/AOSdeKu3/Equv/RLV6wOtehVVmkfE3u2x1FFFMArF1vxZ4c0G7S11zX9I025dBIsV5exwuUJIDBWYHGQRn2NbVed+JL2403xD4/vrKTy7q18LWk8L7Q211fUCpweDggdaANr/hY/gf8A6HLw3/4NIP8A4qt/StSsdXsIr7Sr22vrKXPl3FtKssb4JBwykg4II+oNeGfCrx14qvPFHg+DxLqN61hr+lSToL+C1UXFwg3E25t1BVQuDiXB9q6ye5nsvgl43urOeW3uYZfEEkU0TlHjYXl0QysOQQecigD1KivlLwZ4x8WWHin4c+H/ABLqmoyxS/8AE0W+M7kXtpNbeYEl5y5jfcOc/oM9hovxo1m88Radbpb2d5o+q2N9c2V6bFrQs1ujtkJ9olZkzGVO4RnPTpQB77RXz2nxW+IC+BfDXiKax8Kn/hINTtbCziT7RwH84SGTn5fmSPbjdgbsg8Vb1r4p+MdIk8VQXtv4ciuvCtnaz30eyZlvnlIJEDF1MagEDLK+Wx68AHu560V4B4t+M/iXSNX1TS7TR7GXUWitr/TIHjky9o1vJNOZMPy6eWV4xz2ol+KGp6/LoOo2sFuNEvPGEGlWLJJcQySQY+aR/LlCvknhWBTg5U1i4u4z3+ivBNB+L3iW6uvD819a6O1jqXiGbRHhgglWVVXG2QOZCM88jbzjqM8L4Y+L3iTWb/wTcyQaNHpnibUbq1FqsEhuLVITj5pPM2ljkfwAD3zwuVge9UUUUgCiiigAooooAKKKKACiiqWs6nZ6NpV1qWpzCCytYzLLIQW2qPYAkn0ABJ6CgC7RWBaeLNMvb/QrayeS4TWrOW+tJ0XEZjj8rO7JDAnzlwMdjnGK36ACiiigAoorMstZt7zXdT0qJJRcaekLyswGxhKGK7TnP8JzkD8aANOiiigAooooAKKKoa/cSWmhajcW7bJobaSRGwDhgpIOD70AX6K8B0rxP4pvtI0O6m1LWbjT7m40N5bu8sxZH7RLdRiaGLbHH5kJQ8nDAg43EGuhb4ypFd30UmjpNAlo93Z3NtPN5VyBPHCBulgjUDMqkshkUAHJ45dmB67RXnek/EO7l8Xjw9q+kWlpcreSWks1vqBniUrapc5BaJCeH2kEDG0nmsWD4xz3n9nf2d4Wvbxp7KG+uI7cTzNGsrsoCeXAysQEJy7RjsCecFmB69RRRSAK871L/kqes/8AYG07/wBH3teiV53qX/JU9Z/7A2nf+j72tKXxoT2JNW0+DVdMubC7BMFwhjbHUehHuDgj6V4NJBc2d5c2GoDF9avsl/2vRx7MOfxr6FrjPiF4Vk1mKPUdLUf2rbLt2HgXEfXYT69Sp9T71eIpc6ut0d+XYtYepaXws8qng81QVwJF5Unp9D7Gtbw7rKwqLW93JGmFVmOTF6K3qvo34Gs+2mjnQsmQQxVkYYZGHVWHYj0pZYFlYOCUkX7si8Ef59K89ScWfTTpKqro75FGAQQQRkEcg1MkecZHFcLp+oXunDaCxjHeJdyn6xnkf8BNbtn4ohf5Zhb7x1xL5Z/75cDH51uppnnzozj0OjRPbmpUj+lYT+JrONM/uD/vXKf0zVCfxTPcDbaK3P8Az7r/AO1HAA/AU3JIzVKctEjpr+9hsVw2Gm2lgmcYA/iY/wAK+/5ZNcPc3D6tc+azs1sGDBiCPOYdDjsg7Dv1Pu1o5rsk3rDy2bcYEYlSfV2PLn68VbVM1jOd9Ed+HwvJ70txoA9vXJrqvhlpZlafxBOvEy+RZA9oQfmf/gTD8lHrXP6Doz+KL1oFBXR4X23cwOPNI/5Yof8A0I9hx1r1yKNIYkiiRUjRQqoowFAGABXThqWvOzzM3xqa9hB+v+Rz3xK/5Jz4q/7BV3/6JavWB1ryf4lf8k58Vf8AYKu//RLV6wOtbVt0eCh1FFFAwrgvENtexeLtckk8M6lrWkato9rYObKe2TBSS78xG8yaNhlZ0wVz1PIxXe0UAeUeHdD0/wAPX9neaZ8NfFQubKE29o1xqlrc/ZozwViEt6wjBHHy44rrPBGlSnwhc2ev6Z5P2291CeWxuvLl/dT3c0io4VmQ5SQZAJHJFdXXOfEfS9T1rwLrem6Bc/ZdUubZo4Jd5TDHtuHIyMjPbNADfFA8OeG9CXXdV02zFroFuz2zJaoz2yBQNsPHyZAVcDA6dqo+D9A8LX+nWut2fgvT9ImuUaRBNYWyT7JFwSTGWA3KeRnODgjtXjF58LPEd7o2vRaf4Zj0m1l8O29j/Zrz25+26ijqTcja5QEAEb2IY5z3NewtoV/pnwcGiaFpWm/2omlCFbCeNDbvKU+dWUfIcsWzngk88E0AdIfDmiGwsrE6Ppv2KxlE1rb/AGVPLt5BnDxrjCsMnBGDyax/ER8Gz+MdF03xBYaZdeIrtJH0/wC02Imk2xje22QqQmMZ5I9q+ebz4VeOJ9A8YWtnoM0Carp1iEtTLY26PdRzxNJtjgYRqAFcgnkjqSTiu81b4SWuj+PfBGq6J4Vj1DSLMXJ1OEyxzSmV1+SRjcON4Dkt94kYJAz1APZrrRdLutTTUbnTbKbUEiMC3MkCNKsZzlA5GQpyeM45NV4fDWhQ2dlaQ6JpkdrYzfaLWFLSMJby5J3xqBhWyScjB5rwjw18L/EVjrjXmt2esXeux3txINVtruxjt7iKRSMyMV+0tkceW3yjsVFZzfDCPwb8AP7a1K1/snxrpTJqDTvdGUCSG4cxIMMyDKPgBccsM85rFrXcZ9DxeGNAiEAi0PS0FvcG7hC2kY8uY9ZV44c4+8Oa5ex+FWh23jK38TTTXFzqFvLJNEpgtoEDuMFm8mFGkIHQuWx9aT4H6Hc6X4JXUdVUf21rsz6tfHHIeU7lX6Ku0Y7HNeg1OwBRRRQAUUUUAFFFFABRRRQAVyvxB8OXvimy07Tbe9+xWIvY7i9lTaZSkeXRUVkZGzIsZO4YwDweldVXmnjvxJq3h7xs9zYQR3tja6BPe3FtPfNbxgJKpLrhHBkxwMgdT8woQHPaj8K9ZLWNq0Oh+INMsP7Rjtk1eYxsEufJdWZUgKbkkSXAUKMFMEdrsHwouoWW6lmsbvWIJ9Ja31Kbd56pbCJZ/m2kqXCOMA/Nkbj6O8P+OdQOravbWFqdQutQ1eVrOLUL1reK3gSxtZWXdsfacyZChcZLHjk1bsviyb+3jv7PRkOlRmxW7klvQkyPdbdgijCESgbhzvXPOAcVWoGE3wn1p7K8tlOi28z2c9tLfxTSefqjyTI6yXP7sbSoU95DluCBxWv4y+E1rrGoarPp9ho8KPpcFrYb0Ktb3C3E0skoIU7S3mD5h8xO7PXJm0nxdqXiHx34YlSBLLRLldRWFEvmeS48oqm6WIIFTBBwNzkZ7GsL4gX+vHxhr8sdzPBZabNo0Nu1vqk0WwTXaB8wKoRy4LKSzHAAxnJwagS+JvhPqMx1Oy0G18PRaDc332mGykijXyAbWKMtHvt5kjbekjEKuWDA7lNdh8MvCeqeGVkbWLm3uJX07T7QvE7OTJBEyOSWUcEkYPU98VjzfFO7isXvx4fjlspYL2eyEV/unlW1bEnmR+X+7JAJGGfnCnBNbmi/EPTte8S2ekaNBJOZknneWRtgFvHtVZ0AzvR3YKpJXox7cp3A7aiiikAUUUUAFMljSaJ45UV43UqyMMhgeoI7in0UAVG0ywaztrRrK1NpbGNoITEuyIxkGMquMLtIBGOmBis238HeGbaW5ltvDujRSXSPHO8djEpmVyCyuQvzAkDIPXFbtcr8V/8AklvjL/sC3v8A6IehAM0/4d+FrL+0Y10Wwlsry5S7+xS2sTW8EiRLGDEm3C8Jnucs3ritC58IeGrpLNbrw9o8y2S7LUSWUTCBc5wmV+UZ54xW6etFABRRRQAV53qX/JU9Z/7A2nf+j72vRK871L/kqes/9gbTv/R97WlL40J7GhSUtFdZJx/jHwXFrMpv9NkSz1XHzMR+7nHpIB3/ANocj3rza7S40y8+x6xbPY3R4USHKSe6P0Yfr7V7zUF5a297bvb3sEVxA4w0cqBlP4GsKuHjPVaM9HCZlUw/uvWPY8UC4NOKBx8wBHuM13N98OdNZi+kXd3phP8AyzjYSRf98NnH4EVmyeA9aiJ+z6pp069vOgeM/wDjpIrklhprY9qnm+HkvedjmkgjXkIgPsoqYD8q3E8E+IGPzXWkR++JW/TirkHw+uZCP7Q16UJ3Szt1jz/wJixpLD1H0LlmuGitHf5HJ3Vzb2aBriVUycKDyzH0A6k/StvRPCmo65sl1JZdM0s8mJvluZx6Ef8ALNT7/N9K7fQ/DGj6GxksLNftB63ExMkp/wCBNk/litquinhVHWR5WKzedRctJWX4kFlawWNpFa2cKQW8Q2pGgwqj2qeiius8bc5v4lf8k58Vf9gq7/8ARLV6wOteT/Er/knPir/sFXf/AKJavWB1rCruikOooooAKKKKACiiigAooooAKKKKAGnrRQetFYPdjCiiikAUUUUAFFFFABRRRQAUUUUAFZOseG9C1u4guNZ0XTNQng4iku7WOVo+c/KWBI554rWooAydR8NaFqcE0OpaLpl3DNN9pljntY5Fkl2hfMYEHLbQBuPOABSy+HNEl1C0vpdG0176zUJbXDWqGSBR0CNjKgdgK1agu7u2s033dxDAn96Vwo/WgDAisPDmmeM4I7XQ7GDW7+3ubw3sNpGrssbxLJukA3FiZ19c4bJ6Z2bjSdOuXna4sLSVpzG0peFWMhjbdGWyOSp5XPQ8iuG1LxZoQ8daVqq6pbSabZ6VqUM9xG29Efz9O4yM5++vT1q0/wAWfB44g1Ga5PpBZzP/AOy4pvQtU5vZHT2/hzRLa+vL620bTYr28DLc3EdqiyThvvB2Ay2e+c1YtNK0+ykiks7C0t5IoFtY2ihVCkKnKxggcIOy9BXH/wDC0NHf/Uadr0w9V09wP/HsUv8AwsqzP3dC18/9uyD+b1NylQqP7J3lFcMvxGtD97Q9dX628Z/k9TL8RNL/AOWlhrMf1smb/wBBzRcHQqL7J2dZ/iHVYNC0DU9Xu0ke20+1lu5ViALskaFiFBIGcA4yRWEnxC8OEZkurqH/AK7WM6fqUxWN8QfFmgav8NvF9tp2r2U9y+jXu2FZQJDi3cnCnnoCelNasl05LdHo1FNSRJN2x1baSpwc4PpTqGQFcr8V/wDklvjL/sC3v/oh66quV+K//JLfGX/YFvf/AEQ9NbgdUetFB60UgCiiigArzXXZ1tfiRr87pK6xaHYOViQu7YmvjhVHJPoBXpVcF4k0LxEfGl1q+h2uk3Vtc6fbWjLeX0ls6NFJcMSNsMgIImHcdDV02lK7Bnjs0PjCx1+fxZNpDm/vtNvI4Ird3neEbY2t4Xj8sKhVkOTubLO3StTU7DX7DxdbXU+oa7q13YaTJPbBLKEQT3DH54d6w4QERL1YN8wCtyQfR/sHjf8A6A3hv/wdT/8AyJR9h8b/APQG8N/+Dqf/AORK6OePcmzPM9E1Dx1fiCOW7uYlu7uCJpfsLh7VQsjzMPNtYlCEKiDIcgn7xJroNCvfEFz4t1LRnvHm0/TLmN5L90i3yoYIyIMKoUMXLsxwCFKgY3AjrPsPjf8A6A3hv/wdT/8AyJUNto/jC1EgttA8LQiR2lcR6xMu52OSxxacknqaPaR7hZnParqGqHxjPazXOsWGnQxxtbCw03z0u2IJfzJTE4QDAXb8h75OeMA3ni6107RZtV1DXgb+0e5uvsOlxTSW0wAKW6oIjszvILSZGY8ZTJNejfYfG/8A0BvDf/g6n/8AkSj7D43/AOgN4b/8HU//AMiUe0j3CzPOrHWPFy6rZx6rJqP7uyVrpbTTn8qOZYdzl82580F+MQyg5IAU8mtXwZN4s1HSZ2mv5IbtJlXzdU08tHIu3JMUYW2kUZP8YbpgE9a7D7D43/6A3hv/AMHU/wD8iUfYfG//AEBvDf8A4Op//kSj2ke4WZ55ea/4qh1DxBNZQanfxwRu1nELJoYFO9VUMr26yOQCWzHJIG2ngZUGtY6z4uENuNUu9Ui064uJN15aaXJPdwBUTEZja0j4ZixD+SQAuM5OR6Z9h8b/APQG8N/+Dqf/AORKPsPjf/oDeG//AAdT/wDyJR7SPcLM8sl0/V59W15Vl1i6mvr6ysCt7pcbQSWahC0zkwhWPM/AIA3DKg4qQa543uLSa4tV1ZbyS2lWe2m0wJFZzvIqQiEmPdLtyzMxLoQueOlen/YfG/8A0BvDf/g6n/8AkSj7D43/AOgN4b/8HU//AMiUc8e4WZwutf2yngb4i2+r3VzeW1tYzxWtxc26RPKPsm52GxVBTcxAOP4SMnGa9+HWvKfEvh3xvrfhzVdK/szw3B9utJbXzf7YnbZvQrux9lGcZzjIr1YdayqSUmrDQ6iiiqAKKKKACiiigAooooAKKKKAGnrRQetFYPdjCiiikAUUUUAFFFU9T1Ox0q3M+p3ltaQjnfPIEH5mgaVy5RXAXXxU0NpGi0S31HW5V4P2G2JQH3dsLj3Gaxb/AMd+KLsMLGw0nSUPRrudrmX/AL5jwoP1JpXRvDDVZ7I9ZrP1fW9L0aHzdW1C0s4/WeVUz9M9a8ZuLvWr4k6r4l1WcEcxWm2zj+nyfMfzqrBY2cE5mhtIVnPWZl8yQ/V2y361Lmjrhlk38Tsej3PxJ0tkb+x7PUdUIOA8UBii/wC/km0Y9xmuc1Dxx4pvCy2kOk6RGejOzXcuPw2oD+JrEd2kILszH1JzTWIUZYhR6k4qXNnbTy2lHfULqfWL7P8AaXifWpweq27paJ+SDOPxrKPh3R3ffLYLcSf37mWSZj9SzHNaEdxFK+yAtO/92FTIfyUGtCHS9Um5TTpY1/vXDLEPyJz+lQ6ndm/JQpdkVYYooZ7GOGKOONdO1EBEUAD/AEjTO1P86TA/eNj0Bq62l3C6vp1pLLbxyyabqLblJkVR9o03r93J4NWY/DmT+81JyfSO3AH6saVStGNrvoc9CvTi5+v6IxiSepJpK25/DQKEQ6pPG+OC0CNj9aqReGrxD+8vFulH91/IY8f7jD07j+lZOvA3+t07dShRWodJtowxvBq9oB/EWjkT/vpVYfnj+dSJoNrMu621acjsdsUg/QCj28A+t0/MyA7L91mH0OKJGMsckcwEsciNG6yDcGRgVZSD1BBII7gmtZ/DlwP9VqETegktyP1DH+VRnw/qIX5ZLGQ+glZP5rVKtHuP6xRluzEls7aW7kumgUXcjF3nQmN2YnJJZSCT71eiv9VtgPsWuatAR03TicflKG/nT5dL1aEEyaXOyj+KF0kH6Nn9Kpys8H/Hzb3UH/XWB1/XGK09p5hy0KnZm1b+MfFdr/y96ZqCDtc2zQuf+BIxH/jtR+K/HN7q3gLxXp2paIbWSXRb7bPb3KzR5FtI3IIVhkD0PNY0dzBLgRzROT/dcGode/5FbxJ/2BtQ/wDSWWtITbaOfEYKiqcppbI9OvviXoGnajc2epLqNo0ErRGSSykMbFWxkMoORxnPpWppPjbwzqxC6frunyueiecFb/vk4Neda87Lr2pbWI/0mTof9o1i3dhZXn/H5Z20/vJEpP54zTc9TFZZGUU0z6AUhgCCCPUUtfPNtpqWJzpN3qOln/pyu3Rf++SSv6VeuPHnirwvBbyS3ttrVvJIYhHdw+VKMDJO9OD1A5FNTRzzy2rH4dT3iivOvB3xZ0TX7qOyvkk0nUX4SO4YGOQ+iSDg/Q4Jr0Wne5wzpypvlmrMKKKKZAUUUUAFFFFABRRRQAUUUUAFFFFABQOtFA601uA6iiitxBRRRQAUUUUAFFFFABRRRQA09aKD1orB7sYUVmeJdZt/D+hXmq3qyvb2qb3WJcsecYA+pry/UvGniPWIyLcw6HbMOBFie4I92I2qfoDj1qW0jejh6lb4Eeq6tq2n6RbG41S9t7SEfxTSBQfpnrXE6h8TYJGK+HtJu9SH/PxMfssH4M43H8FrgYrGBLprpw9zet1urpzNKf8AgTdPwxVpmzksfqTUOfY9OllaWtRlzVNf8T6sSLrWk0+3PWDSotrfQzPlvxAFY6aXYLN58lsLq573F87XMh/FyQPwAqR7uIAlSZMdfLG4D6noPxNZV34itICQ08II/hQ+a35LwPzqXJs74YelT+FG+0jsgQu2wdFzwPoOlQySxxZ8yREx/eOK46bxNJO5S3gkk46zSiJf++V/qaqyaldknN9b2oPa1jGf++uTUm1rbI7SS8AAMMM8wJxuWM7R7k46fQGtPT7S2vGCvrFtG2MmKNPnH/feP/Qa8pklt5G3TXN7K/8AeMh/qauWFwd4VL28EJ4KzDeg/BgRUTvbR2IqQm1o7HsqeHtPQfvUurg+sk5AP4JtFWEsrCHiPTbVT6mFSfzINeb2OqavYD/QbiKVAc7A2FP/AAE5A/DFbEPj25hAF9phGOrLkfljd/SuOUaj2Zwzo1Oup3YuJQuyPKr/AHV4A/CkCyMfmbFcknxB09l+a2kDenmgY/MCqsnjiMzL9nMboTylxKq4H+yyjr9ay9jN7mSpT6ROnmQDxXpK9f8AiV6l/wClGnVpsOwz+HFc7b6pbXeuaVdI5iiGmakpMxCgHz9N75weo5BxW6khkjBRg6kcMjA/ka1rqygn2/VnPBNOV+4rKf8AnmPzpm8A8p+tK7mMFnuFjX/poBgfqKzbvXre0I82SC5TOP8ARGMjj3KY6fQmufkb2NVd6WNVJyhyhYH2NI0kbtueCJ3/ALzRqT+ZFMtZ7W8j8y2kjlXvtPI+o7fjU3lJ6UvfWzF7vVDDP6LSec3oKVyiE70IX+9jIoUK4Ji2OPY5pNS7jTj2BZyD0x9DViO5kPSSUfiarESDoMfSk2SHkhvxoU5RBxTJp4orj/j4gt5uh/exK/8AMVzfjTTrCHwV4pmh0+CGYaLf7XiyAM20meOlb481fWqPia1m1LwtrthAuLi8066togxwpeSF0XJ7csK3o1X7SLfdETTUWkP1zQrSfVb2RL69gled2YYSRMljngjOPxrNPh6cA+TqNrKewliaM/mC1dLfSebeTuE3I8jMOOcE1Btjbodv1pyxE1J2NoVpxS1OWl0jVYv+XITj+9bTI/6Eg/pXGePTIj6bDLFNFsWSRlljKEFiAM59kOK9bMLDoc1zmtFm1e5V13oIooipAII25IIP++a0jipW1RvDFSur6njksSTRlJUDKexFeq/CP4hz2N5b+HvEdyZbWUiOxvJW+ZG7ROT1B7H8Ppzmr+F/M3XGk9Tgm1Ix9dhP8j+HpXI3EAlikhmUj+FgRgqR/UV00qqex11KdLG02uv5H2PRXCfB3xS/iXwqqXrZ1PT2+zXOer4Hyv8A8CH6g13dda1Pl5wcJOMt0FFFFMgKKKKACiiigAooooAKKKKACgdaKB1prcB1FFFbiCiiigAooooAKKKKACiiigBp60UHrRWD3YzD8c2I1PwZrln3mspVX/e2HH64rxHSb+ObSLCUtl5IEbavLH5eeBz2r6IdQ6MrdGGD9K8Bl+EupLZtZ6f4mSeOIkR28NmdjDJwJJAwGfr+VZyVz0svxEaPMpmTfeIbeAsokUMP4FHmP+QOB+J/CsC+8RXExJjiREz96c+Yf++eFH5Gug/4VzqWmeUviCSOBX4BtBuRj6bj0Ptitqx8O6XZMGitFeQfxzfOf14H4VPIz11iKbV46nnK2+q6ztIS7vEPQkYjH06LWtZeCr6QD7VPBbL/AHUzI39B/OvQyOKaRT5ET7aT20OSj8FWKjEtxdSN3wVX+QqT/hDdLxgG7/7/AFdQR7UhGRiiyFzyfU5iPwlYxEmOa5U9idrY/MUybw1Pj/R76CX/AGZoyh/MEj9K6nFIqb+Ayg9ME1EqcXuh877nFSaRqVvg/YndR0a3kDj+h/So2vJrXi5EkftNGV/UgV38dvtbcTz2xxUgztwTke/esXRj0KU31PPlu7Wf7yo3vGwP8qSRICp2LLu7Z6V28+m2FxnzrK2kz/eiU5/SqreH9JPJ0+AfQEfyqHR8ylMwbOMxaSggzExs9QOUGD/x8aV7Vkq1yD/rEJHOTCmevqFFdyukWCW/kLbKsWySPaGbpI0TP37tbwn/AIDx1Oax8N6Uelsw+kz/APxVaSi2kk9kZUo8jlfq7/kcW0dxIRm4KDt5cSL6Drj2qKK3hmAfe8w/vNKzgfrxXc/8I5peMeRIM9cXEn/xVS3mh2F2qZgELooRJIflYADABP8AFx65qfZytua8y7HJx/boWV7a5LsvCu3Lr/wIYb8ya07fxdrtqgSTy5gO8nJ/kD+tZuq2z6RKBJcRXAJwBGcTfig6/UflTknk2jLBhj+If596xndfEDpwqbo2x471LG17SNTnqI88f9/KhXxSZ7rfqMcoix0RPIYn13ru+mMg1l+Yjf6yCNs0zy7RiC9qp/H6VK5e35kfVodjrLPxbo07CMi8jXGNyXrN/N8mr7eJ/D9mfMDytJjgyFyfzdsCuHItGTa1uSv904I/KkWKxTlIAvXkCjlj/X/DEPCRfc7M+PtOLYWFyD0zLGCf/HsfrWnZ+I4braDGluzdFuJghP6YP4GvPHjtGBBLgehHHv7UyOwEYP2K42KeqK3y/ip4P5UckWKWEjbQ9iXf/GqAY6q+f6UteR2t5q2mN+6c4H8KOY/05Xt/dFbNr42u4cfalDL382IjH/AkyPzUVLpPoc8sJNbanezhtvypKfQwkbh+B6/SuKjvftd/eFpoWmMz7k2mNwAdoJU8jhRxWxpvjGynAklicKnzMYWWYAd/u8/pXPWTQajp9rcSbXL/ADpLGcOjEk/K2Prnt7VLi4qzRmoSj8SNBQMlh1PrWH4y0xZ7M6pAuJ4iBcgfxJ0DY9QcZPp9K2rcuriGYh2wSjjjzF45x2bkAj6Hoau2sayPLbygNFKhRwR1BGP60oNxdy4VHCSkjmfgzqn9k/EKK3YhYdWgaBgenmJl0P5bh+NfRtfI1nO+l6vpF6D89lfwsT6gOFP6Zr65r16bvE581glWUl1QUUUVoeYFFFFABRRRQAUUUUAFFFFABQOtFA601uA6iiitxBRRRQAUUUUAFFFFABRRRQA09ajkMmcRqo/2mPH5d/0qQ9TSN0rG12xoqPaLKP8ASmafn7rcJ9No4P45qUAAALgAcADtUhplBSK99bQXtrLb3SCSGQYZT/nrXmWo2EmmahLZSkvtG6Nz/GnY/UdK9TbrXK/EGGFdIW/leONrRgS7kLlCcEZP5/hSZ04ao4Tt0ZxpXJNNI4JrHu/FOmREi2aW7P8A0xT5f++jgflWVdeKryTi1tYIQe8rFz+QwP1rNyR7MacpbI6zbUc7JCpaZ1jUdS5Cj9a4G61LUrhSbjUJgncRERL/AOO4P61jTXViJMSzxySehbzG/qanmNlRa+J2PQp/EGlQkg30TsO0QMn/AKCDVKTxVZdIre7k+qBR+prk7cXFz/x56fezDoCIto/XFaEWg6zN92yii/66zD+QpczK5Ka3Zov4smDf6NYBfeSb+gFEPijUrklQtnA47bGckexyP5VCvhTUT/rrq1i9dqk/qf8ACn/8I1BGQbnWUQg9iq4qJJtaA/ZrYkbVNVbrfBR/sQqP55qM3moN97Urk/TYP5LUhsNHQ/vtcDd+LgD+RpDbeGxkPqJf1/eFqy5J/wAwuaPREZuL3vf3fv8AvMUnnXRPN5eE/wDXZqm8nwwP+Xh2x6Ix/wDZacqeGh/FJn/rg/8A8TR7OX8w7r+Urw31/bXMUkUstwqhtyTTtt6YGRznr/KnXF5fXW77RduEP/LOEeWv5jk/nVgDw1/eb/vw/wD8TTgvhg9ZCPrDJ/8AE0/ZytbmFdXvymZFBFECI41XPXjk/X1p+BWkI/DB6XUK/wC8rA/qtOFn4afhdQtR9ZlX+YFR9Xb6le1t0MvH/wBejA+lbC6Losp/cX8BPol0mT+RqUeFInGYbm4IPQq5b+Ro+rvuHt0YQGKAMY6flWxJ4XmTOy9mH++v+OagbQNQGdt1A5/2k/wxUuhIpVUZwH0o2irT6bqkX37SJx6xuf5c1XC3G5g9jdAqMttjLgfXHOPwqXSn2H7SJJHcSoMb8jHQ083CMD5kKlsYyOP8/wD6qrwSRTx+ZA6yR5I3LyOP8/zqTbz0NRdoqyZFdwWlwSfs6g5PJ5OPr1pnhadrDV5NPLEwS8pnscZH6Aj3wKmKNj5WGe2Vz/nrWZqUU8Usd7GUUx4DFSQcZ4Iz3BP4g0173usipBSi0d/GcJsOPl5UY6ds/wA6u2h3SIepwQc9+R/jWHoN7Ld2sJugFlZd25Tw46E+x9R7/hW1ZsIxK8nCoNzZ9BnNYWs7HkyVtDyrxQnlRaiE/wCWdw238JOK+ukJKKT1IFfIOvyl7JpGWQtcXCcLGZGJdweFUEseegr6P/4WNoA48vX/APwn7/8A+M17FCL5Sc20cE97HY0Vx3/CxvD/APzz1/8A8J+//wDjFH/CxvD/APzz1/8A8J+//wDjFbcr7HkHY0Vx3/CxvD//ADz1/wD8J+//APjFH/CxvD//ADz1/wD8J+//APjFHK+wHY0Vx3/CxvD/APzz1/8A8J+//wDjFH/CxvD/APzz1/8A8J+//wDjFHK+wHY0Vx3/AAsbw/8A889f/wDCfv8A/wCMUf8ACxvD/wDzz1//AMJ+/wD/AIxRyvsB2NFcd/wsbw//AM89f/8ACfv/AP4xR/wsbw//AM89f/8ACfv/AP4xRyvsB2NA61xVz8TvDVrbS3F0dbht4kMkkkmg36qigZLEmHAAAzmu1HWhJpq4DqKKK3EFFFFABRRRQAUUUUAFFFFADT1pGodlQFmYKo6knAFRNI7nESYH99xgfgOp/SsthoceOTwByaz31BXO2xiku39Y+EH1c8flk+1V9d1HR9FtxdeItRt4o+qi5cKpP+ync/gTXB678WmI2+HdMzEeFvdTY28R91T77/kKhyNqdKdT4Vc9Baz1K6H7+8SzQ9UtV3P/AN9sMf8Ajo+tcj4y1DwRpWmahZapfW8l5cwvAQzNdXOWUjgfMw6+wrzHW9c1fXiy6rql/dwtwba2/wBCtfof42H1qhaI1lHssY7WwXv9miG8/V2yazdRHp0csqy1k7GJpFvrVxp9uItKdAqBWnu3EKcDGeeSKtnTDkDUPEMEbd4tOhMpHtu/+tWhJbrK++cvO/8AemYuf1p4QAYHA9BWXMe0qMmvekUI9O0SE7v7Ov8AUZB/FfT7VP4D/CtODUJLaPZY6dptmB02RlsfyqLZR5dLmZSw8EPl1PVJfv37qPSKNV/oTVaRp5c+ddXUmf70zY/IECptlJsNK5oqcF0Kn2aLPMYY+rc/zpRBEOkSD/gIq1sNGw0FpJbIgC44Ax+FLzUpQ0mw+lA7kXNFS7TnpSbfagdyOipNvtRt9qAuR5NFP2+1BWgLoiaNG+8in6gUzyIf+eUf4KKn2il20C0YyIvEcwz3ER/6ZzOv8jVuPVNSj+5qFwR6SBZP/QgTVbbRtp3ZDpU3ukXp/FOpWtvuZLGc7goLQspGTjPysAevpWFqmo3+qoy393LKmDiIfLGP+ADj88mp9RiMljOqDLbdwHuOR/KqUeGUMvIIyPxp3Zl7GCloi/4bKm2ljGAVk3AA9ioP861ynB689K5jTwkd2EkUEN+6yfUcr+YJH4VsrFt+6XX/AHWIrGVK7umTYvFM9O4yOajubdbi3khcnZIpXI/Hn+VQo069JSw9GUH/AAqVLiXIEkakf3lP9P8A69ZulJBZknhS/kgum0y7ADgloyOOevHseo98iug1i5+x6NdOD+8lBijx1Jbjp24ya4/U3Ba0u4wfMil4DDBPG7H/AI6Kt6hevqdyJct5C8QofT+8fc/y/Gp9m5SvY5HhueqrbdStoVl9t8ZeH7RRlI5jdP8A7sa5GfxxXuFeZ/CiyNzq2sayy/uowLC3b1x80hH47RXple5ho8sDxc0q+0xDtstAprssaM8jKiKMszHAA9zWN4k8RWmhxhX/AH1667o7dWwSP7zH+FPc/hk15P4h8TXmry/6RKsiLysagiFD/sqfvH/abJ9hVVK0afqZYXBVMQ/d0Xc9H1XxzptruFikl+w/jjISEf8AbRuD/wABzXMXfxFvmB8oWUHoI43nI/Fio/SuAlkeVy8rs7erHNTWNhfai5TTrK4umHXykLAfUiuOeKk/I9qGV0KSvUdzqD4/1rfkXox6fZI/8a0rH4j3akC6igkHqYyn6qT/ACrno/BHiWRQw0wr7NLGD+rVR1Hw/rWmRmS+0y6jhHWTYSv5jIrJYqXcr6rgp+6kvvPW9J8Z6Ze+Wtw/2N3O1TIwMbH0DjgH2bBrpa+cLedkJMTfeG1lIyGHoQeorpfDXjC68P7ECyXOm7vntMljEvdoieRj+4ePQiuunik9JHDicpcVzUXddj2uiqml6haarYRXunzrPbSjKuv6g+hHcVbrsPFatozm/iV/yTnxV/2Crv8A9EtXrA615P8AEr/knPir/sFXf/olq9YHWsKu6KQ6iiigAooooAKKKKACiiigAooooAYyqXDEZI6e1eSeOvirtuJNJ8Fhby8UlJ77Zvhg9QvZ2/HH1r1xwDkEZB6181S6W3h7X9V0GRdq2spltjj78DkshH05U/Suao2j0MvoU61TlmUVtJ5rtr29mknvX63E7+dN+DNwv0UcetWEt0SQvtLSnrIxLMf+BHmrm0+lJt9q522z6iFOEFaKINtJt7GrG32o2+tKxdyvtpNoqxtHpRtFFh3K+0elGyrBUUm0UBcr7KNlWNgpNlAXINtG2p9nHFBTmgLlfbRtNT7KTaf7tAXIdvHtRtPpUhDD+A/nTTvH/LJsexH+NFguM25pNvtT2cgcxS49gD/WoXnQdfPT6xN/hRYXMP257UbfaoTeQ5OLuEH/AG1I/nSiff8A6u4sz/wL/wCvRYOZEgUUbRjpTf8ASWGUa1I7cmgre9Qlsfxb/Ciw+YXYKNgphF8P+WVtj/fb/Ck3Xv8Az725+kxH/stFhcxJsFY0CeUZIDwYm2j/AHeqn8j/ADrUMt2Otkp/3Zh/UVUvFmaRJks5g4+V1BU7l/A9R/jRYTfUq3MWfmAJGMMB1x1BHuDV+zvFZUS5ZBIeFk/gk9wex9qZDtkjV0IZWGQRQ9qCG8tgu45ZSNyt9R/hRcHG+qNTynzjYSfYUSCO3IFy2wkZWJeZG+i9vqcCsuO2mVdsYRV6YWWRR+QqWKyGCshBVuqINoP17n8TTuiOWTGNu1CcSOoWFRtCq2VUZ5UHvn+Ju/QcU6/ecLDa2CeZqF24ht09WPf6Ac1Yup4bK2M05CRrgAAck9gB6+1bvg7w5qml+OdJ1HXEMM2oaZevDZsQTbIktqFJ9HIkYn0DY4OQLpQ9pKxzYzExwlLT4nsd94c0mHQtDs9NtzlLeMKWx99urN+JJNVfFmvx6FYAoEkvpgRBExwOOrt6Ko5PrwBya2ZJEijeSVgkaKWZj0AAyTXhfizWZtW1KaeQsBLjah/5ZxDlE+v8R9z7Cu+tU9nHQ+cwWGeKq67dTP1LUJr2eWSWV5WlbfJI/wB6VuxI7Adl6AfnUmgaPd65f/ZbGJ3K8yOBxGvqScAfiai0bT5tW1S2sbfAkmbG49FHUsfYAE17ZpVhb6ZYR6fpqFLdOWJ6yN3dj3P8q8avW5fVn0NesqEVTp/8MZGk+ELCxRcWOnTTAcvdyPcH8goQfgK6COK8jhWGKWwt4F6JDC2PyG0VYUBRgVDcI8YMybpIlGZI+rKP7y9yB3H5elcvPKR5EpOTvJkYS8SRQ7wTRnqybkYfgcg/nVhZpYG+Vjg+nGahSTgMjBkIBU54I7GpvllX/PFY819tGO1t9jlPE/g7TdYD3Nmgsb77xeIYjc/7Sjp/vD8c15hqFldaVdm2v4jG4GQeoI7EEcEe9e7eW6kFTyOQRWT4k0e11bT2SdUTkgSEcwOejj/ZJ+8tbUqzTtI6qGJdJ2vdHmPhPxDP4Z1IzAs+mTN/pcAGcf8ATRR/eHf1H4V7jbzRXNvHPbyLJDKodHU5DKRkEV8/XVnNp19LZXibJoztI65+ntjkexrtvhTrjW91J4dum/dsrT2JJ6Affj/D7w9s17WFrX91meZ4VSj9Yp/P/M6v4lf8k58Vf9gq7/8ARLV6wOteT/Er/knPir/sFXf/AKJavWB1rorbo8JDqKKKBhRRRQAUUUUAFFFFABRRRQA09a85+MPhqfULO317SYvM1LTA2+JRzcW55dB6kfeHvn1r0Y9aK55K7ZrSqSpSU47o+cbOeK8tYri3YPFINysP89al2+1dN478D3eiXlzrXhe1a4sJiZLvTY/vI3eSEe/dfy9uV0+/tdQh8y0lWQA4YdGU+hHUH61g42Pq8NioV43W5Jt9qNtTU2R0jTdIyovqxwPzqbHTci2igqKpHXdPeXybV3vZ+nl2kTTN/wCOitWx0fxVqmPsXhe5ijI/1l/KsA/75OW/SnytmM8TSp/FJFMtGOrr+dN82LsWb/dQmuqtvhr4quQDdarpGng/w28DzkD6sVFatp8ILZiDq3iLWLs91hZbdT+CjP61XIzknmlCOzueevMFGTDNj1KhR+pFUZ9asoD+8lt09nuEz+QJr2mz+Ffg+2wZNJF2453Xc0k36M2P0roLLwxoNiALPRdNgx08u1QH+VP2ZzSzhfZifN6a7HcHFjE90c4/cRySfyWr0Fv4mu/+PTwzqrA9Ge0aMfm5FfTCKqKFRQqjsBinVXs0YSzeq9kfOsHhXx3cjKaCsI9Zp4l/TeTVyL4d+PpsZfRLYH/npKzEfkte/UUciMZZpXfU8Ni+FnjJv9brmjof9iF2x+YFW4fhP4hJ/feKLRf9ywz/ADYV7PRT5EZvMcQ/tHkSfCXU+PM8V/8AfOnqP/Z6k/4VHeY58VTfhZJ/8VXrNFHKhfX8R/OeTt8I7oj/AJGmf8bJD/Wq0vwauGP/ACMoP+/psZ/9mr2GijlQvr+I/nPEpPgpfZzH4gsSf9rSlH8nrH8S/DDVvD/hvV9Yk1TTZotOsp7wolo6M/lxs+0YfjOMZ7Zzg9K+ha5X4r/8kt8Zf9gW9/8ARD01BXH9fxH8x5lcfCTxTHI4tNW0t0BIQl54yR2yPmAPtzVOX4cePrf/AFbaRcj088/1QV9BnrRS5EWsyxC6nzs3hTx1bj9/4chuF6E295H/ACJqtLYeILb/AI+fCmtL7xQiUD/vkmvpKil7NGsc2rrex8n3032WRpTZ6jZMTmSO6s5EVj65x8p9/wA6is9d02div2pIpAcbZDt/I9K+taoXej6ZeZN5p1ncE9fNgV8/mKTpo2hnM1vE+aje2aJua7t1X18wVJpb3Otz/Z/DlhcanNnBeNdsKf70h4FfQUfg7w1FJ5kfh7SEcfxCzjB/lW1BDHBEsUEaRxqMKiKFA+gFJU0VUzqTXuRseceBPhoum3kereJZo7/VU+aGFB+4tT6qD95v9o/h61d8Zf8AJRvDf/YK1L/0dY131cD4y/5KN4b/AOwVqX/o6xropK0keNVqzqtym7s574kah9k0AW4JBu32Pg/8s1G5x+IAX/gVeMOzSOzucsxJP1NeifFu5JvrS3H8EBb/AL7f/wC1150eAT6DNZYmV52PosopKNDm7l3w/qN/aajINIZIriRDH5rKG2qOW4Ix6Cu0t9f8Wx24i8nTpXxxM4IP1IGP5Vy/ge3Bea5cZKRr+Zyx/pW+0sjMW3tkntWHsYS1kiqyU5PQfNdeLpkYtq8UZI+5HCq/r1rS8D6rNqJe0udQvLbW7bO4O4dZR2YK39MevciskF92dzbh3zUOoWX2pUuLWQwalAd8cwOCfY+1Kph4te7ozKVJONj0SFZ7eYw3KoEkYtA6Z2nuVwehHUD06dKsjIPFZfhLX013TQLmJVuo/kuIWHAkXr/iCP6VvosaAhFbnj5nZsfTJry50tddDjcnHRoZEWK/N1qKZdiuSnmQMMSJjJAxyfceoqDxFbTXvhzV7W1YpczWUywMvVZdh2EfRttXba8S/t7e/t+IruJLmPH911DD9CK0VO0OfzsZc3vWPNviJYoLe2v4mEnksIWcHO+M5KHPfGGUmuOmuZdNkt9Stv8AX2Mqzr2yB94fiuR+NetePbWGTwxeyiNFlXYWKrjzAGzyPX39zXlrRiRDGRww2n6GurDystD2cH+9ouD9D1X4gzx3Xww8SXEB3QzaPcyIfVTAxH6GvXR1rwBLg3P7PmoluWj0S7gP/AI5F/pXv46169R35WfLSjyycew6iiimSFFFFABRRRQAUUUUAFFFFADT1ooPWisHuxhXJ+J/h/4e8RXBu7u0a31DteWjmKX8SOG/EGusopFRk4u8XY8rb4RMGxF4r1YQ+jJGzY/3sf0rW0n4UeGLNxLf28+r3I/5aahKZB/3xwv6V31FKyNZYmrJWcmQWdpbWUIhs7eG3iHRIkCKPwFT0UUzAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsXxtpU+u+DNf0i0eJLnUNPuLSJpSQgeSNlBYgE4yRnANbVFAHK/bvG/8A0L3hv/wfT/8AyHR9u8bf9C94b/8AB9P/APIddVRTv5Acr9u8bf8AQveG/wDwfT//ACHR9u8bf9C94b/8H0//AMh11VFF/IDlft3jb/oXvDf/AIPp/wD5Do+3eNv+he8N/wDg+n/+Q66qii/kByv27xt/0L3hv/wfT/8AyHR9u8b/APQveG//AAfT/wDyHXVUUX8gPlj4c+LPi5N4u1O18P2C614bjvZY0e/mZ7eNBIRiK6ZUdwOgODx/CK9l8VGVvH3hY3CJHOdH1EyJG5dVbzbHIDEAkZ74GfQV6CqhVCqAFAwAOgFcF4y/5KN4b/7BWpf+jrGtIO80J7Hl3xWB/wCEl9vskOP++5a4iYfuJP8AdP8AKvRvi1b7dQ0+fHEsDxfijBh+jN+VefYGMHpXNiFaoz6rLJc2GVjc8GY+wX+B1Kn6jYtawHrXP+DLgQyXFrIcFo8fipwf0KmulVOOlOOwpaSYxV6VIqVPbQPcXEcMQzJIwUZPc0RGO4tku4CDBcs0ltjvb52xuevLhTJ/uyKMcGqS6mUqiUlHqzOktrm2vv7Q0pkS5KhZY5PuTAdM45BHrXSeF/FLXl4dPvYltL0nKxzyEh8/3X598A/melUFWqes6Yb61DREpdxfPC4ODn0/Hj8eawq4eM9epE4xluel20lxHPHJ5MZCsD8kyk8H3xWP4S2Wvh62sWOP7Pkn07kEACCZ4k590RCPYiq3hPWTrejpcOQLqJvLnAGOexx7j9c1oaNI1vrXiK2VsK1xBfIuP4JoFQ/XMlvMfxNcVPWE4NbWZwVIuE1f0IvF23/hGNUyRxA368D9a8pRefxzXoHji+UWd5bKQWkEdvgdyW8xvyVFz/viuBuJFgt5Zn4VELn8BV0FZXPZy5WhJs6GwBHwC8QZ6Gx1Ij6Ylr6IHWvBrm0ay+AeoQyArJ/YNzIwPq8Lv/7NXvI6168lZRR8xVfNUk/NjqKKKszCiiigAooooAKKKKACiiigBp60UHrRWD3YwooopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVwPjL/ko3hv/sFal/6Osa76uB8Zf8lG8N/9grUv/R1jV0/jQnsYHxG01tQ8NvLChe4sX+0ooGSygEOo+qFvxxXj6BWGUIZDyGHQj1r6I+oBHoa8N8UaG3hvX3s1GNPuSZrJvQfxR/VT09iKMVT+2j2cnxCi3Rl12MUM9pexXEX3twI9N3TB9mHH5V29lNHd26TQHMbDv1B7g+9ckYlkQqwyrDmn6XeXOm3SoD5kcjAFWOBJ2HP8L/oa5YStoz2K9Jv3kdtJAXtPsyO0cmoMbQSLw0cW0tPIPdYgwB/vunrViciadnVFjToka8KigYVR7AYA+lMgeOS7upRtzEpsLdSQW2q+bh+OzTKI/pbe9WFjz1rpemh5FJ87dTvt6Eap6VMkfrUiJ6Cp44/WpNWzI8LudP8AFmp6fj9zeILlPZsZP/s36V0V5L9i8S28yJvN5pcsWMgZeCVHRSewxczH2Ck1zVtc2p8bR3HnxLbQWjiSYn5QRnjPQ4yKsanqsetT2awRMLeK7SEO42l0uEktj8voXmhIzgkgcY68KhevJLqjHEQckpdrX/I5/Vrs395uWYzRR52yYwHY8u4HoTgD/ZVaoGwbVr+w0hOt7KBJ/sxL8zn8hj8amdkijZ5GCRoCWY9ABXYfDPRmCS6/eRlZrtNlqjdY4OoPsWPP0xW+HpczS6I9LGVY4PD8sd3ojW+JCqvw38UKg2quk3QAHYCFsCvWR1ryf4lf8k58Vf8AYKuv/RLV6wOtd9bdHyiHUUUUAFFFFABRRRQAUUUUAFFFFADT1ooPWisHuxhRRRSAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArgfGX/JRvDf8A2CtS/wDR1jXfVwPjL/ko3hv/ALBWpf8Ao6xq6fxoT2LVZXiTQ7XxBpUljeAjPzRyr96Jx0ZT/nI4rVorravoxRk4u6PBb+zvNI1I6dq0apdAbo5F+5cL/eQ/zHUVo6RFKm66tgpulZIrQOMqbhztjJ9lOZD/ALMbV6zrej2OuWDWmpwLNCeQejIf7yt1B9689u9Gu9JF7Dpsd3qselfumdVXzPOnjDM2P4jHbsi8cn7S3HFcUsPyS5lse7DNPa0vZS0k9L9PUwNRGy5WPTnMllbIsECXBbOxRtDBgQys2NxIPJJJzU0Or30CgB7zjs3l3C/mdrfnmqMF3BO5jWQCUcNG+UdT/unkVbCk9a5ueSZ7Cw1JxSjsWx4iviCAJgf9mzUH/wAekxUM99fXQ+YMR/08yblH/bNAF/PNIq46cmnHCgs5CqO54o52wWEprWxCsG6QSTu08oGAz4+UeigcKPYVcBkTT9T8kZmW0kniX+9JDieMfi8S1Utrhr6byNHtptRuOmLcZRf95z8qj8a7rwt4Pkhu4bvxFLHM6sGW0gyIo/8Aebq5x9B7HrV0qcpSujlx2KoU6UqberWyMyx8LtrXiCe5uo9nh+Gdnhjbrec5Ukdo+n+99K9FrG8FmQeEdJhmJM1pCbGQnqXt2aBs++YjmtqvQpwUFofNV8ROvLmmzm/iV/yTnxV/2Crv/wBEtXrA615P8Sv+Sc+Kv+wVd/8Aolq9YHWoq7oyQ6iiigAooooAKKKKACiiigAooooAaetFB60Vg92MKKKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcD4y/5KN4b/AOwVqX/o6xrvq4Hxl/yUbw3/ANgrUv8A0dY1dP40J7FqiuI8S+PovD/jCPRbuwY2z2aXH23zcKsrtIscbLjgMYiA2erKMc5q5pnjfTbjTtCuL9Lqyl1aC3ljBtpnhV5lBWPzwnl5ycckfQZrruSdXWTon/IV8Vf9hWP/ANNtjWd/wnXh8iIrd3DiaRoYillOwlkUOSiEJ8zDy2+UZPQfxLmJfG3hi2k1CT7XJF80lxcSm0mCSNFGqSFW2YdkSNQQpJGzkcGhgbuq6Ppurx7NUsLa7HYyxgkfQ9RXOzfDrQWJNt/aFp7QXbhfybIrZvPEujWbBZ9Rtwd0iMUbeEKRmR95GQmEGctjt6jNFPHOgPBJKLm5Uo8cfkvYzrM7SBimyIpvfcFYgqCDtPoaTjGW6NIValP4ZNGePhzpufn1PWWX0+0gfyWrtn4C8OW7q72Bu3XkNeStN+jHH6VZ8C63N4i8NxalcRrG8lxcxhVjaPCxzyRrlW5B2oMg988DpXQUlTgtUi5YmtJWlJ/eMhjjhiWOFEjiXoiKFA+gFPrgZ/HlzDqtzA+lwLZR6i+lpOLstK0wi8wMYtgGznBIckelX9D8bWc2i+HZtYM1veara2sm5LKf7P5syKQgl2lBljgAtnpVXRgbPhb/AJBVx/2FdV/9OVzWtXIR+OvC1ossaXcsUIM9z5n2OcRSEzZmdH2bX/eS87SeWrS1DxXo9hPcQXFzIbiCZLd4YbeWWQyMnmBVRFJf5Pm+UHAznGKFogIPiV/yTnxV/wBgq7/9EtXrA6147421C11T4VeJL2wlEttNpF2yPgjP7pwcg4IIOQQeQa9iHWsau6KQ6iiigAooooAKKKKACiiigAooooAaetFB60Vg92MKKKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcD4y/wCSjeG/+wVqX/o6xrvq4Hxl/wAlG8N/9grUv/R1jV0/jQnsYfiLwXpXiCfU5NS89/7QsE06VAwCqiu7q68cOGcnJyOBx64Z+FGiG80y4N3fk6etosIYQOf9HChPnMZdchBuCMoPPFehV5/8VdW8QafHbR+GotUE7QyuJbWESxlxjajgW8zZJ6f6tcZy44rrdiTfsvCdjZroqxS3JGk3E1zBuZfmaVZFYN8vIxK2MY6Dr3pQ+BNNS4Jkur6eyU3DQ2MjoYITOGEpXChjkO/DMwG44xXIeIofFOveHvEDXc+qW8cEllJb2dtZJmQeVbyS43Rsz7X8wgLyCpBz90SjV/GH/CYWsFvNfnR/OthFLd2Mi/aYSF80yhLQ7HyXHLxBcDK45IB0Vn8NdBt0VG+1zr/Z0mmyCWXPmrISXkbAH7w7mG4Y4P0xFp/wz0vTrdUsLy6tZ4547iG5t7a0hlidFdRykADgrI4O8N17c1kTav4r0Xwppev3tzc3t1K/kXGly28UOXk3JDtG0OG8wx5ycYLHAxXo2kQ3dvpVpDqNz9rvUiVZ59oXzHx8zAAAAE54xRoBW8M6LD4e0ePTraa4njSSWXzJypdmkkaRiSAB95z2rVoopgc7YeDtGstS1PUUtI31G/leWS7kjQzR70ClEfbkLgdMnkmufPwo0Q3mmXBu78nT1tFhDCBz/o4UJ85jLrkINwRlB54r0KilYDzi6+GUUt7aW/8AaN3JoUdld2gt5HQPbea8TJ5JWMcAoeXLEYXqM1cv/hnpWpR3B1O+v727mukuzc3KW8jB1j8v7hi8sjb2KH1GCBXd0UWQHF+LNKg0T4R+IdOtMeTBpF2FIijizmJyTtjVUHJPRRXtA615P8Sv+Sc+Kv8AsFXf/olq9YHWsau6KQ6iiigAooooAKKKKACiiigAooooAaetFOoxWbhdjG0U7FGKXIFxtFOxRijkC42inYoxRyBcbRTsUYo5AuNop2KMUcgXG0U7FGKOQLjaKdijFHIFxtFOxRijkC42inYoxRyBcbRTsUYo5AuNop2KMUcgXG0U7FGKOQLjaKdijFHIFxtFOxRijkC42inYoxRyBcbXNeKfCaa/qOn36atqWmXdlFNAj2QhO9JTGzBhLG46wpgjHeunxRimoNapgcL/AMIHd/8AQ6+JP+/Vh/8AItL/AMIHd/8AQ6+JP+/Vh/8AItdzijFV73cRw3/CB3f/AEOviT/v1Yf/ACLR/wAIHd/9Dr4k/wC/Vh/8i13OKMUe93A8/uPhy9yYTc+LtfmMMgljMkGntscZAZc2vB5PI9an/wCEDu/+h18Sf9+rD/5FrucUYo97uBw3/CB3f/Q6+JP+/Vh/8i0f8IHd/wDQ6+JP+/Vh/wDItdzijFHvdwOG/wCEDu/+h18Sf9+rD/5Fo/4QO7/6HXxJ/wB+rD/5FrucUYo97uBw3/CB3f8A0OviT/v1Yf8AyLR/wgd3/wBDr4k/79WH/wAi13OKMUe93A891P4avqem3VhfeMfEktpdRPBNHssV3IwKsMi2yMgnkV6AOtOxRS5W3dsAoooqwCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Atherosclerosis is a condition in which fatty deposits called \"plaques\" build up in the lining of the blood vessels. As plaques get bigger, the blood vessels get narrow. This means the blood vessels cannot carry as much blood as before.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: What Is Atherosclerosis? National Heart, Lung, and Blood Institute. Available at file://www.nhlbi.nih.gov/health/health-topics/topics/atherosclerosis/.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_15_27891=[""].join("\n");
var outline_f27_15_27891=null;
var title_f27_15_27892="ECG early repolarization tutorial";
var content_f27_15_27892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Electrocardiogram (ECG) in early repolarization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 128px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    J point and ST segment elevation is most prominent in V4 to V6. The ST segment maintains its normal configuration and is slightly concave.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_15_27892=[""].join("\n");
var outline_f27_15_27892=null;
var title_f27_15_27893="Epithelial thymoma Low";
var content_f27_15_27893=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55619&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Predominantly epithelial, polygonal cell-type thymoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The epithelial cells tend to assume a plump, oval, configuration with eosinophilic cytoplasm and uniform, small nuclei. Perivascular spaces are filled by pale eosinophilic fluid and scattered foamy macrophages and lymphocytes. (Hematoxylin and eosin, magnification x 50).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Travis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_15_27893=[""].join("\n");
var outline_f27_15_27893=null;
var title_f27_15_27894="Syndrome of transient headache and neurologic deficits with cerebrospinal fluid lymphocytosis (HaNDL)";
var content_f27_15_27894=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Syndrome of transient headache and neurologic deficits with cerebrospinal fluid lymphocytosis (HaNDL)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/15/27894/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/15/27894/contributors\">",
"     Christine L Lay, MD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/15/27894/contributors\">",
"     Christina Sun-Edelstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/15/27894/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/15/27894/contributors\">",
"     Jerry W Swanson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/15/27894/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/15/27894/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/15/27894/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H267391202\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome of transient headache and neurologic deficits with cerebrospinal fluid lymphocytosis (HaNDL) is a self-limited, benign entity that was first clearly characterized in 1981 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/1\">",
"     1",
"    </a>",
"    ], when it was called a migrainous syndrome with cerebrospinal fluid (CSF) pleocytosis. It was given its current name in 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/2\">",
"     2",
"    </a>",
"    ], and has also been referred to as pseudomigraine with temporary neurologic symptoms and lymphocytic pleocytosis (PMP syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/3\">",
"     3",
"    </a>",
"    ]. As the name implies, HaNDL is characterized by one or more episodes of severe headache, transient neurologic deficits, and lymphocytic pleocytosis in the CSF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267393098\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise etiology of HaNDL is not yet fully understood. Though some initially speculated that the syndrome represented a severe migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], others favored an inflammatory or infectious origin, given the CSF lymphocytosis, frequent viral prodrome, and monophasic course [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, despite extensive viral serological evaluation, there are few reports confirming a viral association. In one early case, echovirus 30 was isolated using cell tissue cultures from a patient with an illness resembling HaNDL [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/6\">",
"     6",
"    </a>",
"    ]. In another case of HaNDL, serologic evidence of human herpesvirus 6 infection was detected by an elevated titer of IgM at presentation that gradually decreased to normal range by four weeks after admission [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Findings on single-photon emission computed tomography (SPECT), perfusion imaging with CT and MRI, transcranial Doppler, and electrophysiology studies of patients with HaNDL are suggestive of a migrainous pathophysiology:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SPECT studies have demonstrated focal or widespread areas of decreased blood flow on the side of origin of the neurologic deficits [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/8-11\">",
"       8-11",
"      </a>",
"      ], suggestive of the spreading depression-like mechanism similar to that proposed for migraine.",
"     </li>",
"     <li>",
"      Head CT perfusion scan showed decreased and delayed perfusion involving an entire hemisphere in a patient with HaNDL [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/12\">",
"       12",
"      </a>",
"      ], while MRI perfusion-weighted imaging showed focal parieto-occipital hypoperfusion involving another patient with HaNDL [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/13\">",
"       13",
"      </a>",
"      ]. In both cases, areas of reduced perfusion correlated with the neurologic deficits.",
"     </li>",
"     <li>",
"      Transcranial Doppler in two patients showed asymmetrical fluctuations in middle cerebral arterial blood flow velocity and pulsatility, indicative of intracranial vasomotor changes [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/14\">",
"       14",
"      </a>",
"      ], resembling those seen in patients with migraine [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/15,16\">",
"       15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormalities on single-fiber electromyography and visual evoked potentials in a 16-year-old girl with HaNDL were similar to those found in patients suffering from migraine with aura [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the findings suggestive of a migrainous pathophysiology, HaNDL is still thought to have a viral or inflammatory etiology. Most likely, a viral infection results in production of antibodies against neuronal or vascular antigens, inducing an aseptic leptomeningeal vasculitis and subsequently headache and neurologic deficits via a spreading depression-like mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/8,14,18\">",
"     8,14,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=see_link&amp;anchor=H130649634#H130649634\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\", section on 'Cortical spreading depression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the symptoms of HaNDL may resemble those of familial hemiplegic migraine, a heteroduplex analysis and DNA sequencing of the CACNA1A gene associated with familial hemiplegic migraine type 1 failed to identify any CACNA1A mutations in eight patients with HaNDL, and therefore did not support a role of the CACNA1A gene in HaNDL [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/60/17354?source=see_link&amp;anchor=H81876416#H81876416\">",
"     \"Hemiplegic migraine\", section on 'Familial hemiplegic migraine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267391216\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HaNDL is a rare condition that is most often seen during the third and fourth decades of life, though cases ranging from age 7 to 52 years have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. Only a minority of patients had a prior history of migraine or family history of migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/1,2,8\">",
"     1,2,8",
"    </a>",
"    ]. A preceding viral illness that may include cough, rhinitis, diarrhea, or generalized fatigue has been reported in 25 to 40 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. No consistent gender predominance has been found for HaNDL; in the two largest reports, men accounted for 44 and 68 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/2,8\">",
"     2,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343993487\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HaNDL is characterized by transient episodes of severe headache and neurologic deficits associated with a lymphocytic pleocytosis in the CSF. The most frequent neurologic symptoms associated with HaNDL are hemiparesis, hemisensory disturbances, and aphasia. Visual signs and symptoms are less common, but may include decreased vision, homonymous hemianopsia, and photopsias [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. Papilledema and sixth nerve palsy have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, some patients with HaNDL have an elevated CSF opening pressure as described below. (See",
"    <a class=\"local\" href=\"#H267391237\">",
"     'Lumbar puncture'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Neurologic symptoms generally last 15 to 120 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/1\">",
"     1",
"    </a>",
"    ], though a range of five minutes to three days has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/8\">",
"     8",
"    </a>",
"    ]. Although HaNDL is considered a monophasic disorder, most patients (approximately 75 percent) have repeated attacks of transient headache and neurologic deficits that occur for weeks or even months following the initial attack [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/2\">",
"     2",
"    </a>",
"    ]. The neurologic deficits often vary from one episode to the next, involving different brain regions. In the two largest reports, the mean duration of the illness was 14 and 21 days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/2,8\">",
"     2,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The headache of HaNDL is moderate to severe, and is usually throbbing in quality. It may be unilateral or bilateral, and can last from one hour to one week, but typically lasts for hours. Often it is associated with nausea and vomiting, and not infrequently with photophobia. Fever was noted in 22 to 33 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/1,2,8\">",
"     1,2,8",
"    </a>",
"    ]. Usually, the headache follows the onset of neurologic symptoms by 15 to 60 minutes, but on occasion the headache occurs first [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267393492\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;HaNDL is included in the second edition of the International Classification of Headache Disorders (ICHD-II), and classified as a \"Headache attributed to nonvascular intracranial disorder\" [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/20\">",
"     20",
"    </a>",
"    ]. The diagnostic criteria are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A) Episodes of moderate or severe headache lasting hours before resolving fully and fulfilling criteria C and D",
"     </li>",
"     <li>",
"      B) Cerebrospinal fluid (CSF) pleocytosis with lymphocytic predominance (&gt;15",
"      <span class=\"nowrap\">",
"       cells/mL)",
"      </span>",
"      and normal neuroimaging, CSF culture, and other tests for etiology",
"     </li>",
"     <li>",
"      C) Episodes of headache are accompanied by or shortly follow transient neurologic deficits, and commence in close temporal relation to the development of CSF pleocytosis",
"     </li>",
"     <li>",
"      D) Episodes of headache and neurologic deficits recur over less than three months",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343993929\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;HaNDL is a diagnosis of exclusion. Given the onset of severe headache and neurologic symptoms, especially in patients lacking a prior history of headache, an extensive work-up is usually prompted at presentation in order to exclude serious conditions such as stroke, other structural brain lesions, meningitis, and seizures. In particular, it is important to rule out treatable entities including Lyme borreliosis, neurosyphilis, human immunodeficiency virus meningitis, encephalitis, and vasculitis of the central nervous system. Thus, a complete evaluation should be obtained when HaNDL is suspected, including brain MRI, electroencephalogram, and angiography.",
"   </p>",
"   <p>",
"    HaNDL can be distinguished from Mollaret meningitis (also known as recurrent benign lymphocytic meningitis) by the presence of neurologic deficits, the absence of meningismus, and the lack of Mollaret cells in the CSF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15417?source=see_link&amp;anchor=H7#H7\">",
"     \"Aseptic meningitis in adults\", section on 'Recurrent (Mollaret's) meningitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HaNDL can be differentiated from familial or sporadic forms of hemiplegic migraine by the presence of CSF lymphocytic pleocytosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/60/17354?source=see_link\">",
"     \"Hemiplegic migraine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267391237\">",
"    <span class=\"h2\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the defining features of HaNDL is a cerebrospinal fluid (CSF) lymphocytic pleocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. In addition, the CSF opening pressure is often elevated and increased protein is common. In the largest series of 50 patients, the mean CSF nucleated cell count was 199",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    (range 10-760",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    with a lymphocytic predominance in all patients of &gt;65 percent of the total cell count, and a lymphocytic predominance in most patients of &gt;90 percent in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/8\">",
"     8",
"    </a>",
"    ]. The CSF protein was elevated in 48 patients (96 percent), with a mean protein of 94",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (range 20-250",
"    <span class=\"nowrap\">",
"     mg/dL).",
"    </span>",
"    In 18 cases where it was measured, the CSF opening pressure was elevated in 10 (56 percent) and ranged between 180 and 370 mmH",
"    <sub>",
"     2",
"    </sub>",
"    O. The CSF glucose was normal in all 50 patients.",
"   </p>",
"   <p>",
"    Although data are limited, it appears that the CSF abnormalities associated with HaNDL resolve slowly over several months. In a series of eight patients with HaNDL who had serial lumbar punctures during and after clinically symptomatic periods, the CSF findings of elevated white blood cell count and lymphocytosis gradually improved but persisted long after the resolution of clinical symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/21\">",
"     21",
"    </a>",
"    ]. At an average follow-up of 99 days (range 56-196), all patients still had CSF lymphocytic pleocytosis, with CSF cell counts in the range of 25 to 67",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"   </p>",
"   <p>",
"    Bacterial, viral, and fungal studies from CSF and blood are negative in HaNDL [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few data regarding CSF IgG levels or oligoclonal bands. In the largest series of 50 patients, IgG was measured in 20, and was increased in 4 patients (20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/8\">",
"     8",
"    </a>",
"    ]. Oligoclonal bands were not found in 18 patients who were tested for them, including those with elevated CSF IgG levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267391244\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Though normal neuroimaging is a criterion for this syndrome, nonspecific abnormalities are occasionally seen on routine head CT or conventional MRI, such as small areas of high signal unrelated to the clinical symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/2,5,8\">",
"     2,5,8",
"    </a>",
"    ]. Although data are limited, brain MRI with gadolinium at admission in a patient with HaNDL revealed diffuse leptomeningeal enhancement that resolved on repeat imaging four weeks later [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/7\">",
"     7",
"    </a>",
"    ]. In other case reports, CT or MRI perfusion techniques have demonstrated global hemispheric or focal regions of hypoperfusion that correlated with neurologic deficits in acutely symptomatic patients with HaNDL [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. In at least one case, diffusion-weighted brain MRI was normal during an acute episode of HaNDL [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial neurovascular imaging for cases of suspected HaNDL should be obtained using MRA or CTA. In the majority of HaNDL cases, conventional cranial angiography is normal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. In one study of HaNDL with 12 patients who underwent angiography, the findings were normal in 11 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/8\">",
"     8",
"    </a>",
"    ]. The one abnormal angiogram showed irregularities suggestive of inflammation in the walls of small cranial arteries in the clinically symptomatic area. In several instances, attacks of HaNDL have been precipitated by angiography [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/1,2,20\">",
"     1,2,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these data, conventional catheter angiography should be considered only in cases where CTA or MRA are normal and there is high suspicion for an alternative diagnosis to HaNDL. Conventional angiography remains the gold standard for diagnosing central nervous system vasculitis, an important differential diagnosis to consider when evaluating patients with headache and focal neurologic symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267391251\">",
"    <span class=\"h2\">",
"     Electroencephalography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electroencephalogram (EEG) done during the symptomatic period in HaNDL is usually abnormal. Unilateral excessive slowing corresponding to the clinical symptoms is often seen, with bilateral slowing occurring less frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/1,2,8\">",
"     1,2,8",
"    </a>",
"    ]. In the largest series with EEG obtained for 42 patients, clear EEG abnormalities were present in 30 (71 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27894/abstract/8\">",
"     8",
"    </a>",
"    ]. The EEG changes disappear after the symptomatic period. Epileptiform abnormalities have",
"    <strong>",
"     not",
"    </strong>",
"    been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267391265\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the self-limited nature of the HaNDL syndrome and the favorable outcome noted in reported patients, therapeutic interventions other than symptomatic treatment of the headache are largely unnecessary. However, education and reassurance about this disorder are important because of the likelihood of further alarming attacks involving transient headache and neurologic deficits that can occur for weeks or even months following the initial attack. These recurrences will almost require emergent evaluation. For patients with a secure diagnosis of HaNDL who present with a characteristic attack within three months of the initial attack, it may be reasonable to limit investigations to a head scan with CT or MRI for each attack and a lumbar puncture for the second attack, though not for subsequent attacks. In the authors&rsquo; clinical experience, these investigations are usually required to reassure the treating physician that the presentation is indeed HaNDL and not a coincident secondary etiology such as infarction or central nervous system infection. However, more extensive repeat testing will likely be needed when the diagnosis of HaNDL is not well-established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267391272\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The syndrome of transient headache and neurologic deficits with cerebrospinal fluid lymphocytosis (HaNDL) is a self-limited condition. As the name implies, HaNDL is characterized by one or more episodes of severe headache, transient neurologic deficits, and lymphocytic pleocytosis in the cerebrospinal fluid (CSF). (See",
"      <a class=\"local\" href=\"#H267391202\">",
"       'Introduction and definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The precise etiology of HaNDL remains elusive. Despite the findings suggestive of a migrainous pathophysiology, HaNDL is still thought to have a viral or inflammatory etiology. (See",
"      <a class=\"local\" href=\"#H267393098\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most frequent neurologic symptoms associated with HaNDL are hemiparesis, hemisensory disturbances, and aphasia. The headache of HaNDL is moderate to severe, and usually throbbing in quality. Many patients have repeated episodes over the duration of the illness, which typically lasts for two to three weeks after onset, but may continue for up to three months. (See",
"      <a class=\"local\" href=\"#H343993487\">",
"       'Clinical features and diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H267393492\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Though HaNDL is a self-limited syndrome, a thorough evaluation should be performed to rule out more sinister etiologies. (See",
"      <a class=\"local\" href=\"#H343993929\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      One of the defining features of HaNDL is a CSF lymphocytic pleocytosis. In addition, the CSF opening pressure is often elevated and increased CSF protein is common. (See",
"      <a class=\"local\" href=\"#H267391237\">",
"       'Lumbar puncture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Though normal neuroimaging is a criterion for HaNDL, nonspecific abnormalities are occasionally seen on routine head CT or conventional MRI. In the majority of cases, conventional cranial angiography is normal. (See",
"      <a class=\"local\" href=\"#H267391244\">",
"       'Neuroimaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Electroencephalography done during the symptomatic period in HaNDL is usually abnormal; unilateral slowing corresponding to the clinical symptoms is often seen. (See",
"      <a class=\"local\" href=\"#H267391251\">",
"       'Electroencephalography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the diagnosis of HaNDL is established, treatment of the syndrome consists essentially of symptomatic headache management. For patients with a secure diagnosis of HaNDL who present with a characteristic attack within three months of the initial attack, it may be reasonable to limit investigations to a head scan with CT or MRI for each attack and a lumbar puncture for the second attack, though not for subsequent attacks. However, more extensive repeat testing will likely be needed when the diagnosis of HaNDL is not well-established. (See",
"      <a class=\"local\" href=\"#H267391265\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27894/abstract/1\">",
"      Bartleson JD, Swanson JW, Whisnant JP. A migrainous syndrome with cerebrospinal fluid pleocytosis. Neurology 1981; 31:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27894/abstract/2\">",
"      Berg MJ, Williams LS. The transient syndrome of headache with neurologic deficits and CSF lymphocytosis. Neurology 1995; 45:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27894/abstract/3\">",
"      Morrison DG, Phuah HK, Reddy AT, et al. Ophthalmologic involvement in the syndrome of headache, neurologic deficits, and cerebrospinal fluid lymphocytosis. Ophthalmology 2003; 110:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27894/abstract/4\">",
"      Day TJ, Knezevic W. Cerebrospinal-fluid abnormalities associated with migraine. Med J Aust 1984; 141:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27894/abstract/5\">",
"      Walter CT, Grogan WA. Migraine with tardy pleocytosis. Neurology 1986; 36:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27894/abstract/6\">",
"      Castels-van Daele M, Standaert L, Boel M, et al. Basilar migraine and viral meningitis. Lancet 1981; 1:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27894/abstract/7\">",
"      Emond H, Schnorf H, Poloni C, et al. Syndrome of transient headache and neurological deficits with CSF lymphocytosis (HaNDL) associated with recent human herpesvirus-6 infection. Cephalalgia 2009; 29:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27894/abstract/8\">",
"      G&oacute;mez-Aranda F, Ca&ntilde;adillas F, Mart&iacute;-Mass&oacute; JF, et al. Pseudomigraine with temporary neurological symptoms and lymphocytic pleocytosis. A report of 50 cases. Brain 1997; 120 ( Pt 7):1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27894/abstract/9\">",
"      Caminero AB, Pareja JA, Arpa J, et al. Migrainous syndrome with CSF pleocytosis. SPECT findings. Headache 1997; 37:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27894/abstract/10\">",
"      Fuentes B, Diez-Tejedor E, Frank A. Syndrome of headache with neurological deficits and CSF lymphocytosis: a spreading depression mechanism? The role of SPECT. Headache 1998; 38:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27894/abstract/11\">",
"      Fuentes B, Diez Tejedor E, Pascual J, et al. Cerebral blood flow changes in pseudomigraine with pleocytosis analyzed by single photon emission computed tomography. A spreading depression mechanism? Cephalalgia 1998; 18:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27894/abstract/12\">",
"      Pettersen JA, Aviv RI, Black SE, et al. Global hemispheric CT hypoperfusion may differentiate headache with associated neurological deficits and lymphocytosis from acute stroke. Stroke 2008; 39:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27894/abstract/13\">",
"      Yilmaz A, Kaleagasi H, Dogu O, et al. Abnormal MRI in a patient with 'headache with neurological deficits and CSF lymphocytosis (HaNDL)'. Cephalalgia 2010; 30:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27894/abstract/14\">",
"      Kappler J, Mohr S, Steinmetz H. Cerebral vasomotor changes in the transient syndrome of headache with neurologic deficits and CSF lymphocytosis (HaNDL). Headache 1997; 37:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27894/abstract/15\">",
"      Thie A, Fuhlendorf A, Spitzer K, Kunze K. Transcranial Doppler evaluation of common and classic migraine. Part II. Ultrasonic features during attacks. Headache 1990; 30:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27894/abstract/16\">",
"      Totaro R, De Matteis G, Marini C, Prencipe M. Cerebral blood flow in migraine with aura: a transcranial Doppler sonography study. Headache 1992; 32:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27894/abstract/17\">",
"      Fumal A, Vandenheede M, Coppola G, et al. The syndrome of transient headache with neurological deficits and CSF lymphocytosis (HaNDL): electrophysiological findings suggesting a migrainous pathophysiology. Cephalalgia 2005; 25:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27894/abstract/18\">",
"      Pascual J, Valle N. Pseudomigraine with lymphocytic pleocytosis. Curr Pain Headache Rep 2003; 7:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27894/abstract/19\">",
"      Chapman KM, Szczygielski BI, Toth C, et al. Pseudomigraine with lymphocytic pleocytosis: a calcium channelopathy? Clinical description of 10 cases and genetic analysis of the familial hemiplegic migraine gene CACNA1A. Headache 2003; 43:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27894/abstract/20\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27894/abstract/21\">",
"      Toth CC. Persistent cerebrospinal fluid abnormalities in the syndrome of headache, neurological deficit, and cerebrospinal fluid lymphocytosis despite resolution of clinical symptomatology. Headache 2002; 42:1038.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14114 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.22.229.50-9649136F8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_15_27894=[""].join("\n");
var outline_f27_15_27894=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H267391272\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H267391202\">",
"      INTRODUCTION AND DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H267393098\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H267391216\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H343993487\">",
"      CLINICAL FEATURES AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H267393492\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H343993929\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H267391237\">",
"      Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H267391244\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H267391251\">",
"      Electroencephalography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H267391265\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H267391272\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/3/15417?source=related_link\">",
"      Aseptic meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/60/17354?source=related_link\">",
"      Hemiplegic migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_15_27895="Digoxin immune Fab: Drug information";
var content_f27_15_27895=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Digoxin immune Fab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/11/1207?source=see_link\">",
"    see \"Digoxin immune Fab: Pediatric drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/56/31619?source=see_link\">",
"    see \"Digoxin immune Fab: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F160237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DigiFab&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F160238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      DigiFab&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F160256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F160240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Each vial of DigiFab&trade; 40 mg will bind ~0.5 mg of digoxin or digitoxin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Estimation of the dose is based on the body burden of digitalis. This may be calculated if the amount ingested is known or the post-distribution serum drug level is known (round the dose up to the nearest whole vial). If the amount ingested is unknown, general dosing guidelines should be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute ingestion of unknown amount:",
"     </b>",
"     I.V.: 20 vials is adequate to treat most life-threatening ingestions. May give as a single dose or give 10 vials, observe the response, and give a second dose of 10 vials if indicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute ingestion of known amount:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Based on number of tablets or capsules ingested:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Step 1: Calculate total body load (mg)",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Digoxin capsules",
"      <b>",
"       or",
"      </b>",
"      digitoxin:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Total body load (mg) = Amount (mg) digoxin capsules",
"     <b>",
"      or",
"     </b>",
"     digitoxin ingested",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <i>",
"      Digoxin tablets:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Total body load (mg) = 0.8 x (amount [mg] digoxin tablets ingested)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Step 2: Calculate number of vials needed",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Digoxin Immune Fab Dose (vials) = Total body load (mg) / (0.5)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Alternatively,",
"     </b>",
"     the following table gives an estimation of the number of vials needed based on the number of",
"     <b>",
"      digoxin",
"     </b>",
"     tablets or capsules ingested.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <thead valign=\"top\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Number of Digoxin Tablets or Capsules Ingested",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dose of Digoxin Immune Fab",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (# of Vials)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"top\">",
"      <tr>",
"       <td align=\"left\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         250 mcg tablets with 80% bioavailability or 200 mcg capsules with 100% bioavailability.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         30",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         40",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         150",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         200",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         80",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Based on steady-state serum",
"      <span style=\"text-decoration: underline\">",
"       digoxin",
"      </span>",
"      concentration:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Digoxin Immune Fab Dose (vials) = (serum digoxin concentration [ng/mL] x weight [kg]) / 100",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Alternatively,",
"     </b>",
"     the following table gives an estimation of the number of vials needed based on the steady-state serum digoxin concentration.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Adult Dose Estimates of DigiFab&trade; (in # of Vials) From Steady-State Serum Digoxin Concentration",
"     </caption>",
"     <col align=\"center\" width=\"75\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <thead valign=\"bottom\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Patient Weight (kg)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"7\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Serum Digoxin Concentration (ng/mL)",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         12",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         16",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         40",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.5 vial",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1 vial",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         5 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         7 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         8 vials",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         60",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.5 vial",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1 vial",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         5 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         7 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         10 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         12 vials",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         70",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1 vial",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         6 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         9 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         11 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         14 vials",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         80",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1 vial",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         7 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         10 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         13 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         16 vials",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         100",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1 vial",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         4 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         8 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         12 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         16 vials",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         20 vials",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Based on steady-state",
"      <span style=\"text-decoration: underline\">",
"       digitoxin",
"      </span>",
"      concentration:",
"     </b>",
"     If the calculated dose based on the digitoxin concentration is different than that for the digoxin concentration, use the higher dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Digoxin Immune Fab Dose (vials) = [serum",
"     <b>",
"      digitoxin",
"     </b>",
"     concentration (ng/mL) x weight (kg)] / 1000",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic toxicity (serum digoxin concentration unavailable):",
"     </b>",
"     I.V.: Adults: 6 vials is adequate to reverse most cases of toxicity",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F160250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/11/1207?source=see_link\">",
"      see \"Digoxin immune Fab: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Each vial of DigiFab&trade; 40 mg will bind ~0.5 mg of digoxin or digitoxin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Estimation of the dose is based on the body burden of digitalis. This may be calculated if the amount ingested is known or the post-distribution serum drug level is known (round the dose up to the nearest whole vial). If the amount ingested is unknown, general dosing guidelines should be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute ingestion of unknown amount:",
"     </b>",
"     I.V.: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute ingestion of known amount:",
"     </b>",
"     I.V.: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Based on steady-state serum",
"      <span style=\"text-decoration: underline\">",
"       digoxin",
"      </span>",
"      concentration:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children &le;20 kg: May require smaller doses; calculate the dose in milligrams (mg), consider dilution of the reconstituted vial with NS, and administer the dose via a tuberculin syringe.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Digoxin Immune Fab Dose (mg) = [(serum digoxin concentration [ng/mL] x weight [kg]) / 100] x (digoxin immune Fab amount per vial [mg/vial])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <b>",
"      <i>",
"       Note:",
"      </i>",
"     </b>",
"     Digoxin immune Fab amount per vial: 40 mg/vial.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Alternatively,",
"     </b>",
"     the following table gives an estimation of the amount of",
"     <b>",
"      DigiFab&trade;",
"     </b>",
"     needed based on the steady-state serum digoxin concentration.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Infants and Small Children Dose Estimates of DigiFab&trade; (in mg) From Steady-State Serum Digoxin Concentration",
"     </caption>",
"     <col align=\"center\" width=\"62\">",
"     </col>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <col align=\"center\" width=\"60\">",
"     </col>",
"     <thead valign=\"bottom\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Patient Weight",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (kg)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"7\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Serum Digoxin Concentration (ng/mL)",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         12",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         16",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"top\">",
"      <tr>",
"       <td align=\"left\" colspan=\"8\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Dilution of reconstituted vial to 1 mg/mL may be desirable.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.4 mg",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1 mg",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1.5 mg",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3 mg",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         5 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         6.5 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         8 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         1 mg",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2.5 mg",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         5 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         10 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         14 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         19 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         24 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2 mg",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         4 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         8 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         16 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         24 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         32 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         40 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         4 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         8 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         16 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         32 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         48 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         64 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         80 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         8 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         16 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         32 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         64 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         96 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         128 mg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         160 mg",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">",
"     Children &gt;20 kg: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Based on steady-state",
"      <span style=\"text-decoration: underline\">",
"       digitoxin",
"      </span>",
"      concentration:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic toxicity (serum digoxin concentration unavailable):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children &le;20 kg: 1 vial is adequate to reverse most cases of toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &gt;20 kg: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F160241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F160242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary; however, use with caution since digoxin-digoxin immune Fab complex is renally eliminated. Patients should undergo prolonged monitoring for recurrence of toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15796118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F160219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [ovine derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DigiFab&reg;: 40 mg [derived from or manufactured using papain]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F160203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F160222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. infusion over at least 30 minutes is preferred. May also be given by bolus injection if cardiac arrest is imminent (infusion-related reaction may occur). Small doses (eg, those required in infants or small children) may be administered using a tuberculin syringe as undiluted digoxin immune Fab or diluted with NS to a concentration of 1 mg/mL digoxin immune Fab. Stopping the infusion and restarting at a slower rate may help if an infusion-related reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F160220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of life-threatening or potentially life-threatening digoxin intoxication, including:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &bull; acute digoxin ingestion (ie, &gt;10 mg in adults; &gt;0.1 mg/kg or &gt;4 mg in children; ingestions resulting in serum concentrations &gt;10 ng/mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &bull; chronic ingestions leading to steady-state digoxin concentrations &gt;6 ng/mL in adults or &gt;4 ng/mL in children",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &bull; manifestations of digoxin toxicity due to overdose (eg, life-threatening ventricular arrhythmias, progressive bradycardia, second- or third-degree heart block not responsive to atropine, serum potassium &gt;5.5 mEq/L in adults or &gt;6 mEq/L in children)",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F160254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Heart failure exacerbation (due to withdrawal of digoxin), orthostatic hypotension, rapid ventricular response (patients with atrial fibrillation; due to withdrawal of digoxin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, serum sickness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F160225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F160207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Digoxin immune Fab is derived from ovine (sheep) Fab immunoglobulin fragments; hypersensitivity reactions (eg, anaphylactic or anaphylactoid reactions, delayed allergic reactions) are possible.  Patients with allergies to sheep proteins and patients with prior exposure to ovine antibodies or ovine Fab may be at a higher risk for hypersensitivity reactions.  In patients who develop an anaphylactic reaction, discontinue the infusion and administer emergency care. Immediate treatment (eg, epinephrine 1:1000, corticosteroids, diphenhydramine) should be available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Processed with papain and may cause hypersensitivity reactions in patients allergic to papaya, other papaya extracts, papain, chymopapain, or the pineapple-enzyme bromelain. There may also be cross allergenicity with dust mite and latex allergens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     &bull; Potassium imbalance: Patients experiencing acute digitalis toxicity may present with significant hyperkalemia due to shifting of potassium into the extracellular space. Upon treatment with digoxin immune Fab, potassium shifts back into the intracellular space and may result in hypokalemia.  Monitor potassium closely, especially during the first few hours after administration; treat hypokalemia cautiously when clinically indicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): In patients chronically maintained on digoxin for HF, administration of digoxin immune Fab may result in exacerbation of HF symptoms due to a reduction in digoxin serum concentration. If reinitiation is required, consider postponing until Fab fragments have been eliminated completely; elimination may take several days or longer, especially in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal failure (experience limited); the Fab-digoxin complex will be eliminated more slowly. Toxicity may recur; prolonged monitoring for recurrence of symptoms and evaluation of free (unbound) digoxin concentrations (if test available) may be warranted in this patient population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring parameters: Serum potassium levels should be monitored closely, especially during the first few hours after administration. Total serum digoxin concentrations will rise precipitously following administration of digoxin immune Fab due to the presence of the Fab-digoxin complex; because digoxin bound to Fab fragments cannot result in toxicity, this rise has no clinical meaning.  Therefore, avoid monitoring total serum digoxin concentrations until the Fab fragments have been eliminated completely;  this may be several days to weeks in patients with renal impairment (Ujhelyi, 1995).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F160215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F160227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Safety and efficacy in pregnant women have not been established. Use during pregnancy only if clearly needed. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F160246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (DigiFab Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (1): $1434.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F160217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prior to the first dose of digoxin immune Fab evaluate serum potassium, serum digoxin concentration, and serum creatinine; closely monitor serum potassium (eg, hourly for 4-6 hours; at least daily thereafter), temperature, blood pressure, and electrocardiogram after administration.",
"     <b>",
"      Total serum digoxin concentrations will rise precipitously following administration of digoxin immune Fab due to the presence of the Fab-digoxin complex; because digoxin bound to Fab fragments cannot result in toxicity, this rise has no clinical meaning.",
"     </b>",
"     Therefore, avoid monitoring total serum digoxin concentrations until the Fab fragments have been eliminated completely;  this may be several days to weeks in patients with renal impairment (Ujhelyi, 1995).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Patients with renal failure may experience a recurrence of toxicity; prolonged monitoring for recurrence of symptoms and evaluation of free (unbound) digoxin concentrations (if test available) may be warranted in this patient population.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F160228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Digibind (GB, NO);",
"     </li>",
"     <li>",
"      Digoxin Immune FAB (Ovine) Digibind (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F160206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Digoxin immune antigen-binding fragments (Fab) are specific antibodies for the treatment of digitalis intoxication in carefully selected patients; binds with molecules of digoxin or digitoxin and is then excreted by the kidneys and removed from the body",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F160224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V.: Digitalis toxicity: Improvement may be seen in &le;30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 15-20 hours; prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine; undetectable amounts within 5-7 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Wenger TL, Butler VP Jr, et al, &ldquo;Treatment of 150 Cases of Life-Threatening Digitalis Intoxication With Digoxin-Specific Fab Antibody Fragments,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1990, 81(6):1744-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/15/27895/abstract-text/2188752/pubmed\" id=\"2188752\" target=\"_blank\">",
"        2188752",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aruna AS and Jue SG, &ldquo;Digoxin Immune Fab Administration Following an Unexplained Increase in Serum Digoxin Concentration,&rdquo;",
"      <i>",
"       J Pharm Sci Technol",
"      </i>",
"      , 1994, 10:246-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bailey B, \"Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(2):133-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/15/27895/abstract-text/12769509/pubmed\" id=\"12769509\" target=\"_blank\">",
"        12769509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bateman DN, \"Digoxin-Specific Antibody Fragments: How Much and When?\"",
"      <i>",
"       Toxicol Rev",
"      </i>",
"      ,  2004, 23(3):135-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/15/27895/abstract-text/15862081 /pubmed\" id=\"15862081 \" target=\"_blank\">",
"        15862081",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bilbault P, Oubaassine R, Rahmani H, et al, &ldquo;Emergency Step-by-Step Specific Immunotherapy in Severe Digoxin Poisoning: An Observational Cohort Study,&rdquo;",
"      <i>",
"       Europ J Emerg Med",
"      </i>",
"      , 2009, 16(3):145-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/15/27895/abstract-text/19262393/pubmed\" id=\"19262393\" target=\"_blank\">",
"        19262393",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/15/27895/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eyer F, Steimer W, Muller C, et al, &ldquo;Free and Total Digoxin in Serum During Treatment of Acute Digoxin Poisoning With Fab Fragments: Case Study,&rdquo;",
"      <i>",
"       Am J Crit Care",
"      </i>",
"      , 2010, 19(4):391-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/15/27895/abstract-text/19875723/pubmed\" id=\"19875723\" target=\"_blank\">",
"        19875723",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hickey AR, Wenger TL, Carpenter VP, et al, &ldquo;Digoxin Immune Fab Therapy in the Management of Digitalis Intoxication: Safety and Efficacy Results of an Observational Surveillance Study,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1991, 17(3):590-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/15/27895/abstract-text/1993775/pubmed\" id=\"1993775\" target=\"_blank\">",
"        1993775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaufman J, Leikin J, Kendzierski D, et al, &ldquo;Use of Digoxin Fab Immune Fragments in a Seven-Day-Old Infant,&rdquo;",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 1990, 6(2):118-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/15/27895/abstract-text/2371148/pubmed\" id=\"2371148\" target=\"_blank\">",
"        2371148",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kockova R, Skvaril J, Cernohous M, et al, &ldquo;Five Year Two Center Retrospective Analysis of Patients With Toxic Digoxin Serum Concentration,&rdquo;",
"      <i>",
"       Internat J Cardiol",
"      </i>",
"      ,  2011, 146(3):447-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/15/27895/abstract-text/21109316/pubmed\" id=\"21109316\" target=\"_blank\">",
"        21109316",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leikin J, Vogel S, Graft J, et al, &ldquo;Use of Fab Fragments of Digoxin-Specific Antibodies in the Therapy of Massive Digoxin Poisoning,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1985, 14(2):175-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/15/27895/abstract-text/3970406/pubmed\" id=\"3970406\" target=\"_blank\">",
"        3970406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martiny SS, Phelps SJ, and Massey KL, &ldquo;Treatment of Severe Digitalis Intoxication With Digoxin-Specific Antibody Fragments, A Clinical Review,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1988, 16(6):629-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/15/27895/abstract-text/3286119/pubmed\" id=\"3286119\" target=\"_blank\">",
"        3286119",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shumaik GM, Wu AW, and Ping AC, &ldquo;Oleander Poisoning: Treatment With Digoxin-Specific Fab Antibody Fragments,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1988, 17(7):732-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/15/27895/abstract-text/3382077/pubmed\" id=\"3382077\" target=\"_blank\">",
"        3382077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ujhelyi MR and Robert S, &ldquo;Pharmacokinetic Aspects of Digoxin-Specific Fab Therapy in the Management of Digitalis Toxicity,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1995, 28(6):483-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/15/27895/abstract-text/7656506/pubmed\" id=\"7656506\" target=\"_blank\">",
"        7656506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Varriale P and  Mossavi A, &ldquo;Rapid Reversal of Digitalis Delirium Using Digoxin Immune Fab Therapy,&rdquo;",
"      <i>",
"       Clin Cardiol",
"      </i>",
"      , 1995, 18(6):351-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/15/27895/abstract-text/7664510/pubmed\" id=\"7664510\" target=\"_blank\">",
"        7664510",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9361 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-3AAB480B33-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_15_27895=[""].join("\n");
var outline_f27_15_27895=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160237\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160238\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160256\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160240\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160250\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160241\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160242\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796118\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160219\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160203\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160222\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160220\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160254\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160225\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160207\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299196\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219862\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160215\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160227\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160246\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323111\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160217\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160228\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160206\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160224\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9361\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9361|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/56/31619?source=related_link\">",
"      Digoxin immune Fab: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/11/1207?source=related_link\">",
"      Digoxin immune Fab: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_15_27896="Infective endocarditis in children";
var content_f27_15_27896=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Infective endocarditis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/15/27896/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/15/27896/contributors\">",
"     Sharon E O'Brien, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/15/27896/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/15/27896/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/15/27896/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/15/27896/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/15/27896/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/15/27896/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infective endocarditis (IE) is an infection of the endocardium",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    heart valves that involves thrombus formation (vegetation), which may damage the endocardial tissue",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    valves. Although uncommon in children, it is important to identify and treat IE because of its significant morbidity and mortality. Prompt diagnosis, rapid treatment, and recognition of complications are imperative for optimal patient outcomes.",
"   </p>",
"   <p>",
"    IE is also referred to as bacterial endocarditis because bacteria are the predominant microbial pathogens. IE is used in this review to include both bacterial and fungal endocarditis.",
"   </p>",
"   <p>",
"    Many aspects of IE are similar in children and adults, but there are some manifestations that are unique to children. An overview of IE in children is presented here. A number of other topics address particular issues in detail, some of which will be addressed here for children:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibiotic prophylaxis of IE (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"       \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antimicrobial therapy for IE (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link\">",
"       \"Antimicrobial therapy of native valve endocarditis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=see_link\">",
"       \"Antimicrobial therapy of prosthetic valve endocarditis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Complications and outcome of IE (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=see_link\">",
"       \"Complications and outcome of infective endocarditis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Diagnostic criteria and approach for IE (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=see_link\">",
"       \"Infective endocarditis: Historical and Duke criteria\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"       \"Diagnostic approach to infective endocarditis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Epidemiology, risk factors and microbiology of IE (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14840?source=see_link\">",
"       \"Epidemiology, risk factors and microbiology of infective endocarditis\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Role of echocardiography in the diagnosis of IE (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=see_link\">",
"       \"Role of echocardiography in infective endocarditis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Surgery for IE (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link\">",
"       \"Surgery for native valve endocarditis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3591?source=see_link\">",
"       \"Surgery for prosthetic valve endocarditis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors and incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children with IE have an identifiable risk factor for the disease.",
"   </p>",
"   <p>",
"    Prior to 1970, rheumatic heart disease (RHD) was the major predisposing cardiac risk factor for IE in children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/1\">",
"     1",
"    </a>",
"    ]. In developed countries, a substantial decline in the incidence of RHD has made it uncommon for a child with IE to have a previous history of RHD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8327?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology and pathogenesis of acute rheumatic fever\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14617?source=see_link\">",
"     \"Natural history, screening, and management of rheumatic heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, since the 1960s, the rate of IE has risen because of the increased survival of children with congenital heart disease (CHD), and increased use of indwelling central venous catheters (CVCs), both of which are predisposing factors for IE in children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Preexisting heart disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with CHD, especially those with cyanotic heart disease, are at a greater risk for IE than the general pediatric population. About 35 to 50 percent of children with IE have CHD [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/2-4\">",
"       2-4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the absence of CHD, an indwelling CVC is a major risk factor for pediatric IE [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/5\">",
"       5",
"      </a>",
"      ]. At-risk pediatric populations for IE include critically ill and premature infants, and children with cancer or connective tissue disorders. The increased use of CVCs in these pediatric groups appears to be a major factor in their greater risk of IE [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/3,5-8\">",
"       3,5-8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A sequence of studies of children with IE treated at the same institution during three different time periods illustrate the changes in the epidemiology of IE [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. The three time periods were 1930 to 1959 (era 1), 1977 to 1992 (era 2), and 1992 to 2004 (era 3). The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median age declined from eight years in the first two eras to 1.5 years in the era 3 due to IE associated with cardiac surgery for young infants.",
"     </li>",
"     <li>",
"      The incidence of rheumatic heart disease decreased from 18, 3, to 1 percent in eras 1, 2, and 3, respectively.",
"     </li>",
"     <li>",
"      In era 3, two-thirds of the patients had congenital heart disease, and 42 percent had undergone cardiac surgery.",
"     </li>",
"     <li>",
"      In era 3, the risk of nonstreptococcal and nonstaphylococcal pathogens as causative agents increased with the rise in hospital-acquired IE.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intravenous drug abuse and degenerative heart disease, which are important predisposing factors in the adult population, are not commonly seen in children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/2,10\">",
"     2,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the incidence of risk factors associated with IE continues to change, it is difficult to ascertain the current incidence of pediatric IE. Data from several pediatric series have demonstrated the increased incidence of IE from its nadir in the 1960s, when the risk of IE from RHD had substantially declined, and prior to the significant increased survival of children with CHD and the use of CVCs in children without cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Preexisting heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with congenital heart disease (CHD) have the highest risk of developing IE. In a Japanese nationwide survey, the reported incidence of IE was 1 in 250 admissions of children and adults with CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/14\">",
"     14",
"    </a>",
"    ]. The risk of IE is increased in patients with complex cyanotic heart disease, especially in those who undergo surgical procedures that introduce prosthetic material, such as conduits and shunts [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/3,7,8,14-16\">",
"     3,7,8,14-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a population-based study, the cumulative incidence of IE after surgical repair of 12 CHD defects was determined in all Oregon children (18 years or younger) who underwent repair for these lesions between 1958 and 1993 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/17\">",
"     17",
"    </a>",
"    ]. The cumulative incidence of IE over 25 years following surgery was determined for the following CHD defects.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Valvular aortic stenosis &mdash; 13.3 percent",
"     </li>",
"     <li>",
"      Coarctation of the aorta &mdash; 3.5 percent",
"     </li>",
"     <li>",
"      Primum atrial septal defect &mdash; 2.8 percent",
"     </li>",
"     <li>",
"      Ventricular septal defect (VSD) &mdash; 2.7 percent",
"     </li>",
"     <li>",
"      Tetralogy of Fallot (TOF) &mdash; 1.7 percent",
"     </li>",
"     <li>",
"      No child with secundum atrial septal defect, patent ductus arteriosus (PDA), or pulmonic stenosis had IE after surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study that reviewed 1588 admissions for IE from the Healthcare Cost and Utilization Project Kids' Inpatient Database for two years in 2000 and 2003, 662 patients (42 percent) had preexisting heart disease, including 535 with CHD (34 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/3\">",
"     3",
"    </a>",
"    ]. The most common CHD lesions were TOF (20 percent), VSD (18 percent), hypoplastic left heart (10 percent), congenital aortic regurgitation (8 percent), D-transposition of the great arteries (6 percent), and PDA (5 percent). Other diagnoses of preexisting heart disease included rheumatic heart disease, cardiomyopathy, and the insertion of intracardiac devices (ie, defibrillators or pacemakers).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IE is the result of a series of complex interactions among blood-borne pathogens, damaged endothelium, fibrin, and platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The endocardial surface is initially injured by shear forces associated with turbulent blood flow in children with congenital heart disease (CHD), or indwelling central venous catheters in children without CHD.",
"     </li>",
"     <li>",
"      At the site of endothelial damage, fibrin, platelets, and occasionally red blood cells are deposited and initially form a noninfected thrombus.",
"     </li>",
"     <li>",
"      Transient bacteremia (which occurs in normal children) or fungemia results in adherence of microbial pathogens to the injured endocardium and thrombus. Subsequent fibrin and platelet deposition over the infected vegetation result in a protective sheath that isolates the organisms from host defenses and permits rapid proliferation of the infectious agent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Involvement of other organs is secondary to embolization or immune-mediated processes (eg, glomerulonephritis). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical manifestations'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a variety of microorganisms can cause IE, streptococci and staphylococci species are the most common pathogens associated with IE in children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/3,18\">",
"     3,18",
"    </a>",
"    ]. This was illustrated in the previously mentioned Kids' Inpatient Databases study that reviewed 1588 admissions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/3\">",
"     3",
"    </a>",
"    ]. The following distribution of pathogens was noted in the 632 admissions in which a causative agent was recorded:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Staphylococcus aureus &mdash; 57 percent",
"     </li>",
"     <li>",
"      Viridans group streptococci &mdash; 20 percent",
"     </li>",
"     <li>",
"      Coagulase-negative staphylococci &mdash; 14 percent",
"     </li>",
"     <li>",
"      Group A streptococcus &mdash; 3 percent",
"     </li>",
"     <li>",
"      Group B streptococcus &mdash; 2 percent",
"     </li>",
"     <li>",
"      Escherichia coli &mdash; 2 percent",
"     </li>",
"     <li>",
"      Streptococci pneumococci &mdash; 1 percent",
"     </li>",
"     <li>",
"      Haemophilus influenzae &mdash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results demonstrate the increasing incidence of endocarditis due to Staphylococcus aureus, which is an acute fulminant process with a high mortality rate, as compared to IE due to most other pathogens. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical manifestations'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18\">",
"     'Mortality'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although patients with indwelling catheters are at risk for bacteremia with gram negative organisms, gram negative bacterial endocarditis is rare. This is probably due to the poor ability of gram negative bacteria to adhere to the endocardium. However, in neonates with IE, likely etiologic agents in addition to S. aureus and coagulase-negative staphylococci can include Klebsiella pneumoniae and Enterobacter species, among others [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to adults, 5 to 7 percent of children with IE have blood cultures that remain negative [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/1,2,10,11,20\">",
"     1,2,10,11,20",
"    </a>",
"    ]. Potential mechanisms include previous administration of antimicrobial agents, inadequate microbiological techniques, or infection with highly fastidious bacteria or nonbacterial pathogen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34646?source=see_link\">",
"     \"Culture-negative endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fungal endocarditis is rare and is typically caused by Candida species [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/2\">",
"     2",
"    </a>",
"    ]. Indwelling catheters and high glucose concentrations in parenteral nutrition have contributed to the occurrence of fungal endocarditis, especially in premature infants [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/8\">",
"     8",
"    </a>",
"    ]. Fungal endocarditis is frequently associated with large, friable vegetations that can embolize, producing important complications. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Complications'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31720?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical manifestations and diagnosis of Candida infection in neonates\", section on 'Endocarditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of pediatric IE is variable. It is dependent upon the extent of the local cardiac disease, degree of involvement of other organs (eg, embolization), and the causative agent.",
"   </p>",
"   <p>",
"    IE is generally classified as a subacute or acute process.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subacute presentation is characterized by a prolonged course of low-grade fever and nonspecific complaints including fatigue, arthralgias, myalgias, weight loss, exercise intolerance, and diaphoresis. The presence of a cluster of these symptoms in a patient at risk for IE (ie, those with preexisting heart disease or indwelling central venous catheter) should raise the possibility of IE as a potential diagnosis. In addition, there is a risk of immunologic sequelae, such as immune-mediated glomerulonephritis. The less virulent pathogens, such as viridans group streptococci and coagulase-negative staphylococci, are usually the causative agents for subacute IE.",
"     </li>",
"     <li>",
"      Acute IE is a rapidly progressive and fulminant disease. These patients typically have high spiking fevers, and appear severely ill. An acute presentation is commonly seen in patients with IE due to Staphylococcus aureus (S. aureus), which can cause rapid destruction of heart valve tissue, abscess formation, embolic phenomena, and a rapidly progressive deterioration in hemodynamic status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical findings of IE correspond to the underlying pathologic phenomena of",
"    <span class=\"nowrap\">",
"     bacteremia/fungemia,",
"    </span>",
"    valvulitis, immunologic response, and embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms associated with bacteremia or fungemia include fever, and vasodilation and tachycardia due to decreased systemic vascular resistance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5449?source=see_link&amp;anchor=H15#H15\">",
"       \"Pathophysiology of sepsis\", section on 'Circulation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Valvulitis may result in a new or changing murmur. In some patients, tachypnea and hypotension are signs of heart failure, which occurs because of perforation of a valve, chordal rupture, or poor ventricular function.",
"     </li>",
"     <li>",
"      In children with cyanotic CHD with either a systemic-pulmonary shunt or conduit procedure, the murmur may not change but a decline in systemic oxygen saturation may occur due to obstruction of blood flow.",
"     </li>",
"     <li>",
"      Glomerulonephritis may develop in children who present with subacute IE as a consequence of immune-mediated disease. Other immunologic sequelae (ie, Roth's spots, Janeway lesions, and Osler nodes) are less common in children than they are in adults. These are described in greater detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link&amp;anchor=H4#H4\">",
"       \"Diagnostic approach to infective endocarditis\", section on 'Physical examination'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In children with IE, septic emboli are common, resulting in extracardiac infection (eg, osteomyelitis or pneumonia) or infarction to major vessels and organs. Emboli to the brain may result in neurologic symptoms (eg, seizures, headache, strokes, or altered mental status). Other major organs that may be at risk for embolic episodes include the kidney, gastrointestinal tract, limbs, and lungs.",
"     </li>",
"     <li>",
"      In the neonate, the signs and symptoms of IE are variable and nonspecific [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. They include feeding intolerance, tachycardia, respiratory distress, hypotension, and a new or changing murmur. Fever may not be present with either subacute or acute IE. Those with right-sided IE in association with central venous catheters characteristically have little clinical evidence of disease other than persistently positive blood cultures in the setting of appropriate antibiotic treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/19\">",
"       19",
"      </a>",
"      ]. Fungal IE is more common in the newborn infant and may present as an acute fulminant disease [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/8\">",
"       8",
"      </a>",
"      ]. The IE presentation may be indistinguishable from septicemia or heart failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of IE is based upon a careful history and physical examination, blood culture and laboratory results, and an echocardiogram. Although there have been several proposed diagnostic criteria for IE, the one most commonly used in the diagnosis of pediatric IE is the revised Duke criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/1,20\">",
"     1,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=see_link\">",
"     \"Infective endocarditis: Historical and Duke criteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    According to the revised Duke criteria, IE is diagnosed based upon the presence of one of two pathologic criteria or, more commonly, with certain combinations of clinical findings (",
"    <a class=\"graphic graphic_table graphicRef73023 \" href=\"UTD.htm?9/26/9644\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pathologic criteria &mdash; One of the following two pathologic criteria are required for the diagnosis of IE:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Direct evidence of endocarditis based upon histological findings",
"     </li>",
"     <li>",
"      Positive Gram stain results or cultures of specimens obtained from surgery or autopsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical criteria &mdash; The clinical criteria are divided into major and minor findings (",
"      <a class=\"graphic graphic_table graphicRef53004 \" href=\"UTD.htm?6/31/6653\">",
"       table 2",
"      </a>",
"      ). The clinical diagnosis of definitive IE requires the presence of either two major criteria, one major and three minor criteria, or five minor criteria (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?4/35/4656?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Blood cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood cultures are performed in all patients, since one of the two major diagnostic criteria is positive blood cultures for typical organisms associated with IE from at least two separate specimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnostic approach to infective endocarditis\", section on 'Blood cultures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A minimum of three blood cultures should be obtained over a time period of a few hours to two days depending upon the severity of the illness. In most patients, three blood cultures are obtained from separate venipunctures in the first 24 hours, and an additional two blood cultures in the next 24 hours if there is no growth [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/1\">",
"     1",
"    </a>",
"    ]. Unless there has been prior antibiotic therapy, more than five blood cultures over two days is generally not warranted. Since bacteremia is generally continuous, the blood cultures do not have to be obtained at any particular time in the fever cycle.",
"   </p>",
"   <p>",
"    It is important to obtain adequate volumes of blood for culture. However, in children, it is often not possible to obtain the large volumes of blood (10 to 20 mL) recommended for adults with suspected IE. In most pediatric settings, the obtained volume of blood for culture is about 1 to 3 mL in infants and young children, and 5 to 7 mL in older children. If there is a limited volume of blood, preferential culturing of the aerobic culture bottle is suggested because almost all cases of bacterial IE are due to aerobic organisms, and culturing for anaerobes is rarely useful.",
"   </p>",
"   <p>",
"    In the critically ill child, three separate venipunctures for blood cultures should be performed as quickly as possible (less than one hour), and empiric antibiotic therapy started. If the patient is not acutely ill, antibiotic therapy can be withheld for 24 to 48 hours while the blood cultures are collected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;An echocardiogram should be performed on all patients in whom there is a reasonable suspicion of IE, as it may detect the presence of a vegetation, a major diagnostic Duke criterion (",
"    <a class=\"graphic graphic_table graphicRef53004 \" href=\"UTD.htm?6/31/6653\">",
"     table 2",
"    </a>",
"    ). Risk factors for IE including pre-existing heart disease, indwelling central lines, presence of prosthetic material, persistent bacteremia, or infection with organisms most associated with IE should prompt early evaluation. Other echocardiographic findings of IE include intracardiac abscess, new or progressive valvular regurgitation, and, in patients with a prosthetic valve, evidence of partial dehiscence.",
"   </p>",
"   <p>",
"    In patients with IE, echocardiography can identify the size and location of a vegetation, extent of valve damage and the degree of valvar stenosis or regurgitation, perivalvar extension of infection, conduit or shunt obstruction, ventricular function, and the presence of a pericardial effusion (",
"    <a class=\"graphic graphic_table graphicRef60777 \" href=\"UTD.htm?32/34/33324\">",
"     table 3",
"    </a>",
"    ). It can be used to serially monitor hemodynamic, valvular function, and the resolution of vegetations in response to medical treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=see_link\">",
"     \"Role of echocardiography in infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most pediatric cases of suspected IE, transthoracic echocardiography (TTE) is adequate to detect the presence of a vegetation, especially in infants and younger children, and to monitor hemodynamic and valvular function. It is much more sensitive diagnostic tool in children compared with adults [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/1,23,24\">",
"     1,23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in some children, TTE provides inadequate imaging due to suboptimal echocardiographic windows, which may be circumvented by transesophageal echocardiography (TEE). Inadequate TTE imaging is most likely in the following patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Overweight children",
"     </li>",
"     <li>",
"      Muscular children",
"     </li>",
"     <li>",
"      Children with significant respiratory disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with complex CHD status post repair, as artifact from prosthetic material (grafts and conduits) and valves, may interfere with TTE imaging [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/25\">",
"       25",
"      </a>",
"      ]. Suboptimal echocardiographic windows are frequently present in the postoperative patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    TEE is also superior to TTE for the detection of periannular extension of IE, and should be considered in all patients with aortic valve endocarditis who exhibit findings consistent with periannular extension (eg, changing aortic root dimensions) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Repeat TTE or TEE may be warranted during treatment of IE to assess for changes in vegetations or valve function. This is particularly true of patients exhibiting clinical deterioration, new murmurs, persistent fevers, or bacteremia. Once treatment is completed, repeat evaluation may be necessary to establish a new baseline of valvar and myocardial function for the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both TTE and TEE may give false negative results if the vegetations are small or if embolization of the vegetation has occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other nonspecific laboratory tests that are supportive of the diagnosis of IE include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low",
"      <span class=\"nowrap\">",
"       hemoglobin/hematocrit",
"      </span>",
"      demonstrating anemia (either hemolytic or anemia of chronic disease), which is a common feature of IE",
"     </li>",
"     <li>",
"      Elevated erythrocyte sedimentation rate and C-reactive protein indicative of inflammation",
"     </li>",
"     <li>",
"      Urinalysis showing hematuria, proteinuria, and red cell casts is suggestive of glomerulonephritis, a minor diagnostic criterion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Electrocardiography is generally not helpful in the diagnosis of IE with the exception of IE with periannular extension, in which prolongation of the PR interval or frank heart block can occur.",
"   </p>",
"   <p>",
"    Chest radiography is also not useful in the diagnosis of IE. Findings that may be seen include cardiomegaly, heart failure, and focal pulmonary infiltrates in patients with pulmonary septic emboli.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a summary of complications seen in children with IE, which are similar to those seen in adults. The complications of IE are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=see_link\">",
"     \"Complications and outcome of infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac complications include:",
"     </li>",
"     <li>",
"      Heart failure due to perforation of the valve, rupture of an infected chordae, or perivalvar leaks or dehiscence in patients with prosthetic valve. Poor ventricular function often accompanies worsening valvar regurgitation. Prompt surgical intervention in a patient with moderate to severe ventricular dysfunction may preserve ventricular function and improve survival. Surgical mortality is increased in patients with ventricular dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link\">",
"       \"Surgery for native valve endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Extension of infection beyond the endothelium may result in a fistula tract or perivalvular infection (eg, abscess), which may cause an arrhythmia or atrioventricular heart block.",
"     </li>",
"     <li>",
"      Extension of infection into a prosthetic shunt or conduits may occlude the graft. These infections require surgical intervention because they rarely respond to medical management.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metastatic infection due to septic emboli resulting in osteomyelitis, pneumonia, or distal abscesses in the kidneys, spleen, brain or soft tissues. In addition to metastatic infection, embolic events can result in damage or infarction of any major artery or organ including the brain, limbs, kidney, lungs, and gastrointestinal tract. Embolic events can occur with any episode of endocarditis, but those with large friable lesions, such as seen in patients with fungal endocarditis, are at particularly high risk.",
"     </li>",
"     <li>",
"      Glomerulonephritis as a result of an immune-mediated secondary process.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Risk factors for IE complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that predispose to the development of complications in children with IE include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prosthetic cardiac valves",
"     </li>",
"     <li>",
"      Left-sided involvement",
"     </li>",
"     <li>",
"      Staphylococcus aureus or fungal IE",
"     </li>",
"     <li>",
"      Previous IE",
"     </li>",
"     <li>",
"      Prolonged symptoms &ge;3 months",
"     </li>",
"     <li>",
"      Cyanotic congenital heart disease",
"     </li>",
"     <li>",
"      Systemic-to-pulmonary shunts",
"     </li>",
"     <li>",
"      Poor clinical response to antimicrobial therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the principles of treatment of IE in children are the same as those in adults. In patients with acute IE, blood cultures should be obtained as quickly as possible so empiric antibiotic therapy can be started.",
"   </p>",
"   <p>",
"    Antibiotic choice, dosage, and duration of treatment are dependent upon the underlying causative microbial agent, and are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link\">",
"     \"Antimicrobial therapy of native valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotic regimens are provided as tables for the more common bacterial pathogens in pediatric IE:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viridans group streptococci and Streptococcus bovis (",
"      <a class=\"graphic graphic_table graphicRef73007 graphicRef53990 \" href=\"UTD.htm?8/10/8367\">",
"       table 4A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Enterococci (",
"      <a class=\"graphic graphic_table graphicRef50418 graphicRef64258 graphicRef66444 \" href=\"UTD.htm?32/62/33760\">",
"       table 5A-C",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Staphylococci (",
"      <a class=\"graphic graphic_table graphicRef81429 \" href=\"UTD.htm?26/56/27533\">",
"       table 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Culture negative endocarditis (",
"      <a class=\"graphic graphic_table graphicRef70094 \" href=\"UTD.htm?8/37/8797\">",
"       table 7",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who fail medical therapy with persistent vegetations despite antibiotic therapy may be candidates for surgical intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Surgical intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consideration for surgical intervention is the same for children and adults with IE. Surgery is indicated in cases in which the procedure is likely to result in a more favorable outcome than medical management based upon an analysis of the relative risks and benefits.",
"   </p>",
"   <p>",
"    Our recommendations for surgical intervention are based upon the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association guidelines on the management of valvular heart disease, which include recommendations for surgery in patients with native valve endocarditis (",
"    <a class=\"graphic graphic_table graphicRef76266 \" href=\"UTD.htm?37/50/38699\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/28\">",
"     28",
"    </a>",
"    ]. These guidelines are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link&amp;anchor=H3#H3\">",
"     \"Surgery for native valve endocarditis\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;We provide antimicrobial prophylaxis in children who are at the highest risk for IE based upon the revised 2007 American Heart Association guidelines for IE prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/29\">",
"     29",
"    </a>",
"    ]. These guidelines, which include defining the highest risk patients and the settings for prophylactic antibiotic therapy, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link&amp;anchor=H9#H9\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\", section on 'Patients at highest risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotic IE prophylactic regimens for children are provided in the following table (",
"    <a class=\"graphic graphic_table graphicRef57182 \" href=\"UTD.htm?39/63/40956\">",
"     table 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link&amp;anchor=H22#H22\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\", section on 'Children'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall mortality rate is about 5 percent in children with IE. Prematurity, cyanotic congenital heart disease (CHD), and IE due to Staphylococcus aureus are risk factors for increased mortality.",
"   </p>",
"   <p>",
"    Data on mortality and associated risk factors were provided by the previously mentioned study based upon the Kids' Inpatient Databases for the two years 2000 and 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27896/abstract/3\">",
"     3",
"    </a>",
"    ]. Of the 1558 cases, there were 84 deaths (5.4 percent), which included 38 deaths in 662 patients with preexisting heart disease (5.7 percent) and 46 deaths in 896 without heart disease (5.1 percent).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the 46 patients who died without preexisting heart disease, 32 were infants (median age 66 days), including 10 premature infants. The mortality rate was higher in premature infants compared to older infants and children (13.3 versus 4.5 percent). Staphylococcus aureus was the causative organism in 13 of the 14 deaths that occurred after infancy.",
"     </li>",
"     <li>",
"      The mortality rate of children with IE and CHD was 6.7 percent. The highest mortality was in patients with tetralogy of Fallot (TOF) and pulmonary atresia (48 percent), followed by TOF alone (19 percent), coarctation of the aorta (18 percent), and complete atrioventricular canal (16 percent). Of note, there was only 1 death in the 96 patients with IE and ventricular septal defect (1 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although uncommon in children, it is important to identify and treat infectious endocarditis (IE) because of its significant morbidity and mortality.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most children with IE have an identifiable risk factor of either preexisting heart disease or an indwelling central venous catheter (CVC). Children with complex cyanotic heart disease (CHD) with palliative shunts, conduits, or other prostheses have the greatest morbidity and mortality from IE. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Complications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the increased survival rate of children with CHD and use of CVCs, the incidence of IE appears to have increased over the last three decades. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors and incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      IE is due to a series of complex interactions among bloodborne pathogens, damaged cardiac endothelium, fibrin, and platelets that result in the formation of an infected thrombus (vegetation) and damage to the endocardium",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      heart valves. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although a variety of microorganisms can cause IE, streptococci and staphylococci species are the most common pathogens associated with IE in children. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of pediatric IE is variable and is generally classified as either a subacute or acute process. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Subacute presentation is characterized by a prolonged course of low-grade fevers and nonspecific complaints, including fatigue, arthralgias, myalgias, weight loss, exercise intolerance, and diaphoresis.",
"     </li>",
"     <li>",
"      Acute IE is a rapidly progressive fulminant disease with high spiking fevers and an increased likelihood of complications, including hemodynamic instability and heart failure. Staphylococcus aureus (S. aureus) is the organism most commonly associated with acute IE. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physical findings consistent with a diagnosis of IE include a new regurgitant heart murmur and evidence of embolic events. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical diagnosis of IE is made by fulfilling Duke's criteria, which is based upon physical and echocardiogram findings consistent with IE, and persistently positive blood cultures (",
"      <a class=\"graphic graphic_table graphicRef53004 \" href=\"UTD.htm?6/31/6653\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?4/35/4656?source=see_link\">",
"       calculator 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=see_link\">",
"       \"Infective endocarditis: Historical and Duke criteria\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Complications of IE include cardiac sequelae (eg, heart failure and perivalvar infection) and end-organ infection or infarction due to embolic events. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Complications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=see_link\">",
"       \"Complications and outcome of infective endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The principles of treatment of IE in children are the same as adults. The choice, dosage, and duration of antibiotic therapy are dependent upon the underlying causative microbial agent (",
"      <a class=\"graphic graphic_table graphicRef73007 graphicRef53990 \" href=\"UTD.htm?8/10/8367\">",
"       table 4A-B",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef50418 graphicRef64258 graphicRef66444 \" href=\"UTD.htm?32/62/33760\">",
"       table 5A-C",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef81429 \" href=\"UTD.htm?26/56/27533\">",
"       table 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef70094 \" href=\"UTD.htm?8/37/8797\">",
"       table 7",
"      </a>",
"      ). &nbsp;Indications for surgical intervention are based upon the 2006 American College of",
"      <span class=\"nowrap\">",
"       Cardiology/American",
"      </span>",
"      Heart Association guidelines on the management of valvular heart disease (",
"      <a class=\"graphic graphic_table graphicRef76266 \" href=\"UTD.htm?37/50/38699\">",
"       table 8",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link\">",
"       \"Surgery for native valve endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prophylactic antibiotic therapy for IE is reserved for patients with the highest risk of IE (",
"      <a class=\"graphic graphic_table graphicRef57182 \" href=\"UTD.htm?39/63/40956\">",
"       table 9",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link&amp;anchor=H9#H9\">",
"       \"Antimicrobial prophylaxis for bacterial endocarditis\", section on 'Patients at highest risk'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The mortality rate for pediatric IE is about 5 percent. Increased mortality is associated with prematurity, cyanotic CHD, and IE due to Staphylococcus aureus. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/1\">",
"      Ferrieri P, Gewitz MH, Gerber MA, et al. Unique features of infective endocarditis in childhood. Circulation 2002; 105:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/2\">",
"      Saiman L, Prince A, Gersony WM. Pediatric infective endocarditis in the modern era. J Pediatr 1993; 122:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/3\">",
"      Day MD, Gauvreau K, Shulman S, Newburger JW. Characteristics of children hospitalized with infective endocarditis. Circulation 2009; 119:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/4\">",
"      Marom D, Levy I, Gutwein O, et al. Healthcare-associated versus community-associated infective endocarditis in children. Pediatr Infect Dis J 2011; 30:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/5\">",
"      Garc&iacute;a-Teresa MA, Casado-Flores J, Delgado Dom&iacute;nguez MA, et al. Infectious complications of percutaneous central venous catheterization in pediatric patients: a Spanish multicenter study. Intensive Care Med 2007; 33:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/6\">",
"      Rastogi A, Luken JA, Pildes RS, et al. Endocarditis in neonatal intensive care unit. Pediatr Cardiol 1993; 14:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/7\">",
"      Rech A, Loss JF, Machado A, Brunetto AL. Infective endocarditis (IE) in children receiving treatment for cancer. Pediatr Blood Cancer 2004; 43:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/8\">",
"      Daher AH, Berkowitz FE. Infective endocarditis in neonates. Clin Pediatr (Phila) 1995; 34:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/9\">",
"      Rosenthal LB, Feja KN, Levasseur SM, et al. The changing epidemiology of pediatric endocarditis at a children's hospital over seven decades. Pediatr Cardiol 2010; 31:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/10\">",
"      Martin JM, Neches WH, Wald ER. Infective endocarditis: 35 years of experience at a children's hospital. Clin Infect Dis 1997; 24:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/11\">",
"      Johnson DH, Rosenthal A, Nadas AS. A forty-year review of bacterial endocarditis in infancy and childhood. Circulation 1975; 51:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/12\">",
"      Zakrzewski,T, and Keith, JD, Bacterial endocarditis in infants and children. J Pediatr 1965; 67:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/13\">",
"      Van Hare GF, Ben-Shachar G, Liebman J, et al. Infective endocarditis in infants and children during the past 10 years: a decade of change. Am Heart J 1984; 107:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/14\">",
"      Niwa K, Nakazawa M, Tateno S, et al. Infective endocarditis in congenital heart disease: Japanese national collaboration study. Heart 2005; 91:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/15\">",
"      Ashkenazi S, Levy O, Blieden L. Trends of childhood infective endocarditis in Israel with emphasis on children under 2 years of Age. Pediatr Cardiol 1997; 18:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/16\">",
"      Dodo H, Child JS. Infective endocarditis in congenital heart disease. Cardiol Clin 1996; 14:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/17\">",
"      Morris CD, Reller MD, Menashe VD. Thirty-year incidence of infective endocarditis after surgery for congenital heart defect. JAMA 1998; 279:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/18\">",
"      Johnson JA, Boyce TG, Cetta F, et al. Infective endocarditis in the pediatric patient: a 60-year single-institution review. Mayo Clin Proc 2012; 87:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/19\">",
"      Milazzo AS Jr, Li JS. Bacterial endocarditis in infants and children. Pediatr Infect Dis J 2001; 20:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/20\">",
"      Stockheim JA, Chadwick EG, Kessler S, et al. Are the Duke criteria superior to the Beth Israel criteria for the diagnosis of infective endocarditis in children? Clin Infect Dis 1998; 27:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/21\">",
"      Millard DD, Shulman ST. The changing spectrum of neonatal endocarditis. Clin Perinatol 1988; 15:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/22\">",
"      Oelberg DG, Fisher DJ, Gross DM, et al. Endocarditis in high-risk neonates. Pediatrics 1983; 71:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/23\">",
"      Kavey RE, Frank DM, Byrum CJ, et al. Two-dimensional echocardiographic assessment of infective endocarditis in children. Am J Dis Child 1983; 137:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/24\">",
"      Penk JS, Webb CL, Shulman ST, Anderson EJ. Echocardiography in pediatric infective endocarditis. Pediatr Infect Dis J 2011; 30:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/25\">",
"      Coward K, Tucker N, Darville T. Infective endocarditis in Arkansan children from 1990 through 2002. Pediatr Infect Dis J 2003; 22:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/26\">",
"      Barbour SI, Louie EK, O'Keefe JP. Penetration of the atrialventricular septum by spread of infection from aortic valve endocarditis: early diagnosis by transesophageal echocardiography and implications for surgical management. Am Heart J 1996; 132:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/27\">",
"      Karalis DG, Bansal RC, Hauck AJ, et al. Transesophageal echocardiographic recognition of subaortic complications in aortic valve endocarditis. Clinical and surgical implications. Circulation 1992; 86:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/28\">",
"      American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease), Society of Cardiovascular Anesthesiologists, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2006; 48:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27896/abstract/29\">",
"      Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 116:1736.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5768 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-F706DDF602-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_15_27896=[""].join("\n");
var outline_f27_15_27896=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors and incidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Preexisting heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Blood cultures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Risk factors for IE complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Surgical intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5768\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5768|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/26/9644\" title=\"table 1\">",
"      Duke criteria for IE I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/31/6653\" title=\"table 2\">",
"      Duke criteria for IE II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/34/33324\" title=\"table 3\">",
"      Guidelines for use of echocardiography in IE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/53/7006\" title=\"table 4A\">",
"      Rx strep endocarditis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/16/22797\" title=\"table 4B\">",
"      Rx strep endocarditis II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/24/31117\" title=\"table 5A\">",
"      Rx entero endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/4/9294\" title=\"table 5B\">",
"      Rx entero endocarditisII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/0/43021\" title=\"table 5C\">",
"      Rx VRE endocarditisII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/56/27533\" title=\"table 6\">",
"      Rx staph endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/37/8797\" title=\"table 7\">",
"      Rx Culture neg endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/50/38699\" title=\"table 8\">",
"      Surgery native valve IE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/63/40956\" title=\"table 9\">",
"      Antibiotic regimens dental",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?4/35/4656?source=related_link\" title=\"calculator 1\">",
"      Calculator: Diagnosis of endocarditis - Duke criteria for definite endocarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=related_link\">",
"      Antimicrobial therapy of native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=related_link\">",
"      Antimicrobial therapy of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31720?source=related_link\">",
"      Clinical manifestations and diagnosis of Candida infection in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=related_link\">",
"      Complications and outcome of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34646?source=related_link\">",
"      Culture-negative endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8327?source=related_link\">",
"      Epidemiology and pathogenesis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14840?source=related_link\">",
"      Epidemiology, risk factors and microbiology of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31094?source=related_link\">",
"      Infective endocarditis: Historical and Duke criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14617?source=related_link\">",
"      Natural history, screening, and management of rheumatic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5449?source=related_link\">",
"      Pathophysiology of sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=related_link\">",
"      Role of echocardiography in infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=related_link\">",
"      Surgery for native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3591?source=related_link\">",
"      Surgery for prosthetic valve endocarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_15_27897="Acanthosis nigricans";
var content_f27_15_27897=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acanthosis nigricans",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/15/27897/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/15/27897/contributors\">",
"     Kathryn Schwarzenberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/15/27897/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/15/27897/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/15/27897/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/15/27897/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/15/27897/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H561155440\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acanthosis nigricans is a benign and common condition characterized by velvety, hyperpigmented plaques on the skin. Intertriginous sites, such as the neck and axillae, are common sites for involvement. Less frequently, acanthosis nigricans appears in other skin sites or on mucosal surfaces.",
"   </p>",
"   <p>",
"    Clinical recognition of acanthosis nigricans is important because the disorder can occur in association with a variety of systemic abnormalities, many of which are characterized by insulin resistance. Obesity and diabetes mellitus are among the most frequently associated disorders. Rarely, acanthosis nigricans develops as a sign of internal malignancy.",
"   </p>",
"   <p>",
"    The epidemiology, diagnosis, and treatment of acanthosis nigricans will be reviewed here. Specific disorders that may present with acanthosis nigricans are reviewed in greater detail separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H561155447\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acanthosis nigricans can affect both males and females, as well as infants, children, and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/1\">",
"     1",
"    </a>",
"    ]. Although prevalence rates of this disorder have varied among studies, it is evident that a significant proportion of obese and diabetic individuals exhibit this finding, and that the prevalence of this disorder may differ among ethnic groups [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. In the United States, acanthosis nigricans appears to be more common in people of African, Hispanic, and Native American origin than in white or Asian individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/2,6-12\">",
"     2,6-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of studies that have evaluated the prevalence of acanthosis nigricans in the United States include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multiethnic cohort of 1730 patients aged 7 to 65 years seen in primary care settings in a variety of sites within the United States in 2007, 19 percent had acanthosis nigricans [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/13\">",
"       13",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      A study of 618 children (ages 7 to 17 years) in an urban community in Illinois performed between 2001 and 2002 found that Caucasian youth were less likely than African-American or Hispanic youth to have acanthosis nigricans on the neck [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/11\">",
"       11",
"      </a>",
"      ]. In the study, 4, 19, and 23 percent of children had acanthosis nigricans, respectively.",
"     </li>",
"     <li>",
"      In a cohort of 2200 Native Americans in the Cherokee Nation (ages 5 to 40 years) evaluated between 1995 and 1999, 47 percent had acanthosis nigricans on the neck [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since obesity is the most common reason for the development of acanthosis nigricans [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/15\">",
"     15",
"    </a>",
"    ], obesity rates are an additional factor in the prevalence of acanthosis nigricans in specific populations. (See",
"    <a class=\"local\" href=\"#H464431\">",
"     'Obesity, endocrine, and metabolic disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H464423\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acanthosis nigricans may be acquired or inherited. Most, if not all, patients with acanthosis nigricans have one of the following categories of disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Endocrine and metabolic disorders, particularly disorders associated with insulin resistance",
"     </li>",
"     <li>",
"      Genetic syndromes with acanthosis nigricans",
"     </li>",
"     <li>",
"      Familial acanthosis nigricans",
"     </li>",
"     <li>",
"      Malignancy",
"     </li>",
"     <li>",
"      Drug reactions &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H464431\">",
"    <span class=\"h2\">",
"     Obesity, endocrine, and metabolic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity and diabetes mellitus are the most common medical disorders linked with acanthosis nigricans [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/2-4,6,16,17\">",
"     2-4,6,16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Insulin resistance likely accounts for the development of acanthosis nigricans in individuals with these conditions. (See",
"    <a class=\"local\" href=\"#H561155454\">",
"     'Pathogenesis'",
"    </a>",
"    below.) In one study of 236 children with acanthosis nigricans and 51 overweight children without the disorder, significant associations of acanthosis nigricans with insulin resistance and abnormal glucose homeostasis were detected [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28567?source=see_link\">",
"     \"Insulin resistance: Definition and clinical spectrum\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Obesity",
"      </strong>",
"      &ndash; The link between acanthosis nigricans and weight was demonstrated in a study of 1133 young patients from multiple communities in the United States in which the prevalence of acanthosis nigricans increased with rising body mass index (BMI) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/19\">",
"       19",
"      </a>",
"      ]. Among subjects aged 7 to 19 years who were of normal weight, overweight, or obese, acanthosis nigricans was detected in 3, 11, and 51 percent, respectively. An increase in acanthosis nigricans with rising weight was also evident among slightly older subjects (ages 20 to 39 years); 3, 12, and 37 percent of subjects in the respective weight groups within this population were affected. Concordantly, a smaller practice-based study found a high rate of acanthosis nigricans in obese children; among children aged 7 to 17 years with a BMI that met or exceeded the 98",
"      <sup>",
"       th",
"      </sup>",
"      percentile, 62 percent had the skin condition [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=see_link&amp;anchor=H10#H10\">",
"       \"Measurement of growth in children\", section on 'Body mass index (BMI)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Diabetes",
"      </strong>",
"      &ndash; Type 2 diabetes mellitus is also strongly associated with acanthosis nigricans [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/3,7,13,16,19\">",
"       3,7,13,16,19",
"      </a>",
"      ]. In the study of 1133 patients mentioned above, type 2 diabetes was present in 15 percent of patients with acanthosis nigricans, compared with 4 percent of patients without the skin condition [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/19\">",
"       19",
"      </a>",
"      ]. After controlling for age, BMI, and number of diabetes risk factors, patients with acanthosis nigricans were twice as likely to have type 2 diabetes as unaffected individuals.",
"      <br/>",
"      <br/>",
"      In addition, a practice-based study with 1730 patients supported the association between type 2 diabetes and acanthosis nigricans [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/13\">",
"       13",
"      </a>",
"      ]. Type 2 diabetes was present in 35 versus 18 percent of patients with or without acanthosis nigricans, respectively. Significantly higher serum levels of insulin were also detected in the patients with acanthosis nigricans.",
"      <br/>",
"      <br/>",
"      The prevalence of acanthosis nigricans in a population of patients with newly diagnosed type 2 diabetes was evaluated in a study of 216 adults in Texas in 1998 and 1999. In the study, acanthosis nigricans was detected in 36 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/7\">",
"       7",
"      </a>",
"      ]. The likelihood of having acanthosis nigricans increased with the degree of obesity, with over 50 percent of individuals with a BMI &ge;30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      demonstrating the disorder. Ethnic differences were also evident; 50 of 95 African-American subjects (53 percent), 28 of 78 Latin-American subjects (36 percent), 1 of 39 non-Hispanic white subjects (3 percent), and none of four Asian subjects were affected [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H561155447\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=see_link&amp;anchor=H5#H5\">",
"       \"Screening for and clinical evaluation of obesity in adults\", section on 'Measurement of BMI'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Other disorders",
"      </strong>",
"      &ndash; In a 2007 cohort of middle-aged Sri Lankan adults, acanthosis nigricans was present in 296 of 1025 subjects with metabolic syndrome (29 percent) and only 217 of 1924 subjects without the syndrome (11 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/3\">",
"       3",
"      </a>",
"      ]. In addition, hypertension and dyslipidemia, components of the metabolic syndrome, have been linked to acanthosis nigricans in children [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/17,18,20-22\">",
"       17,18,20-22",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Examples of other metabolic or endocrine disorders associated with acanthosis nigricans include polycystic ovarian syndrome, acromegaly, and Cushing&rsquo;s syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/23\">",
"       23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"       \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H464447\">",
"    <span class=\"h2\">",
"     Genetic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple genetic disorders have been associated with acanthosis nigricans, many of which are characterized by insulin resistance that results either from defects in the insulin receptor or the production of antibodies against the insulin receptor. Acanthosis nigricans is a clinical feature that can aid in the recognition of these genetic diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/24\">",
"     24",
"    </a>",
"    ]. Some, but not all, patients with acanthosis nigricans with onset in infancy or early childhood, develop the condition as a feature of a genetic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of genetic syndromes characterized by insulin resistance that can present with acanthosis nigricans include Down syndrome, leprechaunism, Rabson-Mendenhall syndrome, congenital generalized lipodystrophy (Berardinelli-Seip syndrome), familial partial lipodystrophy, and Alstrom syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Cutis gyrata syndrome, Crouzon syndrome with acanthosis nigricans, thanatophoric dysplasia, and severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN) are additional genetic syndromes that are not characterized by insulin resistance, but may also present with acanthosis nigricans [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28567?source=see_link\">",
"     \"Insulin resistance: Definition and clinical spectrum\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23352?source=see_link&amp;anchor=H3#H3\">",
"     \"Lipodystrophic syndromes\", section on 'Congenital generalized lipodystrophy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23352?source=see_link&amp;anchor=H12#H12\">",
"     \"Lipodystrophic syndromes\", section on 'Familial partial lipodystrophy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8487?source=see_link&amp;anchor=H5#H5\">",
"     \"Craniosynostosis syndromes\", section on 'Crouzon syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42585?source=see_link&amp;anchor=H2348325#H2348325\">",
"     \"Prenatal diagnosis of the lethal skeletal dysplasias\", section on 'Thanatophoric dysplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H332799\">",
"    <span class=\"h2\">",
"     Familial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Documentation of familial, non-insulin resistance-related, nonsyndromic forms of acanthosis nigricans are limited to reports of a few families [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/25\">",
"     25",
"    </a>",
"    ]. The inheritance pattern is usually autosomal dominant, and the clinical findings are typically first detected in infancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H464455\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, acanthosis nigricans occurs as a paraneoplastic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Abdominal adenocarcinomas, particularly gastric adenocarcinomas, represent the majority of acanthosis-nigricans associated tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. Patients may concurrently develop the sign of Leser-Tr&eacute;lat or tripe palms, which are additional cutaneous disorders that can occur in association with internal malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=see_link&amp;anchor=H9#H9\">",
"     \"Cutaneous manifestations of internal malignancy\", section on 'Acanthosis nigricans'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=see_link&amp;anchor=H15#H15\">",
"     \"Cutaneous manifestations of internal malignancy\", section on 'Tripe palm'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=see_link&amp;anchor=H3208461#H3208461\">",
"     \"Cutaneous manifestations of internal malignancy\", section on 'Sign of Leser-Trelat'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Malignancy-associated acanthosis nigricans is extremely rare in children. Several cases in which children developed acanthosis nigricans in conjunction with gastric adenocarcinoma, Wilms&rsquo; tumor, or osteogenic sarcoma have been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H464810\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infrequently, acanthosis nigricans develops as a side effect of drug exposure. This most commonly occurs in the setting of medications that promote hyperinsulinemia. Medications that have been associated with acanthosis nigricans include systemic glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/28\">",
"     28",
"    </a>",
"    ], insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/35\">",
"     35",
"    </a>",
"    ], oral contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/36\">",
"     36",
"    </a>",
"    ], niacin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/37\">",
"     37",
"    </a>",
"    ], protease inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/38\">",
"     38",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36084?source=see_link\">",
"     palifermin",
"    </a>",
"    (a recombinant human keratinocyte growth factor used to manage severe chemotherapy-induced mucositis) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H561155454\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathways that lead to acanthosis nigricans are not well understood. Abnormalities involving three types of tyrosine kinase receptors: insulin-like growth factor receptor-1 (IGFR1), fibroblast growth factor receptors (FGFR), and epidermal growth factor receptor (EGFR), have been proposed as potential contributing factors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association of acanthosis nigricans with multiple disorders characterized by insulin resistance suggests that hyperinsulinemia plays a key role in the development of acanthosis nigricans. Elevated levels of insulin may stimulate keratinocyte and dermal fibroblast proliferation via interaction with IGFR1, resulting in the plaque-like lesions that typify the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/26\">",
"     26",
"    </a>",
"    ]. Acanthosis nigricans related to genetic syndromes of insulin resistance, obesity, diabetes mellitus, or other disorders associated with insulin resistance may be attributable to this theory. (See",
"    <a class=\"local\" href=\"#H464423\">",
"     'Etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other mechanisms may also be involved in acanthosis nigricans, particularly in cases in which insulin resistance is absent. As an example, mutations in certain FGFRs may contribute to acanthosis nigricans through the promotion of keratinocyte proliferation and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/26\">",
"     26",
"    </a>",
"    ]. Activating mutations in FGFR3 have been linked to several inherited syndromes that present with acanthosis nigricans, including Crouzon syndrome, severe achondroplasia with developmental delay, SADDAN, and thanatophoric dwarfism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, FGFR3 mutations were identified in a family with familial acanthosis nigricans [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/25\">",
"     25",
"    </a>",
"    ], and at least two patients with malignancy-associated skin lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transforming growth factor (TGF)-&alpha;, a cytokine that may exert proliferative effects via activation of EGFR, may also contribute to the development of malignancy-associated acanthosis nigricans [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In support of this theory is a report of a patient in whom reduction of elevated serum TGF-&alpha; levels and amelioration of acanthosis nigricans followed the removal of a malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms by which other forms of acanthosis nigricans occur remain elusive. The predominant distribution of acanthosis nigricans in skin folds suggests a contributory role for friction or irritation in the disorder, but this has not been scientifically proven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H561155461\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acanthosis nigricans typically presents with thickened, velvety to verrucous, grey-brown hyperpigmented plaques on the skin. The back of the neck, sides of the neck, and axillae are the most common sites of involvement (",
"    <a class=\"graphic graphic_picture graphicRef72964 graphicRef52948 graphicRef66384 graphicRef81693 graphicRef61666 \" href=\"UTD.htm?42/1/43034\">",
"     picture 1A-E",
"    </a>",
"    ). Other intertriginous areas, such as the anogenital region and the inframammary, abdominal, antecubital, and inguinal skin folds, are less frequently affected (",
"    <a class=\"graphic graphic_picture graphicRef76234 \" href=\"UTD.htm?40/55/41846\">",
"     picture 2",
"    </a>",
"    ). Additionally, severe cases may demonstrate lesions on the areola, perineum, umbilicus, lips, buccal or other mucosa, and other non-intertriginous areas (",
"    <a class=\"graphic graphic_picture graphicRef50592 graphicRef63422 graphicRef52056 \" href=\"UTD.htm?36/29/37338\">",
"     picture 3A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In mild or early acanthosis nigricans, affected skin has a dirty appearance and a rough or dry texture with minimal plaque-like elevation. As the lesions progress, the skin becomes thicker and demonstrates accentuation of dermatoglyphics (skin lines) and papillomatous projections. Acrochordons (skin tags) may be present within or around affected areas (",
"    <a class=\"graphic graphic_picture graphicRef61666 \" href=\"UTD.htm?27/11/27828\">",
"     picture 1E",
"    </a>",
"    ). Unlike cutaneous lesions, mucosal acanthosis nigricans usually does not demonstrate hyperpigmentation.",
"   </p>",
"   <p>",
"    Acanthosis nigricans typically develops in a symmetrical distribution. Unilateral cases of acanthosis nigricans may instead represent a variant of epidermal nevus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/44-47\">",
"     44-47",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    An acral form of acanthosis nigricans, characterized by hyperpigmented plaques on the knuckles of the hands, elbows, knees, or feet, and most commonly seen in individuals of sub-Saharan African origin, has also been described (",
"    <a class=\"graphic graphic_picture graphicRef70582 \" href=\"UTD.htm?36/56/37765\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/15,28,48\">",
"     15,28,48",
"    </a>",
"    ]. The term acral acanthotic anomaly has been used to refer to these lesions.",
"   </p>",
"   <p>",
"    Acanthosis nigricans is usually asymptomatic. However, lesions in skin folds that become macerated and inflamed may become uncomfortable or malodorous. In particular, this may occur in the setting of secondary bacterial colonization or yeast infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1019361\">",
"    <span class=\"h2\">",
"     Malignancy-associated acanthosis nigricans",
"    </span>",
"    &nbsp;&mdash;&nbsp;The paraneoplastic form of acanthosis nigricans is most frequently diagnosed in older individuals and patients often are not obese. The lesions can arise before or after the detection of malignancy. In some cases, the diagnosis of acanthosis nigricans predates recognition of the malignancy by years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/33,49,50\">",
"     33,49,50",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Features that suggest the possibility of an underlying malignancy in a patient with acanthosis nigricans include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid onset of skin lesions",
"     </li>",
"     <li>",
"      Additional paraneoplastic findings (eg, rapid growth or inflammation of seborrheic keratoses [the sign of Leser-Tr&eacute;lat] or the presence of tripe palms)",
"     </li>",
"     <li>",
"      Extensive involvement",
"     </li>",
"     <li>",
"      Lesions in atypical sites (eg, mucous membranes, palms, or soles)",
"     </li>",
"     <li>",
"      Unexplained weight loss",
"     </li>",
"     <li>",
"      Older adult",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Malignancy-associated acanthosis nigricans may be accompanied by localized or generalized pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, other paraneoplastic dermatoses may occur with malignancy-associated acanthosis nigricans, such as velvety to rugose thickening of the palmar skin (tripe palms) (",
"    <a class=\"graphic graphic_picture graphicRef61955 \" href=\"UTD.htm?14/59/15283\">",
"     picture 5",
"    </a>",
"    ) and the eruptive onset of multiple seborrheic keratoses (sign of Leser-Tr&eacute;lat) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=see_link&amp;anchor=H9#H9\">",
"     \"Cutaneous manifestations of internal malignancy\", section on 'Acanthosis nigricans'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=see_link&amp;anchor=H15#H15\">",
"     \"Cutaneous manifestations of internal malignancy\", section on 'Tripe palm'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=see_link&amp;anchor=H3208461#H3208461\">",
"     \"Cutaneous manifestations of internal malignancy\", section on 'Sign of Leser-Trelat'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H561155468\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkeratosis and epidermal papillomatosis are the major pathological features, and acanthosis is relatively mild. The hyperkeratosis is primarily responsible for the clinical finding of cutaneous hyperpigmentation; however, increased melanin in the basal layer of the epidermis also is sometimes detected [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dermis may demonstrate a mild infiltrate with lymphocytes, plasma cells and, occasionally, a few neutrophils. However, inflammation is not a prominent feature. Biopsies of mucosal lesions exhibit mild parakeratosis with epidermal hyperplasia and papillomatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The histological features of acanthosis nigricans are consistent among the various forms of the condition. For example, microscopy cannot be used to distinguish paraneoplastic acanthosis nigricans from other types of acanthosis nigricans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H561155475\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND PATIENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical examination is usually sufficient to establish a diagnosis of acanthosis nigricans. In the rare cases in which the diagnosis is uncertain, a skin biopsy can be performed to confirm the clinical impression. (See",
"    <a class=\"local\" href=\"#H561155468\">",
"     'Histopathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Due to the association of acanthosis nigricans with other abnormalities, the assessment for signs or symptoms of other disorders is an important component of the evaluation of affected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/54\">",
"     54",
"    </a>",
"    ]. In general, we proceed with the following work-up in children and adults with acanthosis nigricans:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Patient history",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Age of onset",
"      </strong>",
"      (onset in infancy or early childhood suggests the possibility of a syndromic or familial disorder, and malignancy-associated acanthosis nigricans is more common in adults than in children)",
"     </li>",
"     <li>",
"      <strong>",
"       History or symptoms suggestive of an underlying endocrinopathy",
"      </strong>",
"      (this information may help to identify the presence of type 2 diabetes, polycystic ovarian syndrome, acromegaly, Cushing&rsquo;s syndrome, or other endocrine disorders)",
"     </li>",
"     <li>",
"      <strong>",
"       Family history of acanthosis nigricans",
"      </strong>",
"      (in the absence of other underlying causes, may suggest familial acanthosis nigricans)",
"     </li>",
"     <li>",
"      <strong>",
"       Possible exposure to drugs that may induce acanthosis nigricans",
"      </strong>",
"      (See",
"      <a class=\"local\" href=\"#H464810\">",
"       'Medications'",
"      </a>",
"      above.)",
"      <strong>",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Physical examination",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Height and weight",
"      </strong>",
"      (used to establish the presence or absence of obesity, a common cause of acanthosis nigricans)",
"     </li>",
"     <li>",
"      <strong>",
"       Growth rate in children",
"      </strong>",
"      (abnormal growth may suggest the presence of an endocrinopathy or genetic syndrome)",
"     </li>",
"     <li>",
"      <strong>",
"       Physical signs suggestive of an underlying endocrinopathy",
"      </strong>",
"      (may help to identify the presence of type 2 diabetes, polycystic ovarian syndrome, acromegaly, Cushing&rsquo;s syndrome, or other endocrine disorders)",
"     </li>",
"     <li>",
"      <strong>",
"       Blood pressure assessment",
"      </strong>",
"      (assesses for hypertension, which may occur at increased frequency in patients with acanthosis nigricans)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Laboratory studies",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Patients with acanthosis nigricans should be evaluated for the possibility of diabetes mellitus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=see_link&amp;anchor=H6#H6\">",
"       \"Screening for diabetes mellitus\", section on 'Screening tests'",
"      </a>",
"      .) Additional laboratory studies and other investigational tests are ordered based upon the findings on history and physical examination and suspicion for specific disorders. For example, women with features that suggest polycystic ovarian syndrome should be evaluated for this condition. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"       \"Diagnosis of polycystic ovary syndrome in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=see_link\">",
"       \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28567?source=see_link&amp;anchor=H6#H6\">",
"       \"Insulin resistance: Definition and clinical spectrum\", section on 'Clinical spectrum'",
"      </a>",
"      .)",
"      <strong>",
"       &nbsp;",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The possibility of an occult malignancy should always be considered in older, non-obese adults with new-onset acanthosis nigricans without another identifiable cause",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinical features suggestive of malignancy-associated acanthosis nigricans. (See",
"    <a class=\"local\" href=\"#H1019361\">",
"     'Malignancy-associated acanthosis nigricans'",
"    </a>",
"    above.) However, there is little consensus on the appropriate cancer evaluation in such patients. At minimum, patients should be evaluated with a thorough review of symptoms, a complete physical examination, and age-appropriate cancer screening. Because many of the associated tumors involve the gastrointestinal tract, referral to gastroenterology is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H561155482\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple other cutaneous disorders share features with acanthosis nigricans. The possibility of such disorders should be considered in patients with lesions that are not classic for acanthosis nigricans.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Confluent and reticulated papillomatosis of Gougerot and Carteaud",
"      </strong>",
"      &ndash; This is an uncommon disorder that typically affects young adults. Reticulated, hyperpigmented, and slightly scaly plaques occur on the neck, chest (especially inframammary chest), and upper back (",
"      <a class=\"graphic graphic_picture graphicRef67566 graphicRef76296 \" href=\"UTD.htm?39/27/40375\">",
"       picture 6A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Granular parakeratosis",
"      </strong>",
"      &ndash; Granular parakeratosis is a disorder characterized by the appearance of hyperkeratotic brown-red papules that coalesce to form plaques (",
"      <a class=\"graphic graphic_picture graphicRef73591 \" href=\"UTD.htm?7/25/7572\">",
"       picture 7",
"      </a>",
"      ). Although the axilla is the most common site for involvement, the disorder may also occur in other intertriginous sites. Pruritus is typically present.",
"     </li>",
"     <li>",
"      <strong>",
"       Linear epidermal nevus",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Epidermal nevi are benign hamartomatous growths that are usually present at birth or become evident during the first year of life. The skin lesions are well-defined and often linear hyperpigmented, papillomatous plaques (",
"      <a class=\"graphic graphic_picture graphicRef64855 \" href=\"UTD.htm?3/48/3844\">",
"       picture 8",
"      </a>",
"      ). Epidermal nevi may become more prominent over time.",
"     </li>",
"     <li>",
"      <strong>",
"       Reticulated pigmented anomaly of the flexures (Dowling-Degos disease)",
"      </strong>",
"      &ndash; This is a rare, autosomal dominant disorder that presents with reticulated hyperpigmentation that has a predilection for flexural areas (",
"      <a class=\"graphic graphic_picture graphicRef77681 \" href=\"UTD.htm?9/10/9380\">",
"       picture 9",
"      </a>",
"      ). Lesions typically appear in early adulthood. Some patients also exhibit comedones and pitted facial scars.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other diagnostic considerations include Hailey-Hailey disease (",
"    <a class=\"graphic graphic_picture graphicRef61689 graphicRef80862 graphicRef74552 \" href=\"UTD.htm?25/6/25706\">",
"     picture 10A-C",
"    </a>",
"    ) (which is distinguished by the presence of inflammatory and erosive intertriginous plaques), pellagra (which can present with hyperpigmented plaques on the neck and other sun-exposed areas), and cutaneous hyperpigmentation related to Addison&rsquo;s disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H561155489\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since acanthosis nigricans is a benign, often asymptomatic disorder, cosmetic concerns are typically the primary indications for treatment. Treatment of the underlying cause, when feasible, is the preferred method of management, and obesity-related, drug-induced, and malignancy-associated acanthosis nigricans appear to frequently respond well to this intervention. In contrast, the likelihood for clinically significant improvement in acanthosis nigricans following the treatment of insulin resistant states is less certain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients in whom reversal of the underlying cause of acanthosis nigricans is impossible, in whom the degree of improvement is unsatisfactory, or who desire accelerated improvement in the cosmetic appearance of lesions, topical therapies that normalize epidermal proliferation, such as topical retinoids and topical vitamin D analogs, may be of benefit. Systemic retinoids have also been utilized for this indication, but are not indicated for the treatment of most patients.",
"   </p>",
"   <p>",
"    Patient with acanthosis nigricans sometimes attempt to improve the appearance of lesions through excessive scrubbing of the affected skin during bathing. Such behavior should be discouraged, since it may result in lichenification (thickening of the skin) and worsening hyperpigmentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1018712\">",
"    <span class=\"h2\">",
"     Treatment of underlying disorders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1018719\">",
"    <span class=\"h3\">",
"     Obesity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss has been linked to improvements in acanthosis nigricans in obese patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. We support and encourage weight loss efforts in patients with obesity-related acanthosis nigricans. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18378?source=see_link\">",
"     \"Management of childhood obesity in the primary care setting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1018726\">",
"    <span class=\"h3\">",
"     Insulin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agents that improve insulin sensitivity, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    , may have some benefit for acanthosis nigricans related to insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/55,58-63\">",
"     55,58-63",
"    </a>",
"    ]. A small, unblinded, non-placebo-controlled, 12-week randomized trial that compared metformin to rosiglitazone in overweight and obese patients with acanthosis nigricans found no significant change in lesion severity, and only modest improvement in skin texture [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/59\">",
"     59",
"    </a>",
"    ]. In a separate uncontrolled study, subjective improvement in acanthosis nigricans was noted in three out of five adolescents and adults with insulin resistance or diabetes who were treated with metformin for six months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/60\">",
"     60",
"    </a>",
"    ]. Additional studies are necessary to explore the efficacy and safety of such agents in the treatment of acanthosis nigricans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1018733\">",
"    <span class=\"h3\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications associated with the onset of acanthosis nigricans should be discontinued if medically feasible. Discontinuation of the inciting drug often results in the resolution of the skin lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H464810\">",
"     'Medications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1018740\">",
"    <span class=\"h3\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of the underlying malignancy is the preferred therapeutic intervention for patients with malignancy-associated acanthosis nigricans. Improvement or resolution of acanthosis nigricans has been reported in multiple patients following successful treatment of the associated malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/15,32-34,64-67\">",
"     15,32-34,64-67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1019164\">",
"    <span class=\"h3\">",
"     Other interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other therapies that have been associated with improvement of acanthosis nigricans in isolated patients include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    in an obese adolescent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/68\">",
"     68",
"    </a>",
"    ], and fish oil supplementation in a patient with a lipodystrophic form of diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H807895\">",
"    <span class=\"h2\">",
"     Skin-directed therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the efficacy of therapies aimed at directly improving the skin lesions of acanthosis nigricans are limited to case reports and documentation of clinical experience. Although improvement has been reported with several topical and systemic agents, the optimal approach to treatment, the likelihood for treatment success, and the long-term efficacy of these interventions remains unknown.",
"   </p>",
"   <p>",
"    Topical agents, such as topical retinoids, vitamin D analogs, and keratolytics are the primary agents used in the treatment of localized lesions. Topical therapy is impractical for the management of patients with widespread involvement, and treatment options for this population are limited.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Topical retinoids",
"      </strong>",
"      &ndash; Retinoids have keratinolytic effects on the skin, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1862?source=see_link\">",
"       topical tretinoin",
"      </a>",
"      0.1% gel applied to localized areas of acanthosis nigricans for up to two weeks has been linked to improvement in acanthosis nigricans in a few patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/70,71\">",
"       70,71",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Combination therapy with tretinoin and other agents may also be effective. Once-daily application of tretinoin 0.05% cream and twice-daily application of 12% ammonium lactate cream or lotion for a few months was associated with improvement in acanthosis nigricans on the front of the neck in a series of five patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/72\">",
"       72",
"      </a>",
"      ]. Of note, improvement was not detected on the sides of the neck, which were treated with either agent as monotherapy. In addition, a triple combination cream containing tretinoin 0.05%,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/59/36788?source=see_link\">",
"       hydroquinone",
"      </a>",
"      4%, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36192?source=see_link\">",
"       fluocinolone",
"      </a>",
"      acetonide 0.01% applied daily for one month was effective in a patient with limited neck and face lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Topical",
"      </strong>",
"      <strong>",
"       vitamin D",
"      </strong>",
"      <strong>",
"       analogs",
"      </strong>",
"      &ndash; Topical vitamin D analogs are capable of reducing keratinocyte proliferation, and have been associated with lesion improvement in several patients [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/58,74,75\">",
"       58,74,75",
"      </a>",
"      ]. As an example, calcipotriol (calcipotriene) 0.005% cream applied twice daily for three months led to improvement in acanthosis nigricans in flexural areas in an obese man with bladder cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/74\">",
"       74",
"      </a>",
"      ]. Moreover, twice daily use of calcipotriol ointment for four weeks by a man with hypogonadism-associated acanthosis nigricans was associated with complete remission of the lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Skin irritation is a potential adverse effect of topical retinoids and topical vitamin D analogs.",
"    <br/>",
"    <br/>",
"    Other local therapies that have been suggested for the treatment of acanthosis nigricans include topical urea, salicylic acid, and laser therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/15,76\">",
"     15,76",
"    </a>",
"    ]. Improvement in axillary acanthosis nigricans in a patient treated with long-pulsed alexandrite laser therapy has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/76\">",
"     76",
"    </a>",
"    ]. Greater than 95 percent clearance of the lesions was observed after five to seven treatments.",
"   </p>",
"   <p>",
"    Treatment with systemic retinoids such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    has been associated with moderate to marked improvement in several patients with extensive acanthosis nigricans [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/58,61,77,78\">",
"     58,61,77,78",
"    </a>",
"    ]. However, systemic retinoids have a wide range of potential adverse effects, and relapse appears to be common upon tapering or discontinuation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/58,61\">",
"     58,61",
"    </a>",
"    ]. Treatment with these agents is not indicated in most patients.",
"   </p>",
"   <p>",
"    Case reports have documented beneficial effects of pharmacologic interventions in small numbers of patients with malignancy-associated acanthosis nigricans [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. A reduction in pruritus was noted in a lung cancer patient with treated psoralen plus ultraviolet A (PUVA) phototherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/79\">",
"     79",
"    </a>",
"    ], and marked improvement in signs and symptoms of the disorder was reported in a patient with both gastric and prostate cancer who was treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/25/19862?source=see_link\">",
"     cyproheptadine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H324473\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acanthosis nigricans is a chronic disorder that persists in the absence of removal of the underlying cause or successful skin-directed therapy. In isolation, the long-term persistence of acanthosis nigricans usually has no physical adverse consequences.",
"    <br/>",
"    <br/>",
"    However, patients with acanthosis nigricans associated with obesity or medical disorders are subject to disease-specific sequelae. The prognosis for malignancy-associated acanthosis nigricans often is poor since malignancy is frequently diagnosed at an advanced stage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27897/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H335766\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Referral to a dermatologist is indicated if the diagnosis of skin lesions is uncertain. Evaluation by a clinician with expertise in the management of endocrine or metabolic disorders is indicated if such disorders are detected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9557805\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acanthosis nigricans is a common, benign disorder that typically presents with velvety, hyperpigmented plaques on the skin. Mucosal involvement is an occasional feature. Individuals of any age may be affected. (See",
"      <a class=\"local\" href=\"#H561155461\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H561155447\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A wide variety of endocrine, metabolic, genetic, and malignant disorders may contribute to the development of acanthosis nigricans. An evaluation for the underlying cause should always be performed. Obesity is the most common cause of this disorder. Acanthosis nigricans may also be induced by drugs. (See",
"      <a class=\"local\" href=\"#H464423\">",
"       'Etiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H561155475\">",
"       'Diagnosis and patient evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Insulin resistance likely plays a key role in many cases of acanthosis nigricans, including cases linked to obesity, diabetes, and some genetic syndromes. (See",
"      <a class=\"local\" href=\"#H561155454\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Malignancy is a rare cause of acanthosis nigricans. In particular, the possibility of an occult malignancy should be considered in adults with extensive or atypical presentations of acanthosis nigricans or new onset acanthosis nigricans of unknown cause. (See",
"      <a class=\"local\" href=\"#H1019361\">",
"       'Malignancy-associated acanthosis nigricans'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H561155475\">",
"       'Diagnosis and patient evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=see_link&amp;anchor=H9#H9\">",
"       \"Cutaneous manifestations of internal malignancy\", section on 'Acanthosis nigricans'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of the clinical manifestations of acanthosis nigricans is not required since the condition does not induce physical harm. The primary indications for treatment of the skin lesions are cosmetic concerns of the patient. (See",
"      <a class=\"local\" href=\"#H561155489\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H561155475\">",
"       'Diagnosis and patient evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Data are limited on the treatments for acanthosis nigricans. If an underlying cause is present, treatment or removal of the inciting cause should be attempted. Obesity-related, drug-induced, and malignancy-associated acanthosis nigricans often respond to this form of therapy. The role of agents that improve insulin sensitivity in patients with acanthosis nigricans related to insulin resistance remains uncertain. (See",
"      <a class=\"local\" href=\"#H1018712\">",
"       'Treatment of underlying disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who desire accelerated improvement of acanthosis nigricans or in whom treatment of the underlying disorder is not possible or satisfactory, we suggest a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1862?source=see_link\">",
"       topical tretinoin",
"      </a>",
"      or a topical vitamin D analog, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/54/5988?source=see_link\">",
"       calcipotriol (calcipotriene)",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Systemic retinoids may lead to clinical improvement in patients with extensive or severe disease, but relapse is common after treatment discontinuation. (See",
"      <a class=\"local\" href=\"#H807895\">",
"       'Skin-directed therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/1\">",
"      Sharda S, Panigrahi I, Gupta K, et al. A newborn with acanthosis nigricans: can it be Crouzon syndrome with acanthosis nigricans? Pediatr Dermatol 2010; 27:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/2\">",
"      Hud JA Jr, Cohen JB, Wagner JM, Cruz PD Jr. Prevalence and significance of acanthosis nigricans in an adult obese population. Arch Dermatol 1992; 128:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/3\">",
"      Dassanayake AS, Kasturiratne A, Niriella MA, et al. Prevalence of Acanthosis Nigricans in an urban population in Sri Lanka and its utility to detect metabolic syndrome. BMC Res Notes 2011; 4:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/4\">",
"      Chang Y, Woo HY, Sung E, et al. Prevalence of acanthosis nigricans in relation to anthropometric measures: community-based cross-sectional study in Korean pre-adolescent school children. Pediatr Int 2008; 50:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/5\">",
"      Ogbera AO, Akinlade A, Ajose O, Awobusuyi J. Prevalence of acanthosis nigricans and its correlates in a cross-section of Nigerians with type 2 diabetes mellitus. Trop Doct 2009; 39:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/6\">",
"      Rafalson L, Eysaman J, Quattrin T. Screening obese students for acanthosis nigricans and other diabetes risk factors in the urban school-based health center. Clin Pediatr (Phila) 2011; 50:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/7\">",
"      Litonjua P, Pi&ntilde;ero-Pilo&ntilde;a A, Aviles-Santa L, Raskin P. Prevalence of acanthosis nigricans in newly-diagnosed type 2 diabetes. Endocr Pract 2004; 10:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/8\">",
"      Nguyen TT, Keil MF, Russell DL, et al. Relation of acanthosis nigricans to hyperinsulinemia and insulin sensitivity in overweight African American and white children. J Pediatr 2001; 138:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/9\">",
"      Stuart CA, Pate CJ, Peters EJ. Prevalence of acanthosis nigricans in an unselected population. Am J Med 1989; 87:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/10\">",
"      Stuart CA, Driscoll MS, Lundquist KF, et al. Acanthosis nigricans. J Basic Clin Physiol Pharmacol 1998; 9:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/11\">",
"      Brickman WJ, Binns HJ, Jovanovic BD, et al. Acanthosis nigricans: a common finding in overweight youth. Pediatr Dermatol 2007; 24:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/12\">",
"      Kopping D, Nevarez H, Goto K, et al. A longitudinal study of overweight, elevated blood pressure, and acanthosis nigricans among low-income middle school students. J Sch Nurs 2012; 28:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/13\">",
"      Kong AS, Williams RL, Rhyne R, et al. Acanthosis Nigricans: high prevalence and association with diabetes in a practice-based research network consortium--a PRImary care Multi-Ethnic network (PRIME Net) study. J Am Board Fam Med 2010; 23:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/14\">",
"      Stoddart ML, Blevins KS, Lee ET, et al. Association of acanthosis nigricans with hyperinsulinemia compared with other selected risk factors for type 2 diabetes in Cherokee Indians: the Cherokee Diabetes Study. Diabetes Care 2002; 25:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/15\">",
"      Sinha S, Schwartz RA. Juvenile acanthosis nigricans. J Am Acad Dermatol 2007; 57:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/16\">",
"      Stuart CA, Gilkison CR, Smith MM, et al. Acanthosis nigricans as a risk factor for non-insulin dependent diabetes mellitus. Clin Pediatr (Phila) 1998; 37:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/17\">",
"      Otto DE, Wang X, Tijerina SL, et al. A comparison of blood pressure, body mass index, and acanthosis nigricans in school-age children. J Sch Nurs 2010; 26:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/18\">",
"      Brickman WJ, Huang J, Silverman BL, Metzger BE. Acanthosis nigricans identifies youth at high risk for metabolic abnormalities. J Pediatr 2010; 156:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/19\">",
"      Kong AS, Williams RL, Smith M, et al. Acanthosis nigricans and diabetes risk factors: prevalence in young persons seen in southwestern US primary care practices. Ann Fam Med 2007; 5:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/20\">",
"      Brown B, Noonan C, Bentley B, et al. Acanthosis nigricans among Northern Plains American Indian children. J Sch Nurs 2010; 26:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/21\">",
"      Ice CL, Murphy E, Minor VE, Neal WA. Metabolic syndrome in fifth grade children with acanthosis nigricans: results from the CARDIAC project. World J Pediatr 2009; 5:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/22\">",
"      Valery PC, Moloney A, Cotterill A, et al. Prevalence of obesity and metabolic syndrome in Indigenous Australian youths. Obes Rev 2009; 10:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/23\">",
"      Jabbour SA. Cutaneous manifestations of endocrine disorders: a guide for dermatologists. Am J Clin Dermatol 2003; 4:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/24\">",
"      Huang-Doran I, Savage DB. Congenital syndromes of severe insulin resistance. Pediatr Endocrinol Rev 2011; 8:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/25\">",
"      Berk DR, Spector EB, Bayliss SJ. Familial acanthosis nigricans due to K650T FGFR3 mutation. Arch Dermatol 2007; 143:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/26\">",
"      Torley D, Bellus GA, Munro CS. Genes, growth factors and acanthosis nigricans. Br J Dermatol 2002; 147:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/27\">",
"      Mu&ntilde;oz-P&eacute;rez MA, Camacho F. Acanthosis nigricans: a new cutaneous sign in severe atopic dermatitis and Down syndrome. J Eur Acad Dermatol Venereol 2001; 15:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/28\">",
"      Schwartz RA. Acanthosis nigricans. J Am Acad Dermatol 1994; 31:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/29\">",
"      Talsania N, Harwood CA, Piras D, Cerio R. Paraneoplastic Acanthosis Nigricans: The importance of exhaustive and repeated malignancy screening. Dermatol Online J 2010; 16:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/30\">",
"      Amjad M, Shah AA. Malignant acanthosis nigricans: an early diagnostic clue. J Coll Physicians Surg Pak 2010; 20:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/31\">",
"      Rigel DS, Jacobs MI. Malignant acanthosis nigricans: a review. J Dermatol Surg Oncol 1980; 6:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/32\">",
"      Anderson SH, Hudson-Peacock M, Muller AF. Malignant acanthosis nigricans: potential role of chemotherapy. Br J Dermatol 1999; 141:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/33\">",
"      Krawczyk M, Mykaï¿½ï¿½a-Cieï¿½ï¿½la J, Koï¿½ï¿½odziej-Jaskuï¿½ï¿½a A. Acanthosis nigricans as a paraneoplastic syndrome. Case reports and review of literature. Pol Arch Med Wewn 2009; 119:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/34\">",
"      Lee SS, Jung NJ, Im M, et al. Acral-type Malignant Acanthosis Nigricans Associated with Gastric Adenocarcinoma. Ann Dermatol 2011; 23:S208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/35\">",
"      Fleming MG, Simon SI. Cutaneous insulin reaction resembling acanthosis nigricans. Arch Dermatol 1986; 122:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/36\">",
"      Skouby SO. Update on the metabolic effects of oral contraceptives. J Obstet Gynaecol (Lahore) 1986; 6 Suppl 2:S104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/37\">",
"      Stals H, Vercammen C, Peeters C, Morren MA. Acanthosis nigricans caused by nicotinic acid: case report and review of the literature. Dermatology 1994; 189:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/38\">",
"      Mellor-Pita S, Yebra-Bango M, Alfaro-Mart&iacute;nez J, Su&aacute;rez E. Acanthosis nigricans: a new manifestation of insulin resistance in patients receiving treatment with protease inhibitors. Clin Infect Dis 2002; 34:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/39\">",
"      Lane SW, Manoharan S, Mollee PN. Palifermin-induced acanthosis nigricans. Intern Med J 2007; 37:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/40\">",
"      Lee M, Grassi M. Acanthosis nigricans in a patient treated with palifermin. Cutis 2010; 86:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/41\">",
"      Hida Y, Kubo Y, Nishio Y, et al. Malignant acanthosis nigricans with enhanced expression of fibroblast growth factor receptor 3. Acta Derm Venereol 2009; 89:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/42\">",
"      Haase I, Hunzelmann N. Activation of epidermal growth factor receptor/ERK signaling correlates with suppressed differentiation in malignant acanthosis nigricans. J Invest Dermatol 2002; 118:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/43\">",
"      Koyama S, Ikeda K, Sato M, et al. Transforming growth factor-alpha (TGF alpha)-producing gastric carcinoma with acanthosis nigricans: an endocrine effect of TGF alpha in the pathogenesis of cutaneous paraneoplastic syndrome and epithelial hyperplasia of the esophagus. J Gastroenterol 1997; 32:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/44\">",
"      Jeong JS, Lee JY, Yoon TY. Unilateral nevoid acanthosis nigricans with a submammary location. Ann Dermatol 2011; 23:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/45\">",
"      Krishnaram AS. Unilateral nevoid acanthosis nigricans and neurofibromatosis 1: an unusual association. Indian J Dermatol Venereol Leprol 2010; 76:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/46\">",
"      de Waal AC, van Rossum MM, Bovenschen HJ. Extensive segmental acanthosis nigricans form of epidermal nevus. Dermatol Online J 2010; 16:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/47\">",
"      Ersoy-Evans S, Sahin S, Mancini AJ, et al. The acanthosis nigricans form of epidermal nevus. J Am Acad Dermatol 2006; 55:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/48\">",
"      Schwartz RA. Acral acanthotic anomaly (AAA). J Am Acad Dermatol 1981; 5:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/49\">",
"      Brantsch KD, Moehrle M. Acanthosis nigricans in a patient with sarcoma of unknown origin. J Am Acad Dermatol 2010; 62:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/50\">",
"      Thomas M, Radhakrishnan S, Sunny B, et al. Malignant acanthosis nigricans with occult primary. Indian J Dermatol Venereol Leprol 2002; 68:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/51\">",
"      Pentenero M, Carrozzo M, Pagano M, Gandolfo S. Oral acanthosis nigricans, tripe palms and sign of leser-tr&eacute;lat in a patient with gastric adenocarcinoma. Int J Dermatol 2004; 43:530.",
"     </a>",
"    </li>",
"    <li>",
"     Weedon D. Miscellaneous conditions. In: Weedon's Skin Pathology, 3rd ed, Elsevier Limited, 2010. p.501.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/53\">",
"      Hall JM, Moreland A, Cox GJ, Wade TR. Oral acanthosis nigricans: report of a case and comparison of oral and cutaneous pathology. Am J Dermatopathol 1988; 10:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/54\">",
"      Higgins SP, Freemark M, Prose NS. Acanthosis nigricans: a practical approach to evaluation and management. Dermatol Online J 2008; 14:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/55\">",
"      Romo A, Benavides S. Treatment options in insulin resistance obesity-related acanthosis nigricans. Ann Pharmacother 2008; 42:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/56\">",
"      Kuroki R, Sadamoto Y, Imamura M, et al. Acanthosis nigricans with severe obesity, insulin resistance and hypothyroidism: improvement by diet control. Dermatology 1999; 198:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/57\">",
"      Pasquali R, Antenucci D, Casimirri F, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989; 68:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/58\">",
"      Hermanns-L&ecirc; T, Hermanns JF, Pi&eacute;rard GE. Juvenile acanthosis nigricans and insulin resistance. Pediatr Dermatol 2002; 19:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/59\">",
"      Bellot-Rojas P, Posadas-Sanchez R, Caracas-Portilla N, et al. Comparison of metformin versus rosiglitazone in patients with Acanthosis nigricans: a pilot study. J Drugs Dermatol 2006; 5:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/60\">",
"      Tankova T, Koev D, Dakovska L, Kirilov G. Therapeutic approach in insulin resistance with acanthosis nigricans. Int J Clin Pract 2002; 56:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/61\">",
"      Walling HW, Messingham M, Myers LM, et al. Improvement of acanthosis nigricans on isotretinoin and metformin. J Drugs Dermatol 2003; 2:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/62\">",
"      Wasniewska M, Arrigo T, Crisafulli G, et al. Recovery of acanthosis nigricans under prolonged metformin treatment in an adolescent with normal weight. J Endocrinol Invest 2009; 32:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/63\">",
"      Lee PJ, Cranston I, Amiel SA, et al. Effect of metformin on glucose disposal and hyperinsulinaemia in a 14-year-old boy with acanthosis nigricans. Horm Res 1997; 48:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/64\">",
"      Ellis DL, Kafka SP, Chow JC, et al. Melanoma, growth factors, acanthosis nigricans, the sign of Leser-Tr&eacute;lat, and multiple acrochordons. A possible role for alpha-transforming growth factor in cutaneous paraneoplastic syndromes. N Engl J Med 1987; 317:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/65\">",
"      Vassilopoulou-Sellin R, Cangir A, Samaan NA. Acanthosis nigricans and severe insulin resistance in an adolescent girl with thyroid cancer: clinical response to antineoplastic therapy. Am J Clin Oncol 1992; 15:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/66\">",
"      Yeh JS, Munn SE, Plunkett TA, et al. Coexistence of acanthosis nigricans and the sign of Leser-Tr&eacute;lat in a patient with gastric adenocarcinoma: a case report and literature review. J Am Acad Dermatol 2000; 42:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/67\">",
"      Kebria MM, Belinson J, Kim R, Mekhail TM. Malignant acanthosis nigricans, tripe palms and the sign of Leser-Tre'lat, a hint to the diagnosis of early stage ovarian cancer: a case report and review of the literature. Gynecol Oncol 2006; 101:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/68\">",
"      Lunetta M, Di Mauro M, Le Moli R, Burrafato S. Long-term octreotide treatment reduced hyperinsulinemia, excess body weight and skin lesions in severe obesity with acanthosis nigricans. J Endocrinol Invest 1996; 19:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/69\">",
"      Sherertz EF. Improved acanthosis nigricans with lipodystrophic diabetes during dietary fish oil supplementation. Arch Dermatol 1988; 124:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/70\">",
"      Darmstadt GL, Yokel BK, Horn TD. Treatment of acanthosis nigricans with tretinoin. Arch Dermatol 1991; 127:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/71\">",
"      Berger BJ, Gross PR. Another use for tretinoin--pseudoacanthosis nigricans. Arch Dermatol 1973; 108:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/72\">",
"      Blobstein SH. Topical therapy with tretinoin and ammonium lactate for acanthosis nigricans associated with obesity. Cutis 2003; 71:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/73\">",
"      Adigun CG, Pandya AG. Improvement of idiopathic acanthosis nigricans with a triple combination depigmenting cream. J Eur Acad Dermatol Venereol 2009; 23:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/74\">",
"      B&ouml;hm M, Luger TA, Metze D. Treatment of mixed-type acanthosis nigricans with topical calcipotriol. Br J Dermatol 1998; 139:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/75\">",
"      Gregoriou S, Anyfandakis V, Kontoleon P, et al. Acanthosis nigricans associated with primary hypogonadism: successful treatment with topical calcipotriol. J Dermatolog Treat 2008; 19:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/76\">",
"      Rosenbach A, Ram R. Treatment of Acanthosis nigricans of the axillae using a long-pulsed (5-msec) alexandrite laser. Dermatol Surg 2004; 30:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/77\">",
"      Swineford SL, Drucker CR. Palliative treatment of paraneoplastic acanthosis nigricans and oral florid papillomatosis with retinoids. J Drugs Dermatol 2010; 9:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/78\">",
"      Katz RA. Treatment of acanthosis nigricans with oral isotretinoin. Arch Dermatol 1980; 116:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/79\">",
"      Bonnekoh B, Thiele B, Merk H, Mahrle G. [Systemic photochemotherapy (PUVA) in acanthosis nigricans maligna: regression of keratosis, hyperpigmentation and pruritus]. Z Hautkr 1989; 64:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/80\">",
"      Greenwood R, Tring FC. Treatment of malignant acanthosis nigricans with cyproheptadine. Br J Dermatol 1982; 106:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27897/abstract/81\">",
"      CURTH HO, HILBERG AW, MACHACEK GF. The site and histology of the cancer associated with malignant acanthosis nigricans. Cancer 1962; 15:364.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13754 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C070ECA3F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_15_27897=[""].join("\n");
var outline_f27_15_27897=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9557805\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H561155440\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H561155447\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H464423\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H464431\">",
"      Obesity, endocrine, and metabolic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H464447\">",
"      Genetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H332799\">",
"      Familial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H464455\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H464810\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H561155454\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H561155461\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1019361\">",
"      Malignancy-associated acanthosis nigricans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H561155468\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H561155475\">",
"      DIAGNOSIS AND PATIENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H561155482\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H561155489\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1018712\">",
"      Treatment of underlying disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1018719\">",
"      - Obesity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1018726\">",
"      - Insulin resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1018733\">",
"      - Drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1018740\">",
"      - Malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1019164\">",
"      - Other interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H807895\">",
"      Skin-directed therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H324473\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H335766\">",
"      INDICATIONS FOR REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9557805\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13754\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13754|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/40/17026\" title=\"picture 1A\">",
"      Acanthosis nigricans on neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/10/12449\" title=\"picture 1B\">",
"      Acanthosis nigricans on neck close view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/31/4598\" title=\"picture 1C\">",
"      Acanthosis nigricans - axilla",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/43/15030\" title=\"picture 1D\">",
"      Acanthosis nigricans - close view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/11/27828\" title=\"picture 1E\">",
"      Acanthosis nigricans with acrochordae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/55/41846\" title=\"picture 2\">",
"      Acanthosis nigricans in groin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/35/9781\" title=\"picture 3A\">",
"      Umbilical acanthosis nigricans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/7/43126\" title=\"picture 3B\">",
"      Acanthosis nigricans on lips",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/8/13445\" title=\"picture 3C\">",
"      Acanthosis nigricans on the nipple",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/56/37765\" title=\"picture 4\">",
"      Acral acanthosis nigricans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/59/15283\" title=\"picture 5\">",
"      Tripe palm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/10/36003\" title=\"picture 6A\">",
"      Confluent and reticulated papillomatosis - back",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/8/25729\" title=\"picture 6B\">",
"      Confluent and reticulated papillomatosis - chest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/25/7572\" title=\"picture 7\">",
"      Granular parakeratosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/48/3844\" title=\"picture 8\">",
"      Epidermal nevus on neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/10/9380\" title=\"picture 9\">",
"      Reticulated pigmented anomaly of the flexures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/47/19186\" title=\"picture 10A\">",
"      Hailey-Hailey 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/63/35828\" title=\"picture 10B\">",
"      Hailey Hailey",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/51/3893\" title=\"picture 10C\">",
"      Hailey-Hailey 2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=related_link\">",
"      Clinical features and diagnosis of polycystic ovary syndrome in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/18/8487?source=related_link\">",
"      Craniosynostosis syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/18/21802?source=related_link\">",
"      Cutaneous manifestations of internal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=related_link\">",
"      Diagnosis of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28567?source=related_link\">",
"      Insulin resistance: Definition and clinical spectrum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23352?source=related_link\">",
"      Lipodystrophic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18378?source=related_link\">",
"      Management of childhood obesity in the primary care setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/14/31976?source=related_link\">",
"      Measurement of growth in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42585?source=related_link\">",
"      Prenatal diagnosis of the lethal skeletal dysplasias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=related_link\">",
"      Screening for and clinical evaluation of obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=related_link\">",
"      Screening for diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_15_27898="A primer of red blood cell antigens and antibodies";
var content_f27_15_27898=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   A primer of red blood cell antigens and antibodies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/15/27898/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/15/27898/contributors\">",
"     David W Cohen, MA, MT(ASCP)SBB",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/15/27898/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/15/27898/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/15/27898/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/15/27898/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/15/27898/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individual blood groups of the red cell membrane are serologically linked antigenic structures, due to their presence on the same biochemically-related lipids or proteins. Some antigens, such as those of the ABO blood group, are surface structures, while others (eg, Rh) are carried on molecules that span the width of the red cell membrane.",
"   </p>",
"   <p>",
"    This topic review will discuss the basic biochemistry of each of the major blood groups, along with unusual phenotypes within each system. An emphasis will be placed on disease association as well as the clinical significance of antibodies produced against each blood group. Finally, the cell lines and tissues on which the blood group is expressed will be listed; the potential deleterious effect of antibodies produced against a given blood group on transplanted organs will also be discussed. Additional reading for subjects not covered here is available to the interested reader [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ABO (ABH) BLOOD GROUP SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The four common blood groups in the",
"    <span class=\"nowrap\">",
"     ABO/ABH",
"    </span>",
"    system are O, A, B, and AB. These occur in the Caucasian population at frequencies of 45, 40, 11, and 4 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/4\">",
"     4",
"    </a>",
"    ]. These percentages vary somewhat among different ethnic groups. The function of the ABH antigens is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Natural alloantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an individual lacks the A",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    B antigen on the red cells, the plasma will contain naturally-occurring antibodies to the missing antigen(s). They generally appear in the blood by four to six months of age following exposure to bacterial antigens that are similar in structure to the A and B blood group antigens as the gut becomes colonized in early infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Group A individuals will have anti-B antibodies",
"     </li>",
"     <li>",
"      Group B individuals will have anti-A antibodies",
"     </li>",
"     <li>",
"      Group O individuals will have both anti-A and anti-B antibodies",
"     </li>",
"     <li>",
"      Group AB individuals will have neither anti-A nor anti-B",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Absence of expected alloantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absence of the expected alloantibodies in adult individuals with blood groups A, B, or O might occur under the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Presence of a weakly expressed ABO subgroup where the patient appears to be Group O yet does not have both anti-A and anti-B (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Unusual phenotypes'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      History of an ABO incompatible hematopoietic cell transplantation",
"     </li>",
"     <li>",
"      Hypogammaglobulinemia (eg, common variable immunodeficiency) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17209?source=see_link&amp;anchor=H15#H15\">",
"       \"Selective antibody deficiency with normal immunoglobulins\", section on 'Isohemagglutinins'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Co-mingling of circulating red cells in utero between fraternal twins, resulting in tolerance being induced to the lacking AB antigen (eg, a group O twin who never forms anti-A because of exposure in utero to group A cells from its fraternal twin) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Loss of anti-A in routine blood group testing has been described in a patient treated with high doses of anti-snake venom derived from healthy hyperimmunized horses [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/10\">",
"       10",
"      </a>",
"      ]. Apparently, A or A-like substances are properties of horse serum itself, and it is likely that these substances in the anti-snake venom neutralized the patient's anti-A.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     High titers of alloantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;High titers of anti-A or anti-B may be seen following pregnancy, recent vaccination, and ingestion of high-dose live bacteria (eg, probiotic therapy). Infusion of plasma-containing blood products (eg, platelets) from donors with extremely high anti-A or anti-B titers may result in severe hemolytic transfusion reactions in recipients, even if the amounts of plasma are small [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of this potential problem, some medical centers obtain alloantibody titers in all group O platelets to see if their anti-A and anti-B titers were under 200 before deciding whether they could be given to other than group O recipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Basic biochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ABO blood groups are defined by the presence of immunodominant sugars: n-acetylgalactosamine for the \"A\" antigen and D-galactose for the \"B\" antigen. Both sugars are built upon the \"H\" antigen, the immunodominant sugar of which is L-fucose. If the \"H\" antigen is unmodified, the individual types as Group O. All of these sugars are attached to oligosaccharides carried on glycosphingolipid and glycoprotein chains. Thus, ABH antigens are not an integral part of the membrane and actually extend out above the red cell surface.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Unusual phenotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The products of the ABH genes are glycosyl transferases, which transfer the immunodominant sugar of each blood group to the backbone chain. Examples of unusual phenotypes at the ABH locus include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the Bombay phenotype, fucosyl transferase, which conveys H antigen specificity, is lacking. Since the H antigen is the building block for the A and B antigens, neither A nor B can be produced, even in the presence of their respective transferase enzymes. Thus, red cells of the Bombay phenotype lack A, B and H antigens. These individuals naturally produce anti-A, anti-B, and broad thermal range anti-H antibodies, and they can only be transfused with blood from other individuals of the Bombay phenotype (usually a relative, although autologous blood can be obtained by apheresis prior to a surgical procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/11\">",
"       11",
"      </a>",
"      ]), or risk a severe hemolytic transfusion reaction.",
"     </li>",
"     <li>",
"      Weak subgroups may also occur within the ABO blood group system, in which the A or B antigens are difficult to detect [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/12\">",
"       12",
"      </a>",
"      ]. It is advisable to transfuse group O red cells when the ABO blood group is uncertain because of such weak A or B antigens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Individuals with the A subtype known as A",
"    <sub>",
"     pae",
"    </sub>",
"    are actually type O and express the Forssman antigen. (See",
"    <a class=\"local\" href=\"#H17331729\">",
"     'FORS blood group system'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Disease associations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Acquired B antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquisition of the B antigen occurs in approximately 5 percent of patients with genetic A1, a strong A antigen found in 80 percent of A individuals, resulting from production of a deacetylase enzyme by bacteria such as E. coli K-12 or Clostridium tertium. When these bacteria gain a foothold in necrotic malignant lesions",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gastrointestinal obstructions and elaborate the enzymes into the circulation, a B-like antigen is generated at the expense of the A1 antigen. The resulting ABO discrepancy may be the first indication to the clinician that an ongoing infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    malignancy exists. Once the infection is successfully treated, the patient's ABO group will return to group A1 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with the acquired B antigen should never be transfused with AB or B blood, as such blood is likely to be cleared from circulation at a rapid rate, because of the existence of pre-formed anti-B antibody. However, this anti-B does not react with the patient's own acquired B antigen.",
"   </p>",
"   <p>",
"    A, B, and H antigens often act as tumor markers, and may be weakened or lost in various myeloid malignancies (eg, acute myeloid leukemia, myeloproliferative neoplasms, myelodysplastic syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/14-16\">",
"     14-16",
"    </a>",
"    ], chromosomal aberrations, and thalassemia. Gastric cancers appear to be more prevalent in group A individuals, gastric and duodenal ulcers occur more often in those who are Group O, and pancreatic cancers appear to be more common in those who are of non-O blood types (ie, A, AB, or B) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/38/618?source=see_link&amp;anchor=H21#H21\">",
"     \"Risk factors for gastric cancer\", section on 'Blood group'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27866?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and risk factors for exocrine pancreatic cancer\", section on 'Other inherited risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Thrombotic risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subjects with blood groups A, B, or AB have a higher risk of venous thromboembolic disease than those of blood group O, probably related to the effect of the ABO system on levels of von Willebrand factor and factor VIII [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17049?source=see_link&amp;anchor=H5#H5\">",
"     \"Biology and normal function of von Willebrand factor\", section on 'Plasma VWF'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=see_link&amp;anchor=H10#H10\">",
"     \"Activated protein C resistance and factor V Leiden\", section on 'Other genetic influences'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Factor VIII'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Expression of antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphocytes and platelets have ABH antigens that are absorbed from the plasma; rare individuals have platelets which highly express ABH antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. There is broad tissue distribution as well, particularly on glandular epithelial and endothelial cells. The strength of the A and B antigens is not fully developed on cord cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3912?source=see_link&amp;anchor=H14#H14\">",
"     \"Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues\", section on 'ABO-induced disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Clinical significance of antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most deaths from blood transfusion are the result of transfusing ABO incompatible blood, since the A and B antigens are the most immunogenic and the corresponding antibodies are often strongly hemolytic both in vitro and in vivo (",
"    <a class=\"graphic graphic_table graphicRef57717 \" href=\"UTD.htm?14/29/14811\">",
"     table 1",
"    </a>",
"    ). These errors tend to be primarily clerical in nature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link&amp;anchor=H7#H7\">",
"     \"Immunologic blood transfusion reactions\", section on 'Acute hemolytic reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As opposed to the severe nature of transfusion reactions, hemolytic disease of the newborn (HDN) caused by ABO antibodies tends to be relatively mild in nature, since the A and B antigens are not well developed at birth. The exception is in group B African-American newborns of group O mothers. The B antigen appears to be more developed at birth in this ethnic group, and ABO HDN can be of a more severe nature, sometimes requiring exchange transfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3912?source=see_link&amp;anchor=H14#H14\">",
"     \"Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues\", section on 'ABO-induced disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Effect of antibodies on transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Donor kidneys should be ABO compatible with the recipient's ABO antibodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=see_link&amp;anchor=H3#H3\">",
"     \"HLA and ABO sensitization and desensitization in renal transplantation\", section on 'ABO incompatibility'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ABO compatibility is not required between donor and recipient for bone marrow transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H12#H12\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'ABO and Rh status'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ABO mismatches at the time of bone marrow transplantation may lead to self-limited hemolysis or graft versus host disease, where, for example, group O donor lymphocytes produce anti-A antibodies against red cells and tissues of a group A recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RH BLOOD GROUP SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Rh antigens are located on non-glycosylated polypeptides. They are transmembrane proteins and thus integral components of the red cell membrane. The antigens commonly recognized on the red cell include D, C, c, E, and e [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/27\">",
"     27",
"    </a>",
"    ]. Each chromosome will be either D positive or D negative (there is no \"d\" antigen), C or c positive, and E or e positive. Rh antigens (eg, the Rh haplotype) are inherited as a linked group of two genes (RhD, RhCE) in close proximity on chromosome 1, with RhCE encoding both",
"    <span class=\"nowrap\">",
"     C/c",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     E/e",
"    </span>",
"    on a single molecule. The most common phenotype in Caucasians and blacks are DCe and Dce, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rh D positivity occurs in the Caucasian population at a frequency of 83 percent, with variation among different ethnic groups, reaching &ge;98 percent in Asian blood donors [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/4,29\">",
"     4,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Immunogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RhD antigen is highly immunogenic in subjects who are not immunosuppressed (",
"    <a class=\"graphic graphic_table graphicRef57717 \" href=\"UTD.htm?14/29/14811\">",
"     table 1",
"    </a>",
"    ). As an example, infusion of as little as 0.5 mL of D+ red cells into healthy male D- volunteers lead to an 80 percent anti-D alloimmunization rate at a mean of 80 days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/30\">",
"     30",
"    </a>",
"    ]. However, the RhD antigen may be less immunogenic in other populations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies in hospitalized patients, patients with malignancy, and AIDS patients have indicated much lower alloimmunization rates, in the range of 22 percent or less [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a preliminary report, 24 RhD-negative patients who underwent orthotopic liver transplantation along with immune suppression received transfusions with a mean of 13 units of RhD-positive blood perioperatively [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/33\">",
"       33",
"      </a>",
"      ]. None developed anti-D antibodies during follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Unusual phenotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rh deletion cells exist in the population, which result in one or more of the Rh antigen sites being absent from the red cell membrane. These deletions can occur at the Ee locus, at both the Cc and Ee loci, or at all three loci. In the latter circumstances, no Rh antigens are produced, a condition referred to as \"Rh null.\" This latter condition is due to mutations in the RhAG (Rh-associated glycoprotein) gene on chromosome 6, which is important for targeting RhCE and RhD to the red cell membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/28\">",
"     28",
"    </a>",
"    ]. In the absence of RhAG, neither RhCE nor RhD reach the cell membrane. Patients with these deletion types, when transfused, may form one or more antibodies to high frequency Rh antigens, which makes it extremely difficult to procure compatible blood.",
"   </p>",
"   <p>",
"    Aberrations in the Rh system appear to be more common in the African-American population, particularly at the D and e loci. Such patients may actually type as D+ and demonstrate anti-D or type as e+ and have anti-e-like activity. Interestingly, once one mosaicism is identified (a portion of the antigen appearing to be absent), other mosaicisms will often be detected at a later date.",
"   </p>",
"   <p>",
"    Several D antigen variants, variously called partial D, weak D, Rh mod, D(u), and D(el) exist, which may or may not type as D+ by all available serologic reagents. Patients harboring these variants are potentially at risk for developing anti-D, and their blood may incite anti-D antibody formation in D- negative recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rare weak D antigen, DEL, found primarily in the Japanese and Chinese population, is exceedingly difficult to detect, particularly when using monoclonal Rh reagents. Data in the literature suggest that a DEL positive donor unit is extremely unlikely to cause primary immunization in an Rh negative recipient, although it may prompt a secondary response in already immunized Rh negative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Disease associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perhaps the most dramatic disease association is the compensated hemolytic anemia seen in most individuals with Rh null or Rh mod red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/37\">",
"     37",
"    </a>",
"    ]. This is not unexpected, since the carrier molecules for the antigens project through the red cell membrane, and the absence of such proteins would be expected to affect the material properties of the red cell, causing loss of red cell membrane, and reducing the ratio of surface area to volume. As a result, Rh null red cells do not appear as biconcave discs, but rather as stomatocytes (cup shaped) and spherocytes, and demonstrate increased osmotic fragility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42200?source=see_link&amp;anchor=H11#H11\">",
"     \"Stomatocytosis\", section on 'Rh-null disease'",
"    </a>",
"    .) The anemia is usually mild in nature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Blood group function and expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rh antigens (or more properly, their carrier molecule) are specific to the erythroid cell line and appear to be expressed on cord blood red cells. The RhAG and Rh proteins appear to function as",
"    <span class=\"nowrap\">",
"     ammonia/ammonium",
"    </span>",
"    transporters [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical significance of Rh antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a number of examples of anti-E and anti-Cw (a replacement antigen at the Cc loci) can be naturally occurring IgM specificities, the majority of the antibodies are IgG in nature; all are capable of causing significant hemolytic transfusion reactions (HTRs) as well as hemolytic disease of the newborn (HDN) (",
"    <a class=\"graphic graphic_table graphicRef57717 \" href=\"UTD.htm?14/29/14811\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Anti-D, the originally described anti-Rh, causes the most severe form of HDN, sometimes resulting in hydrops and, on occasion, fetal demise. Fortunately, since the advent of Rh immune globulin, HDN due to anti-D has become much less prevalent. Currently, anti-c and anti-E are the antibodies most often responsible for HDN, and they are frequent causes of delayed HTRs. Since Rh antibodies rarely, if ever, bind complement, red cell destruction is mediated almost exclusively via splenic trapping. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=see_link\">",
"     \"Overview of Rhesus (Rh) alloimmunization in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3912?source=see_link&amp;anchor=H6#H6\">",
"     \"Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues\", section on 'High risk antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anti-C can be difficult to detect and yet has been reported on more than one occasion to cause hemolysis and hemoglobinuria. Anti-e, which reacts with 98 percent of random donors, presents a problem with availability of compatible units, particularly in patients needing chronic transfusions.",
"   </p>",
"   <p>",
"    Patients with sickle cell disease who have aberrations at the e locus present particularly difficult transfusion problems, especially if they have already formed anti-E antibody and then develop an e-like alloantibody. Screening of blood donors (particularly siblings) using the patient's serum may allow for detection of compatible donors. However, one generally must contact the AABB or ARC rare donor file in an attempt to procure compatible blood.",
"   </p>",
"   <p>",
"    Anti-Cw and anti-V are antibodies directed against low frequency antigens that often appear in multi-sensitized patients. Anti-Cw is usually seen in conjunction with anti-c. Anti-V is often found in conjunction with anti-D + C. In severely immunized sickle cell patients (eg, the presence of anti-C, E, Jkb, Fya, K, S), one-quarter of African-American donors will be compatible, but only about 1:400 random donors. The subsequent detection of anti-V will significantly reduce the number of available black donors, since even though the V antigen is infrequent in the random donor population (1 percent), it is present in 30 percent of random black donors. The same would hold true if anti-Jsa were to be subsequently formed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of the management of sickle cell disease\", section on 'Alloimmunization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In autoimmune hemolytic anemia, a high percentage of autoantibodies demonstrate Rh system specificity, with anti-e being most commonly seen. In the absence of hemolysis, e negative blood need not be given and should be reserved for patients who have formed allo anti-e. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs\", section on 'Antigens on proteins of the Rh complex'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Effect of antibody on transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;On occasion, production of anti-D by lymphocytes from an Rh negative bone marrow transplant donor may cause self-limited graft-versus-host disease in an Rh positive recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/38\">",
"     38",
"    </a>",
"    ]. Conversely, should the recipient be Rh negative and receive hematopoietically active cells from an Rh positive donor, the recipient's remaining immunologically-reactive cells may produce anti-D and develop a chronic hemolytic anemia, although production of anti-D may ultimately diminish over time [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     LEWIS, P1, AND I BLOOD GROUP SYSTEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of these antigens are structurally related, having identical red cell glycosphingolipid backbones.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lewis antigens are adsorbed onto the red cells from the plasma and are located on type 1 glycosphingolipids",
"     </li>",
"     <li>",
"      Paragloboside is the precursor antigen for the P1 antigen, which has a terminal galactose as its immunodominant sugar",
"     </li>",
"     <li>",
"      The I and i determinants are carbohydrate structures on lipids integral to red cells, and are also present on proteins in the plasma. The I antigen, found primarily on adult red cells, is located on branched chains, while the i antigen, found primarily on",
"      <span class=\"nowrap\">",
"       cord/infant",
"      </span>",
"      red cells, is found on unbranched chains [",
"      <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Unusual phenotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The I negative adult phenotype (also called i positive) occurs in less than 1 percent of the population. Such individuals will form naturally occurring anti-I, which often has an increased thermal range. Its clinical significance is variable, and RBC survival studies would need to be undertaken before deciding whether I negative red cells would be required for transfusion of an anemic I negative patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Disease associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lewis antigens may disappear from red cells in infectious mononucleosis-associated hemolysis, severe alcohol-induced cirrhosis, or pancreatitis. The P1 antigen may be weakened in various types of carcinoma. Varied expression of both I and i have been associated with Tk polyagglutination, leukemia and other hemolytic conditions.",
"   </p>",
"   <p>",
"    Anti-I is often the causative antibody responsible for chronic cold agglutinin disease, as well as the acute, self-limited hemolysis sometimes seen subsequent to mycoplasma pneumonia infection. Anti-i has been associated with hemolysis in conjunction with infectious mononucleosis and lymphoma (",
"    <a class=\"graphic graphic_table graphicRef61974 \" href=\"UTD.htm?25/58/26540\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Blood group function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Lewis antigen is thought to be the receptor for Helicobacter pylori [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/41\">",
"     41",
"    </a>",
"    ], although this has been brought into question. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/44/4809?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathophysiology of and immune response to Helicobacter pylori infection\", section on 'Bacterial factors'",
"    </a>",
"    .) The P antigen is a receptor site for certain strains of E. coli; rare subjects with the P-null phenotype are resistant to infection with these strains. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16102?source=see_link&amp;anchor=H3#H3\">",
"     \"Bacterial adherence and other virulence factors for urinary tract infection\", section on 'Adhesins'",
"    </a>",
"    .) The function of the I antigen is not known, although an association between the adult i phenotype and congenital cataracts has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Expression of antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;P1 antigens can be found on lymphocytes, granulocytes, monocytes, and platelets. Interestingly, the P1 antigen is also a component of pigeon egg white as well as hydatid and echinococcus cyst fluid. Lewis antigens are found in all body fluids (except cerebrospinal fluid) and on lymphocytes, monocytes, and platelets. They are also widely distributed in body tissues, including the renal cortex, gastric mucosa and the small and large intestine. The",
"    <span class=\"nowrap\">",
"     I/i",
"    </span>",
"    system antigens can be found in most body fluids, all blood cell lines, and virtually all body tissues. P1, Lewis and I antigens are weak or absent on cord blood cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Clinical significance of antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-P1 is generally considered to be of little clinical significance. It is often naturally occurring and does not cause hemolytic disease of the newborn (HDN). On rare occasions, the antibody may show a broad thermal range, particularly in pigeon breeders who are P1 negative, or patients with hydatid or echinococcus cysts. Transfusion of P1 negative blood may be advisable in such instances, or when the antibody is IgG in nature.",
"   </p>",
"   <p>",
"    Lewis antibodies, like anti-P1, are common during gestation and the immediate postpartum period, and are formed primarily by individuals who type as Le(a-b-). The antibodies do not cause HDN, and rarely if ever are responsible for transfusion reactions. Anti-Le(a), when hemolytic in vitro, may have clinical significance. In such cases, \"crossmatch compatible\" donor units would be acceptable for transfusion.",
"   </p>",
"   <p>",
"    The rare instance of hemolytic or IgG reactive anti-Le(a) and anti-Le(b) in a group O Le(a-b-) individual scheduled for a surgical procedure requiring a large number of red cell transfusions presents a special problem. Rather than attempting to obtain Le(a-b-) units, which are found in only 6 percent of the random donor population,",
"    <strong>",
"     in vivo",
"    </strong>",
"    neutralization of the anti-Le(b) may be a viable option. One to two units of fresh or fresh frozen plasma from a Le(b+) donor may be used to neutralize the anti-Le(b) antibody activity. Transfusion can then be accomplished using Le(a-b+) donor units [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/43\">",
"     43",
"    </a>",
"    ], since almost four out of five random ABO compatible donor units will type as Le(a-b+). These units will shed their Le(b) antigens and take on the Le(a-b-) phenotype of the recipient within 24 hours post-transfusion. If and when the patient's anti-Le(b) antibody activity returns, which normally occurs within 48 to 72 hours, the transfused red cells will no longer be subject to red cell destruction.",
"   </p>",
"   <p>",
"    Most examples of anti-I (anti-i is rare) are IgM in nature, reactive at room temperature or below, and rarely cause problems from a transfusion standpoint. Anti-I does not cause HDN. In the rare I negative individual with the adult i phenotype, increased red cell destruction may ensue if random donor units are transfused. In rare instances of patients with auto anti-I with an increased thermal range (&gt;31&ordm;C), the use of a blood warmer may be required. The patient's core body temperature should be maintained as close to 37&ordm;C as possible, in order to avoid cold-induced exacerbation of the hemolysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33672?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins\", section on 'Special precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mycoplasma pneumoniae has been reported to cause acute self-limiting hemolysis in some individuals. The organism is capable of modifying the patient's red cell i antigen, making it more immunogenic. This causes an increase in the titer and thermal range of the patient's naturally occurring auto anti-i. When the infection is successfully treated with antibiotics, the patient's i antigen converts back to normal and the previously increased levels of anti-i destroy a portion of the patient's own red cells, until the antibody level has diminished.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Effect of antibodies or transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal graft survival appears to be reduced in recipients whose red cells type as Le(a-b-), suggesting that Le(a+) or Le(b+) donor kidneys may be rejected at an accelerated rate in the presence of Lewis antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     MNSS BLOOD GROUP SYSTEM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Basic biochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The M and N antigens are carried on glycophorin A and the S and s antigens are carried on glycophorin B, both of which are sialoglycoproteins. MN antigens are closely linked with the Ss antigens and generally will be inherited together.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Unusual phenotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extremely rare En(a-) phenotype results from the absence of glycophorin A. It is seen more frequently in Finland. Glycophorin B is lacking from the red cells of U-negative individuals. The S-s- phenotype (also U negative in the great majority of cases) is found in approximately 1 percent of Afro-Americans. The exceedingly rare",
"    <span class=\"nowrap\">",
"     Mk/Mk",
"    </span>",
"    phenotype results in the absence of both glycophorin A and B. Such red cells are severely deficient in sialic acid residues, but do not undergo hemolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Disease associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a sialic acid dependent site for Plasmodium falciparum invasion located primarily on glycophorin A, as well as a receptor for some E. coli species and viruses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Blood group function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glycophorin can act as a complement receptor. The net negative charge of the red cell membrane is primarily due to sialic acid residues carried on Glycophorin A and B. Glycophorin A also associates with band 3 of the RBC membrane.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Expression of antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;MNSs antigens have not been described on other blood cells, but have been found in the epithelium and endothelium of the kidney. All MNSs antigens are well developed on cord cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Clinical significance of antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-M is usually an IgM or cold reactive IgG antibody. It can be naturally occurring and will sometimes react better if the patient's serum is acidified. The antibody rarely is the cause of transfusion reactions unless it is reactive at body temperature. HDN has only rarely been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anti-N is generally considered to have little if any clinical significance. It is almost always IgM in nature, and may be found as an autoantibody in dialysis patients whose equipment was sterilized with formaldehyde. Anti-En(a) is capable of causing severe hemolytic transfusion reactions (HTRs) and HDN. Fortunately, the En(a-) phenotype is extremely rare.",
"   </p>",
"   <p>",
"    Both anti-S and anti-s are capable of causing hemolytic transfusion reactions, although the majority are mild to moderate in nature. Anti-S and anti-s are mainly IgG, and thus can cross the placental barrier and cause HDN. Severe cases are rare. Anti-S will frequently be found as an underlying alloantibody in patients with warm autoantibodies. Anti-U can cause both severe HTRs and severe HDN.",
"   </p>",
"   <p>",
"    Since 1 percent of blacks lack the U antigen, anti-U can present as a relatively common serologic problem. If no anti-U is available to screen for compatible donors and a relatively large black donor population exists, soybean lectin may be used for screening, since it will react with red cells containing reduced amounts of sialic acid (eg, U(-) RBCs). The U status of soybean + red cells can then be confirmed with anti-U.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Effect of antibodies on transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no transplant rejection reports have been reported in association with MNSs system antibodies, theoretically they could have an effect on kidney transplants because of antigen expression on renal epithelium and endothelium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     THE KELL BLOOD GROUP SYSTEM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Basic biochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 24 Kell system antigens are located on a highly folded membrane glycoprotein, and are produced by alleles located on chromosome 7. The Kell proteins require intact disulfide bonds to maintain antigenic integrity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Unusual phenotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antigens that are most readily recognized are K and its alternate allele k (cellano), Kpa and Kpb, and Jsa and Jsb. In a phenotype called Kmod, there is marked reduction of all Kell system antigens (only detectable via",
"    <span class=\"nowrap\">",
"     adsorption/elution",
"    </span>",
"    techniques). The Ko phenotype results in no production of K system antigens, and an increase in what is thought to be precursor substance, Kx.",
"   </p>",
"   <p>",
"    The McLeod phenotype (see below), also results in marked reduction of all Kell system antigens, and the absence of Kx from the red cell. The sensitized Ko individual will produce an antibody called anti-Ku as will Kmod patients. Both of these types of individuals must receive only Ko blood. Ko units, being exceedingly rare, should be procured through the American Rare Donor File located in Philadelphia, PA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Disease associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Kx gene appears to be closely linked with x-linked chronic granulomatous disease (CGD) in males. There is no evidence to suggest, however, that the absence of the Kx antigen is responsible for the white blood cell defect seen in CGD.",
"   </p>",
"   <p>",
"    Approximately",
"    <span class=\"nowrap\">",
"     1/250",
"    </span>",
"    patients with warm-reacting autoimmune hemolytic anemia will have autoantibody directed against Kell blood group system antigens. Microbial infection will sometimes cause transient depression of Kell system antigens (particularly Kpb).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     McLeod phenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The McLeod phenotype is associated with uniformly weak K system antigens and red cell morphology which demonstrates profound acanthocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/46\">",
"     46",
"    </a>",
"    ], and a compensated hemolytic anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9305?source=see_link&amp;anchor=H14#H14\">",
"     \"Spiculated cells (echinocytes and acanthocytes) and target cells\", section on 'Blood group abnormalities'",
"    </a>",
"    .) The McLeod phenotype can occur with or without CGD. In",
"    <span class=\"nowrap\">",
"     CGD-/McLeod+",
"    </span>",
"    patients, the antibody found after transfusion is anti-Km; these patients can receive McLeod or Ko blood. In patients who are",
"    <span class=\"nowrap\">",
"     CGD+/McLeod+,",
"    </span>",
"    sensitized patients form an antibody called anti-KL (anti-Km and anti-Kx), and can only be transfused with blood from ABO compatible donors who also have the McLeod phenotype. Non-CGD McLeod males also suffer muscular and neurologic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/47\">",
"     47",
"    </a>",
"    ], as well as cardiomyopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Blood group function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The system as a whole may have some enzymatic properties, possibly activating and inactivating bioactive peptides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Antigen expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kell system antigens appear to be red cell specific. All Kell system antigens are expressed on cord cells. There is no evidence that Kx antigen is found on granulocytes, either in normal individuals or patients with x-linked CGD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Clinical significance of Kell system antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-K is capable of causing severe HTRs and HDN. In fact, anti-K, along with anti-c and anti-E, currently make up the great majority of cases of clinically significant HDN (",
"    <a class=\"graphic graphic_table graphicRef57717 \" href=\"UTD.htm?14/29/14811\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3912?source=see_link&amp;anchor=H2#H2\">",
"     \"Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bacteria are capable of eliciting production of anti-K, probably due to the presence of cross-reactive antigens. Anti-k is one of the most common antibodies directed against high frequency antigens (approximately",
"    <span class=\"nowrap\">",
"     1/500",
"    </span>",
"    random individuals lack k) and like anti-Jsb and anti-Kpb, can cause mild to moderate HDN and HTRs. Sometimes, in autoimmune hemolytic anemia, the Kpb antigen becomes transiently depressed and the autoantibody \"appears\" to be an alloantibody. This can create a dilemma as to whether the patient should receive Kp(b-) blood. Radiochromium red cell survival studies may be useful in determining the antibody's clinical significance at a particular point in time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36326?source=see_link\">",
"     \"Red blood cell survival: Normal values and measurement\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anti-Jsb is produced primarily by African-American patients. Anti-Jsa and anti-Kpa are directed against low frequency antigens in the random donor population. Both can cause mild to moderate HTRs and HDN. Formation of anti-Jsa in multisensitized sickle cell patients, who are receiving blood primarily from black donors, may reduce the available donor pool by approximately 30 percent (the frequency of the Jsa antigen in blacks). Because of the scarcity of reagent grade anti-Jsa, the patient's serum may need to be used for finding Js(a-) donor units, providing the antibody is reactive stronger than 1+ in the antiglobulin phase of testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Effect of antibody on transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of Kell system antibodies does not appear to affect kidney transplantation. If a bone marrow recipient were to have produced anti-K from previous transfusions, it would be advisable to select a K-negative marrow donor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     DUFFY BLOOD GROUP SYSTEM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Basic biochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The carrier molecule of the Duffy blood group antigens is a multi-pass membrane glycoprotein. The antigens themselves have not yet been fully characterized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Unusual phenotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Fy(a-b-) phenotype, while extremely rare in the random donor population, occurs in 68 percent of the black population. Fy(a-b-) red cells lack the Duffy protein and Fy(a-b-) subjects may occasionally form anti-Fy5 in response to transfusion, which will react with any red cell positive for Fya",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Fyb, but not with Fy(a-b-) red cells. Although Fy(a-b-) blacks also lack Fy3 in their red cells, anti-Fy3 is rarely found in blacks. Anti-Fy3 has been produced in three Caucasians and one Crete Indian who had the Fy(a-b-) genotype; anti-Fy3 is usually preceded by the formation of anti-Fya. The production of anti-Fyb has only rarely been seen in Fy(a-b-) blacks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Disease associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perhaps the most interesting association is between the Duffy blood group and malaria. Approximately 70 percent of West African blacks type as Fy(a-b-) and the same percentage is resistant to infection with Plasmodium vivax. In some fascinating experiments, it was confirmed that merozoites from P. vivax and P. knowlesi would not be internalized into the red cells of Fy(a-b-) individuals, but the membranes of Fya+",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Fyb+ red cells would invaginate and allow the merozoites to enter the red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/48\">",
"     48",
"    </a>",
"    ]. Thus the Duffy antigen is the receptor site which allows invasion of both vivax and knowlesi. Although the merozoite attaches to Fy(a-b-) red cells, it will not enter the cell and eventually detaches, leaving widespread deformation of the red cell in its wake. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24585?source=see_link&amp;anchor=H4#H4\">",
"     \"Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins\", section on 'Duffy blood group system'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Function of Duffy blood groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duffy antigens are carried on an integral red cell membrane glycoprotein known as the Duffy antigen receptor for chemokines (DARC, CD234), which acts as a receptor for certain pro-inflammatory cytokines (eg, IL-8, monocyte chemotactic protein-1, RANTES) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Antigen expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duffy antigens are not present on other blood cells, but can be found in brain, colon, endothelium, lung, spleen, thyroid, thymus and kidney tissue. Duffy antigens are exposed on cord blood cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Antibody formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all Fy(a-) patients receiving at least one unit of Fy(a+) blood become alloimmunized. This has been attributed, at least in part, to the fact that the Fya antigen is considerably less immunogenic than the A, B, Rh(D), k, c, and E blood group antigens (",
"    <a class=\"graphic graphic_table graphicRef57717 \" href=\"UTD.htm?14/29/14811\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HLA-DRB1 polymorphism may also be operative in affecting antibody production. In a study of 67 subjects from southern Europe who had developed anti-Fya and 200 unrelated controls, 96 percent of those with anti-Fya had at least one HLA-DRB1*04 or HLA-DRB1*15 allele, compared with 34 percent of controls [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=see_link&amp;anchor=H19#H19\">",
"     \"Human leukocyte antigens (HLA): A roadmap\", section on 'How do HLA antigens confer disease susceptibility?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Clinical significance of antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-Fya can cause significant HTRs as well as HDN (",
"    <a class=\"graphic graphic_table graphicRef57717 \" href=\"UTD.htm?14/29/14811\">",
"     table 1",
"    </a>",
"    ). Anti-Fyb, on the other hand, is not commonly found, since the Fyb antigen is a poor immunogen. The antibody is usually produced in patients who have already been sensitized to multiple blood group antigens. HDN caused by anti-Fyb is rare and, when present, is mild in nature; anti-Fyb can occasionally cause HTRs.",
"   </p>",
"   <p>",
"    Anti-Fy5 is distinguished from anti-Fy3 by the fact that, unlike anti-Fy3, anti-Fy5 will not react with Rh null cells of common Duffy type. HDN rarely occurs with either of these two antibodies. Significant transfusion reactions have occurred with anti-Fy3. Anti-Fy5 caused a mild, delayed HTR in one reported case. In the presence of either anti-Fy3 or anti-Fy5, Fy(a-b-) donor units should be transfused. Such units can be readily located by screening units from African-American donors, since 70 percent of such donors are Fy(a-b-).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Effect of antibody on transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is no report in the literature, anti-Fya could theoretically interfere with kidney transplant survival if the recipient had formed anti-Fy(a) and the kidney was from an Fy(a+) donor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h1\">",
"     KIDD BLOOD GROUP SYSTEM",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h2\">",
"     Basic biochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biochemistry of the Kidd blood group system has yet to be elucidated; the carrier molecule is known to be a multipass membrane protein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h2\">",
"     Unusual phenotypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Jk(a-b-) phenotype, also known as Jk(3-), is seen in approximately 1 percent of Polynesians (peoples of the South Pacific). All of the Jk(3-) individuals we have encountered have been of Filipino origin, although some have been described in individuals of African and subcontinental Indian descent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Jk(a-b-) red cells are resistant to lysis by 2 molar urea, a procedure used in some automated hematology analyzers to lyse red cells prior to performing a white blood cell (WBC) or platelet count [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/54\">",
"     54",
"    </a>",
"    ]. This can result in an abnormally high machine count; however, a blood smear prepared for the differential count will not demonstrate large numbers of WBCs or platelets, confirming this as a technical artifact. Of interest, inability to lyse red cells in 2M urea has been used as a screening test for the Jk(a-b-) phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h2\">",
"     Disease associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jk(a-b-) individuals are unable to maximally concentrate their urine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h2\">",
"     Blood group function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Kidd blood group system is thought to be responsible for transporting urea across the red cell membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h2\">",
"     Expression of antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Jk3 antigen is present in kidney tissue. Kidd antigens are expressed on cord blood cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60\">",
"    <span class=\"h2\">",
"     Clinical significance of Kidd system blood group antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-Jka, and to a lesser extent anti-Jkb, are responsible for a great percentage of serious hemolytic transfusion reactions (",
"    <a class=\"graphic graphic_table graphicRef57717 \" href=\"UTD.htm?14/29/14811\">",
"     table 1",
"    </a>",
"    ). The reasons are threefold:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Kidd antibodies, which are usually IgG, will bind complement and can cause in vivo hemolysis.",
"     </li>",
"     <li>",
"      The antibodies will often react much better with cells containing a double dose of the antigen (eg, Jk(a+b-)) than a single dose (eg, Jk(a+b+)), and in fact a Jk(a+b+) donor unit might be compatible in vitro, but incompatible in vivo.",
"     </li>",
"     <li>",
"      Kidd antibodies tend to disappear rapidly from the circulation and may not be detectable using very sensitive serologic techniques the next time the patient requires transfusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transfusion of antigen positive \"compatible blood\" will therefore often result in a dramatic anamnestic response, and rapid red cell destruction may ensue 3 to 14 days post transfusion. If multiple units are involved, renal shutdown",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    coagulopathies may occur. For these reasons, we recommend that anyone who has had anti-Jka or anti-Jkb identified in their serum obtain a Medic Alert bracelet stating that they have formed anti-Jka or anti-Jkb in the past.",
"   </p>",
"   <p>",
"    Anti-Jka and anti-Jkb usually only cause mild hemolytic disease in the newborn. Anti-Jk3 can cause a significant HTR and in vivo hemolysis, but HDN has only rarely been reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3513?source=see_link\">",
"     \"Significance of minor red blood cell antibodies during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61\">",
"    <span class=\"h2\">",
"     Effect of antibodies on transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We have seen a Jk(a-b-) Filipino male who was transplanted with a kidney from a non-Jk(a-b-) donor, who went on to form anti-Jk3. The antibody was not present prior to transplant. The presence of anti-Jk3 did not appear to have a deleterious effect on the transplanted kidney.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS BLOOD GROUPS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63\">",
"    <span class=\"h2\">",
"     Lutheran blood group",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are 18 antigens in the Lutheran system, with Lu(a) and Lu(b) being the most commonly recognized. Lu(a) occurs in approximately 7.5 percent of the population while Lu(b) is absent from the red cells of approximately",
"    <span class=\"nowrap\">",
"     1/500",
"    </span>",
"    random individuals. Lutheran antigens are resistant to enzyme treatment (ficin or papain), but are inactivated by the sulfhydryl reagent 0.2 Molar dithiothreitol (DTT). The antigens are only weakly expressed on cord cells. Lutheran antigens may have some adhesive properties and mediate intracellular signaling, and are linked to the erythrocyte cytoskeleton through a direct interaction with spectrin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    Anti-Lu(a) characteristically shows a mixed field appearance versus antigen positive red cells (ie, the presence of agglutinated cells against a background of unagglutinated cells). The great majority of Lutheran antibodies do not cause HDN. Anti-Lu(b) can cause mild to moderate transfusion reactions, but there is no data or only limited case reports of mild HTRs for other Lutheran system antibodies. Anti-Lu(a), however does not cause HTRs. Sera in which anti-Lu(a) is detected often contain HLA antibodies.",
"   </p>",
"   <p>",
"    The null type Lu(a-b-) can arise from either a dominant or recessive background. Anti-Lu3 is formed only by those individuals of the recessive Le(a-b-) genotype. No concrete data are available on the clinical significance of anti-Lu3.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64\">",
"    <span class=\"h2\">",
"     Vel blood group",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Vel antigen is of high frequency, is enhanced by enzyme treatment, and is resistant to treatment with dithiothreitol. The antigen is only weakly expressed on cord cells and consequently, anti-Vel does not cause HDN. The antibody, which is often a mix of IgM and IgG components and capable of binding complement, can cause severe in vivo hemolysis when Vel+ blood is transfused into a patient with anti-Vel. The antigen is variably expressed on adult red cells, such that donors with weak Vel antigens may be mistyped as Vel-.",
"   </p>",
"   <p>",
"    When present solely as an IgM antibody, anti-Vel in a group O patient may at first glance appear to be a harmless cold agglutinin (ie, anti-I), since it will be non-reactive with cord red cells, which do not express the Vel or I antigens (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Lewis, P1, and I blood group systems'",
"    </a>",
"    above). Group O Vel-positive donor units, however, will be incompatible at room temperature, and the patient's autocontrol (the patient's own red cells in the patient's own serum) will be non-reactive at room temperature. These findings would suggest that further serologic work is required before calling the antibody a harmless cold agglutinin, which in this case would be incorrect and would have potentially disastrous consequences were the patient to be transfused with Vel positive blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65\">",
"    <span class=\"h2\">",
"     Globoside blood group (P and Pk)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Globoside is universally found in body tissues as well as all blood cells except platelets, basophils, and eosinophils. Globoside is the receptor site for Parvovirus and pyelonephritogenic E. coli, and the presence of Pk may protect against infection with HIV-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=see_link\">",
"     \"Clinical manifestations and pathogenesis of human parvovirus B19 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both the P and Pk antigens are produced from lactosyl ceramide. The null phenotype pp lacks P and Pk and the antibody, anti-Tja (anti-P, P1, Pk) can cause severe intravascular transfusion reactions. Cytotoxic IgM or IgG3 antibody directed against the P and Pk antigens has been associated with an increased rate of spontaneous abortion in women of the pp, P1K and P2K phenotypes, the latter two lacking P, but not Pk [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anti-P when seen as an alloantibody is often naturally occurring and may be IgM or IgG in nature. It can cause serious HTRs and may be hemolytic in vivo. The P system antibodies react better with enzyme treated cells and also react with 0.2 Molar DTT- treated red cells. Although the P and Pk antigen are well expressed on cord cells, HDN in the presence of anti-P is not severe. It is important to keep in mind that neither anti-P nor anti-Tja (anti-P1, PK,P) will react with pp red cells, such that anti-P may be mistaken for anti-Tja. Anti-Tja, however, will react with P1K and P1K red cells.",
"   </p>",
"   <p>",
"    Auto anti-P is often the causative antibody in paroxysmal cold hemoglobinuria (PCH) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/61\">",
"     61",
"    </a>",
"    ], where it acts as a biphasic hemolysin, the classical Donath-Landsteiner antibody. This cold reactive IgG antibody binds to red cells at reduced temperatures and causes complement mediated hemolysis as the",
"    <span class=\"nowrap\">",
"     serum/cell",
"    </span>",
"    mixture is warmed to body temperature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16422?source=see_link&amp;anchor=H2#H2\">",
"     \"Paroxysmal cold hemoglobinuria\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66\">",
"    <span class=\"h2\">",
"     Chido-Rodgers blood group",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Chido and Rodgers antigens are located on the C4d complement components of C4a and C4b, and are adsorbed onto the red cell from the surrounding plasma. The antigens are absent from cord cells and are inactivated by proteolytic enzymes, but not DTT. Both antigens are present in greater than 90 percent of the population.",
"   </p>",
"   <p>",
"    The antibodies demonstrate fragile agglutination at the indirect antiglobulin stage that dissipates relatively easily. Anti-Chido and anti-Rodgers are neutralizable by pooled plasma, and both react strongly with in vitro prepared C4d coated RBCs. The antibodies are of little clinical significance, except that an anaphylactic reaction has occurred in one patient with anti-Chido 3. The etiology of the reaction remains uncertain.",
"   </p>",
"   <p>",
"    The null phenotype",
"    <span class=\"nowrap\">",
"     (CH/RG",
"    </span>",
"    &ndash;1, -2, -3) results in C4-deficient RBCs. Inherited low levels of C4 may predispose individuals towards such diseases as autoimmune chronic active hepatitis and insulin dependent diabetes. Lack of C4B (Ch-) results in increased susceptibility to bacterial meningitis in children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/62\">",
"     62",
"    </a>",
"    ], while lack of C4A (Rg-) results in a predisposition to develop systemic lupus erythematosus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/63\">",
"     63",
"    </a>",
"    ]. There is an association between the Rg- phenotype and the HLA haplotype 1-8.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67\">",
"    <span class=\"h2\">",
"     Gerbich blood group system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Gerbich antigens are located on membrane sialoglycoproteins glycophorin A and glycophorin B. The Ge 2 and 4 antigens are sensitive to proteolytic enzyme treatment, while Ge3 is resistant. All components are unaffected by DTT treatment. Gerbich is expressed on cord cells. HDN has not been reported, but anti-Ge2 and anti-Ge3 have caused HTRs, some of which have resulted in intravascular hemolysis.",
"   </p>",
"   <p>",
"    Gerbich-negative phenotypes have been seen more commonly in Melanesians and in the Hispanic population in the United States; the only examples of anti-Ge which we have encountered have been in Mexican-Americans. Anti-Gerbich is the most commonly encountered antibody to a high frequency antigen in the Hispanic population of Southern California.",
"   </p>",
"   <p>",
"    Not all Gerbich negative donors are compatible with individual examples of anti-Gerbich antibody, since the specificity can be directed against various portions of the Ge 2,3,4 complex. It is thus always important to check sample segments from frozen Ge-negative red cell units for compatibility with a given patient's antibody, prior to deglycerolizing the entire donor blood unit.",
"   </p>",
"   <p>",
"    The Gerbich-null cell (which most Mexican-American donors appear to be) is called the Leach phenotype (Ge-2-3-4). Plasmodium falciparum parasites have a reduced ability to invade the red cells of the Leach phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/64\">",
"     64",
"    </a>",
"    ]. Hereditary elliptocytosis without hemolysis has been associated with marked reduction of glycophorin C and the presence of the Leach phenotype. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/56/43911?source=see_link&amp;anchor=H8#H8\">",
"     \"Hereditary elliptocytosis: Genetics and pathogenesis\", section on 'Glycophorin mutation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Auto anti-Gerbich has been reported to cause severe hemolytic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/65\">",
"     65",
"    </a>",
"    ]. However, in other patients with anti-Gerbich, red cell survival was essentially normal when Ge-positive red cells were transfused [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Allo-anti-Ge2 may be naturally occurring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68\">",
"    <span class=\"h2\">",
"     Colton blood group system",
"    </span>",
"    &nbsp;&mdash;&nbsp;This system consists of two alleles, Coa (frequency 99.7 percent) and Cob (frequency 10.5 percent). Both anti-Coa and anti-Cob can cause hemolytic transfusion reactions, and anti-Coa is also capable of causing HDN. Both antibodies react better with enzyme-treated cells. The Colton blood group antigen polymorphism is a single amino acid substitution in an extracellular domain of aquaporin-1. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37224?source=see_link&amp;anchor=H18#H18\">",
"     \"Control of red blood cell hydration\", section on 'Water channels'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anti-Cob is rarely seen as a single antibody, due to its weak immunogenicity, and is usually formed after other blood group antibodies are detected. Because of the lack of commercial anti-Cob reagents on the market, transfusion of patients who had previously formed anti-Cob and whose antibody is no longer detectable becomes problematic, since 1 out of 10 random units will be Cob positive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69\">",
"    <span class=\"h2\">",
"     Diego blood group system",
"    </span>",
"    &nbsp;&mdash;&nbsp;This system consists of two independent pairs of alleles,",
"    <span class=\"nowrap\">",
"     Dia/Dib",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     Wra/Wrb",
"    </span>",
"    (Wright). The Dia antigen is of anthropologic interest, since while its frequency in the random donor population is &lt;1 percent, up to 35 percent of South American Indians and Native Americans may be Dia+. Both anti-Dia and anti-Dib can cause HTRs and HDN.",
"   </p>",
"   <p>",
"    HDN due to anti-Dia is much more prevalent in the aforementioned populations because of the antigen's increased prevalence. In fact, a number of cases of HDN due to anti-Dia were not detected until the immediate post-partum period because the antibody detection cells which had previously been used to screen the mother's blood for unexpected antibodies during pregnancy had lacked the Dia antigen. Such ethnic differences in blood group distribution are now taken into account by commercial antibody screen red cell producers, when preparing screening cells in various countries and for specific populations.",
"   </p>",
"   <p>",
"    With respect to the Wright antigens, there have been only a very few individuals whose red cells have typed as Wrb+. Anti-Wrb is primarily seen as a component of warm autoantibody production.",
"   </p>",
"   <p>",
"    The Wra antigen is only found in",
"    <span class=\"nowrap\">",
"     1/1500",
"    </span>",
"    random individuals, but its corresponding antibody is much more prevalent. In fact, the antibody can be naturally occurring (present in the absence of previous transfusion or pregnancy), and appears to be a frequency marker which indicates increased immune system function. AS an example, the frequency in the random population of anti-Wra is",
"    <span class=\"nowrap\">",
"     1/200,",
"    </span>",
"    <span class=\"nowrap\">",
"     1/50",
"    </span>",
"    in pregnancy, and",
"    <span class=\"nowrap\">",
"     1/3",
"    </span>",
"    in patients with warm autoantibody in their serum. Anti-Wra is capable of causing severe HTRs, as well as HDN, both of which are relatively uncommon because of the low incidence of the Wra antigen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70\">",
"    <span class=\"h2\">",
"     Cartwright blood group system",
"    </span>",
"    &nbsp;&mdash;&nbsp;This system consists of the antigens Yta and Ytb. Approximately",
"    <span class=\"nowrap\">",
"     1/500",
"    </span>",
"    individuals lack the Yta antigen, and 8 percent of the random population are Ytb+. Both antigens are destroyed when red cells are treated with the sulfhydryl compound, dithiothreitol (DTT).",
"   </p>",
"   <p>",
"    Anti-Ytb is a rarely seen antibody, and has not been reported to cause either HTRs or HDN. Anti-Yta often presents as a weak antibody, and has variable clinical significance from one patient to the next. Because the Yta antigen is not well developed at birth, it has not been reported to cause clinical HDN. Given anti-Yta's variable clinical significance from the standpoint of causing HTRs, its clinical relevance may be predicted by performing a monocyte monolayer assay [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/68\">",
"     68",
"    </a>",
"    ]. When the assay results suggest that the antibody will not cause an acute transfusion reaction, transfusion may be accomplished with random, ABO matched, \" least incompatible\" donor units.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16461178\">",
"    <span class=\"h2\">",
"     Knops blood group system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Knops blood group system, composed of eight antigens, is located on complement receptor type 1 (CR1, CD35). African Knops blood group antigens may confer a survival advantage in the setting of P. falciparum malaria as well as resistance to infection with M. tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24585?source=see_link&amp;anchor=H10#H10\">",
"     \"Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins\", section on 'Complement receptor type 1 and Knops blood group'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17331729\">",
"    <span class=\"h2\">",
"     FORS blood group system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals previously thought to be blood type A",
"    <sub>",
"     pae",
"    </sub>",
"    are now considered to be type O and to express the Forssman (Fs) antigen, a glycolipid synthesized by globoside alpha-1,3-N-acetylgalactosaminyltransferase 1 (GBGT1) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/15/27898/abstract/70\">",
"     70",
"    </a>",
"    ]. GBGT1 is an enzyme similar to the ABO glycosyl transferases that was previously thought to function only in non-human mammals. The human form of this enzyme is inactive, but a polymorphism in the GBGT1 gene allows the enzyme to become functional and to synthesize Fs. Individuals with this polymorphism are blood type O and FORS positive. The clinical consequences of Fs expression are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11691369\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individual blood groups of the red cell membrane are serologically linked antigenic structures, due to their presence on the lipids or proteins of the red cell membrane. Some antigens, such as those of the ABO blood group, are surface structures, while others (eg, Rh) are carried on molecules that span the red cell membrane.",
"     </li>",
"     <li>",
"      Many of the blood groups, especially ABO and Rh, are highly immunogenic, and can be responsible for severe or fatal transfusion reactions. Anti-K, along with anti-c and anti-E, currently make up the great majority of cases of clinically significant hemolytic disease of the newborn (",
"      <a class=\"graphic graphic_table graphicRef57717 \" href=\"UTD.htm?14/29/14811\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3912?source=see_link&amp;anchor=H2#H2\">",
"       \"Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues\", section on 'Pathogenesis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=see_link&amp;anchor=H2#H2\">",
"       \"Overview of Rhesus (Rh) alloimmunization in pregnancy\", section on 'The Rhesus system'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Compatibility testing by the transfusion service is routinely limited to testing for ABO and Rh antigens. More extensive testing can be performed if the patient to be transfused has developed clinically significant antibodies to other red cell antigens. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2407?source=see_link\">",
"       \"Compatibility testing\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27480?source=see_link\">",
"       \"The incompatible crossmatch\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Platelets express ABH antigens on their surface. These antigens are intrinsic to the platelet membrane and passively adsorbed from plasma. Studies have demonstrated that ABO-incompatible platelet transfusions are associated with a reduced post-transfusion increment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37945?source=see_link&amp;anchor=H18#H18\">",
"       \"Refractoriness to platelet transfusion therapy\", section on 'ABO matched platelets'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Donor kidneys should be ABO compatible with the recipient's ABO antibodies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=see_link&amp;anchor=H3#H3\">",
"       \"HLA and ABO sensitization and desensitization in renal transplantation\", section on 'ABO incompatibility'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ABO compatibility is not required between donor and recipient for bone marrow transplantation. ABO mismatches at the time of bone marrow transplantation may, however, lead to self-limited hemolysis, pure red cell aplasia, or graft versus host disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H12#H12\">",
"       \"Donor selection for hematopoietic cell transplantation\", section on 'ABO and Rh status'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Subjects with blood groups A, B, or AB have a higher risk of venous thromboembolic disease than those of blood group O, probably related to the effect of the ABO system on levels of von Willebrand factor and factor VIII. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=see_link&amp;anchor=H624057#H624057\">",
"       \"Clinical presentation and diagnosis of von Willebrand disease\", section on 'Variations in VWF levels in health and disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anti-I is often the causative antibody responsible for chronic cold agglutinin disease, as well as the acute, self-limited hemolysis sometimes seen subsequent to mycoplasma pneumonia infection. Anti-i has been associated with hemolysis in conjunction with infectious mononucleosis and lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30535?source=see_link&amp;anchor=H5#H5\">",
"       \"Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease\", section on 'The antibodies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The Duffy antigen is the receptor site that allows invasion of both vivax and knowlesi malaria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24585?source=see_link&amp;anchor=H4#H4\">",
"       \"Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins\", section on 'Duffy blood group system'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An autoantibody to the P antigen (anti-P) is often the causative antibody in paroxysmal cold hemoglobinuria (PCH), where it acts as a biphasic hemolysin, the classical Donath-Landsteiner antibody. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16422?source=see_link&amp;anchor=H2#H2\">",
"       \"Paroxysmal cold hemoglobinuria\", section on 'Pathophysiology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Reid MR, Lomas-Francis C. The blood group antigen facts book, Harcourt Brace and Company, 1997.",
"    </li>",
"    <li>",
"     Issitt PD, Anstee DJ. Applied blood group serology, Montgomery Scientific Publications, 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/3\">",
"      Anstee DJ. The relationship between blood groups and disease. Blood 2010; 115:4635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/4\">",
"      Garratty G, Glynn SA, McEntire R, Retrovirus Epidemiology Donor Study. ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States. Transfusion 2004; 44:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/5\">",
"      Daniel-Johnson J, Leitman S, Klein H, et al. Probiotic-associated high-titer anti-B in a group A platelet donor as a cause of severe hemolytic transfusion reactions. Transfusion 2009; 49:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/6\">",
"      Julius CJ, Wade M, Waheed A, et al. Common variable immunodeficiency: diagnosis by absent ABO reverse type. Immunohematology 1997; 13:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/7\">",
"      Linz WJ, Currie RT. ABO discrepancy: reverse type. Transfusion 2007; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     Beattie KM. Perspectives on some usual and unusual ABO phenotypes. In: A seminar on antigens on blood cells and body fluids, Bell CA (Ed), American Association of Blood Banks, Washington, DC 1980. p.97.",
"    </li>",
"    <li>",
"     The ABO Blood Group System. In: Modern Blood Banking and Transfusion Practices, Harmening DM (Ed), 1999. p.113.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/10\">",
"      Shastry S, Bhat SS, Singh K. A rare case of missing antibody due to anti-snake venom. Transfusion 2009; 49:2777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/11\">",
"      Sprawka N, Young C, O'Brien B. Bombay blood type and use of red cell apheresis during pregnancy. Obstet Gynecol 2011; 117:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/12\">",
"      Olsson ML, Irshaid NM, Hosseini-Maaf B, et al. Genomic analysis of clinical samples with serologic ABO blood grouping discrepancies: identification of 15 novel A and B subgroup alleles. Blood 2001; 98:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/13\">",
"      Roath S, Todd CE, Shaw D. Transient acquired blood group B antigen associated with diverticular bowel disease. Acta Haematol 1987; 77:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/14\">",
"      Bianco T, Farmer BJ, Sage RE, Dobrovic A. Loss of red cell A, B, and H antigens is frequent in myeloid malignancies. Blood 2001; 97:3633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/15\">",
"      Sheppard CA, O'Reilly KC, Schniederjan SD, et al. Transfusion medicine illustrated. Detection of mixed-field agglutination due to loss of red cell antigen in hematopoietic malignancy. Transfusion 2006; 46:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/16\">",
"      Bianco-Miotto T, Hussey DJ, Day TK, et al. DNA methylation of the ABO promoter underlies loss of ABO allelic expression in a significant proportion of leukemic patients. PLoS One 2009; 4:e4788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/17\">",
"      Reid ME, Bird GW. Associations between human red cell blood group antigens and disease. Transfus Med Rev 1990; 4:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/18\">",
"      Wolpin BM, Chan AT, Hartge P, et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst 2009; 101:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/19\">",
"      Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 2009; 41:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/20\">",
"      Risch HA, Yu H, Lu L, Kidd MS. ABO blood group, Helicobacter pylori seropositivity, and risk of pancreatic cancer: a case-control study. J Natl Cancer Inst 2010; 102:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/21\">",
"      Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 2001; 21:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/22\">",
"      Morange PE, Tregouet DA, Frere C, et al. Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. Br J Haematol 2005; 128:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/23\">",
"      Tr&eacute;gou&euml;t DA, Heath S, Saut N, et al. Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. Blood 2009; 113:5298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/24\">",
"      Curtis BR, Edwards JT, Hessner MJ, et al. Blood group A and B antigens are strongly expressed on platelets of some individuals. Blood 2000; 96:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/25\">",
"      Curtis BR, Fick A, Lochowicz AJ, et al. Neonatal alloimmune thrombocytopenia associated with maternal-fetal incompatibility for blood group B. Transfusion 2008; 48:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/26\">",
"      Chan KW, Unrau L, Denegri JF. ABO incompatible marrow transplant. Transfusion 1983; 23:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/27\">",
"      Avent ND, Reid ME. The Rh blood group system: a review. Blood 2000; 95:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/28\">",
"      Westhoff CM. The Rh blood group system in review: a new face for the next decade. Transfusion 2004; 44:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/29\">",
"      Lin M. Taiwan experience suggests that RhD typing for blood transfusion is unnecessary in southeast Asian populations. Transfusion 2006; 46:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/30\">",
"      Gunson HH, Stratton F, Cooper DG, Rawlinson VI. Primary immunization of Rh-negative volunteers. Br Med J 1970; 1:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/31\">",
"      Yazer MH, Triulzi DJ. Detection of anti-D in D- recipients transfused with D+ red blood cells. Transfusion 2007; 47:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/32\">",
"      Gonzalez-Porras JR, Graciani IF, Perez-Simon JA, et al. Prospective evaluation of a transfusion policy of D+ red blood cells into D- patients. Transfusion 2008; 48:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/33\">",
"      Yuan S, Davis R, Lu Q, et al. Low risk of alloimmunization to the D antigen in D- orthotopic liver transplant recipients receiving D+ RBCs perioperatively. Transfusion 2008; 48:2653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/34\">",
"      Denomme GA, Wagner FF, Fernandes BJ, et al. Partial D, weak D types, and novel RHD alleles among 33,864 multiethnic patients: implications for anti-D alloimmunization and prevention. Transfusion 2005; 45:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/35\">",
"      Kumpel B. Are weak D RBCs really immunogenic? Transfusion 2006; 46:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/36\">",
"      Shao CP. Transfusion of RhD-positive blood in \"Asia type\" DEL recipients. N Engl J Med 2010; 362:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/37\">",
"      Schmidt PJ. Hereditary hemolytic anemias and the null blood types. Arch Intern Med 1979; 139:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/38\">",
"      Ramsey G, Israel L, Lindsay GD, et al. Anti-Rho(D) in two Rh-positive patients receiving kidney grafts from an Rh-immunized donor. Transplantation 1986; 41:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/39\">",
"      Alexander SI, Smith N, Hu M, et al. Chimerism and tolerance in a recipient of a deceased-donor liver transplant. N Engl J Med 2008; 358:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/40\">",
"      Yu LC, Twu YC, Chang CY, Lin M. Molecular basis of the adult i phenotype and the gene responsible for the expression of the human blood group I antigen. Blood 2001; 98:3840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/41\">",
"      Bor&eacute;n T, Falk P, Roth KA, et al. Attachment of Helicobacter pylori to human gastric epithelium mediated by blood group antigens. Science 1993; 262:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/42\">",
"      Yu LC, Twu YC, Chou ML, et al. The molecular genetics of the human I locus and molecular background explain the partial association of the adult i phenotype with congenital cataracts. Blood 2003; 101:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/43\">",
"      Hossaini AA. Neutralization of Lewis antibodies in vivo and transfusion of Lewis incompatible blood. Am J Clin Pathol 1972; 57:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/44\">",
"      Oriol R, Opelz G, Chun C, Terasaki PI. The Lewis system and kidney transplantation. Transplantation 1980; 29:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/45\">",
"      Wikman A, Edner A, Gryfelt G, et al. Fetal hemolytic anemia and intrauterine death caused by anti-M immunization. Transfusion 2007; 47:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/46\">",
"      Symmans WA, Shepherd CS, Marsh WL, et al. Hereditary acanthocytosis associated with the McLeod phenotype of the Kell blood group system. Br J Haematol 1979; 42:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/47\">",
"      Marsh WL, Marsh NJ, Moore A, et al. Elevated serum creatine phosphokinase in subjects with McLeod syndrome. Vox Sang 1981; 40:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/48\">",
"      Miller LH, Mason SJ, Clyde DF, McGinniss MH. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med 1976; 295:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/49\">",
"      Neote K, Mak JY, Kolakowski LF Jr, Schall TJ. Functional and biochemical analysis of the cloned Duffy antigen: identity with the red blood cell chemokine receptor. Blood 1994; 84:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/50\">",
"      Afenyi-Annan A, Kail M, Combs MR, et al. Lack of Duffy antigen expression is associated with organ damage in patients with sickle cell disease. Transfusion 2008; 48:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/51\">",
"      Schonewille H, van de Watering LM, Loomans DS, Brand A. Red blood cell alloantibodies after transfusion: factors influencing incidence and specificity. Transfusion 2006; 46:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/52\">",
"      Picard C, Frassati C, Basire A, et al. Positive association of DRB1 04 and DRB1 15 alleles with Fya immunization in a Southern European population. Transfusion 2009; 49:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/53\">",
"      Wester ES, Johnson ST, Copeland T, et al. Erythroid urea transporter deficiency due to novel JKnull alleles. Transfusion 2008; 48:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/54\">",
"      Heaton DC, McLoughlin K. Jk(a-b-) red blood cells resist urea lysis. Transfusion 1982; 22:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/55\">",
"      Sands JM, Gargus JJ, Fr&ouml;hlich O, et al. Urinary concentrating ability in patients with Jk(a-b-) blood type who lack carrier-mediated urea transport. J Am Soc Nephrol 1992; 2:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/56\">",
"      McDougall DC, McGregor M. Jk:-3 red cells have a defect in urea transport: a new urea-dependent lysis test. Transfusion 1988; 28:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/57\">",
"      Parsons SF, Lee G, Spring FA, et al. Lutheran blood group glycoprotein and its newly characterized mouse homologue specifically bind alpha5 chain-containing human laminin with high affinity. Blood 2001; 97:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/58\">",
"      An X, Gauthier E, Zhang X, et al. Adhesive activity of Lu glycoproteins is regulated by interaction with spectrin. Blood 2008; 112:5212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/59\">",
"      Lund N, Olsson ML, Ramkumar S, et al. The human P(k) histo-blood group antigen provides protection against HIV-1 infection. Blood 2009; 113:4980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/60\">",
"      Cantin G, Lyonnais J. Anti-PP1Pk and early abortion. Transfusion 1983; 23:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/61\">",
"      WORLLEDGE SM, ROUSSO C. STUDIES ON THE SEROLOGY OF PAROXYSMAL COLD HAEMOGLOBINURIA (P.G.H.), WITH SPECIAL REFERENCE TO ITS RELATIONSHIP WITH THE P BLOOD GROUP SYSTEM. Vox Sang 1965; 10:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/62\">",
"      Rowe PC, McLean RH, Wood RA, et al. Association of homozygous C4B deficiency with bacterial meningitis. J Infect Dis 1989; 160:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/63\">",
"      Dunckley H, Gatenby PA, Hawkins B, et al. Deficiency of C4A is a genetic determinant of systemic lupus erythematosus in three ethnic groups. J Immunogenet 1987; 14:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/64\">",
"      Pasvol G, Anstee D, Tanner MJ. Glycophorin C and the invasion of red cells by Plasmodium falciparum. Lancet 1984; 1:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/65\">",
"      Reynolds MV, Vengelen-Tyler V, Morel PA. Autoimmune hemolytic anemia associated with autoanti-Ge. Vox Sang 1981; 41:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/66\">",
"      Mochizuki T, Tauxe WN, Ramsey G. In vivo cross-match by chromium-51 urinary excretion from labeled erythrocytes: a case of anti-Gerbich. J Nucl Med 1990; 31:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/67\">",
"      Hildebrandt M, Hell A, Etzel F, et al. Determination and Successful Transfusion of Anti-Gerbich-Positive Red Blood Cells in a Patient with a Strongly Reactive Anti-Gerbich Antibody. Infusionsther Transfusionsmed 2000; 27:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/68\">",
"      Eckrich RJ, Mallory DM. Correlation of Monocyte Monolayer Assays and Post-Transfusion Survival of Yt(a+) cells in patients with anti-Yta (abstract). Transfusion 1993; 33(Suppl):18S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/69\">",
"      Noumsi GT, Tounkara A, Diallo H, et al. Knops blood group polymorphism and susceptibility to Mycobacterium tuberculosis infection. Transfusion 2011; 51:2462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/15/27898/abstract/70\">",
"      Svensson L, Hult AK, Stamps R, et al. Forssman expression on human erythrocytes: biochemical and genetic evidence of a new histo-blood group system. Blood 2013; 121:1459.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7924 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-83254367CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_15_27898=[""].join("\n");
var outline_f27_15_27898=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11691369\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ABO (ABH) BLOOD GROUP SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Natural alloantibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Absence of expected alloantibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - High titers of alloantibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Basic biochemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Unusual phenotypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Disease associations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Acquired B antigen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Thrombotic risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Expression of antigens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Clinical significance of antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Effect of antibodies on transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RH BLOOD GROUP SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Immunogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Unusual phenotypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Disease associations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Blood group function and expression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical significance of Rh antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Effect of antibody on transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      LEWIS, P1, AND I BLOOD GROUP SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Unusual phenotypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Disease associations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Blood group function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Expression of antigens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Clinical significance of antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Effect of antibodies or transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      MNSS BLOOD GROUP SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Basic biochemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Unusual phenotypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Disease associations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Blood group function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Expression of antigens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Clinical significance of antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Effect of antibodies on transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      THE KELL BLOOD GROUP SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Basic biochemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Unusual phenotypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Disease associations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - McLeod phenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Blood group function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Antigen expression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Clinical significance of Kell system antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Effect of antibody on transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      DUFFY BLOOD GROUP SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Basic biochemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Unusual phenotypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Disease associations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Function of Duffy blood groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Antigen expression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Antibody formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Clinical significance of antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Effect of antibody on transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      KIDD BLOOD GROUP SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      Basic biochemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      Unusual phenotypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      Disease associations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      Blood group function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      Expression of antigens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60\">",
"      Clinical significance of Kidd system blood group antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H61\">",
"      Effect of antibodies on transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62\">",
"      MISCELLANEOUS BLOOD GROUPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63\">",
"      Lutheran blood group",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64\">",
"      Vel blood group",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H65\">",
"      Globoside blood group (P and Pk)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H66\">",
"      Chido-Rodgers blood group",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H67\">",
"      Gerbich blood group system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68\">",
"      Colton blood group system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69\">",
"      Diego blood group system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70\">",
"      Cartwright blood group system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16461178\">",
"      Knops blood group system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17331729\">",
"      FORS blood group system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11691369\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7924\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7924|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/29/14811\" title=\"table 1\">",
"      Immunogenicity RBC antigens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/58/26540\" title=\"table 2\">",
"      Types of cold agglutinins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/35/28218?source=related_link\">",
"      Activated protein C resistance and factor V Leiden",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16102?source=related_link\">",
"      Bacterial adherence and other virulence factors for urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17049?source=related_link\">",
"      Biology and normal function of von Willebrand factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33672?source=related_link\">",
"      Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/54/22377?source=related_link\">",
"      Clinical manifestations and pathogenesis of human parvovirus B19 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/13/24794?source=related_link\">",
"      Clinical presentation and diagnosis of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2407?source=related_link\">",
"      Compatibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37224?source=related_link\">",
"      Control of red blood cell hydration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27866?source=related_link\">",
"      Epidemiology and risk factors for exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=related_link\">",
"      HLA and ABO sensitization and desensitization in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3912?source=related_link\">",
"      Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/56/43911?source=related_link\">",
"      Hereditary elliptocytosis: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=related_link\">",
"      Human leukocyte antigens (HLA): A roadmap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32982?source=related_link\">",
"      Overview of Rhesus (Rh) alloimmunization in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16422?source=related_link\">",
"      Paroxysmal cold hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30535?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/2/20521?source=related_link\">",
"      Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/44/4809?source=related_link\">",
"      Pathophysiology of and immune response to Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24585?source=related_link\">",
"      Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36326?source=related_link\">",
"      Red blood cell survival: Normal values and measurement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37945?source=related_link\">",
"      Refractoriness to platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/38/618?source=related_link\">",
"      Risk factors for gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17209?source=related_link\">",
"      Selective antibody deficiency with normal immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3513?source=related_link\">",
"      Significance of minor red blood cell antibodies during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9305?source=related_link\">",
"      Spiculated cells (echinocytes and acanthocytes) and target cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/13/42200?source=related_link\">",
"      Stomatocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27480?source=related_link\">",
"      The incompatible crossmatch",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_15_27899="Contraindications perc liver bx";
var content_f27_15_27899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Contraindications to a percutaneous liver biopsy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Absolute",
"       </td>",
"       <td class=\"subtitle1\">",
"        Relative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inability of patient to cooperate with procedure",
"       </td>",
"       <td>",
"        Morbid obesity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Significant coagulopathy or thrombocytopenia (unless corrected prior to the liver biopsy)",
"       </td>",
"       <td>",
"        Ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemophilia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NSAID use (including aspirin) within last 7 to 10 days",
"       </td>",
"       <td>",
"        Infection within the right pleural cavity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient refusal to accept blood transfusion or inability to provide blood transfusion support",
"       </td>",
"       <td>",
"        Infection below right hemidiaphragm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suspected hemangioma, vascular tumor, or echinococcal cyst",
"       </td>",
"       <td>",
"        Amyloidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inability to identify an adequate biopsy site by percussion and/or ultrasound",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dilated biliary tree",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344:495.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_15_27899=[""].join("\n");
var outline_f27_15_27899=null;
var title_f27_15_27900="Acute stroke syndromes";
var content_f27_15_27900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F75487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F75487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Acute stroke syndromes according to vascular territory and mechanism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"25%\">",
"     </colgroup>",
"     <colgroup width=\"50%\">",
"     </colgroup>",
"     <colgroup width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Artery involved",
"       </td>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pathophysiology",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Anterior cerebral artery",
"       </td>",
"       <td>",
"        <p>",
"         Motor and/or sensory deficit (leg &gt;&gt; face, arm)",
"        </p>",
"        <p>",
"         Grasp, sucking reflexes",
"        </p>",
"        Abulia, paratonic rigidity, gait apraxia",
"       </td>",
"       <td>",
"        Embolic &gt; atherothrombotic",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Middle cerebral artery",
"       </td>",
"       <td>",
"        <p>",
"         Dominant hemisphere: aphasia, motor and sensory deficit (face, arm &gt; leg &gt; foot), may be complete hemiplegia if internal capsule involved, homonymous hemianopia",
"        </p>",
"        Non-dominant hemisphere: neglect, anosognosia, motor and sensory deficit (face, arm &gt; leg &gt; foot), homonymous hemianopia",
"       </td>",
"       <td>",
"        Embolic &gt; atherothrombotic",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Posterior cerebral artery",
"       </td>",
"       <td>",
"        Homonymous hemianopia; alexia without agraphia (dominant hemisphere); visual hallucinations, visual perseverations (calcarine cortex); sensory loss, choreoathetosis, spontaneous pain (thalamus); III nerve palsy, paresis of vertical eye movement, motor deficit (cerebral peduncle, midbrain)",
"       </td>",
"       <td>",
"        Embolic &gt; atherothrombotic",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Penetrating vessels",
"       </td>",
"       <td>",
"        <p>",
"         Pure motor hemiparesis (classic lacunar syndromes)",
"        </p>",
"        <p>",
"         Pure sensory deficit",
"        </p>",
"        <p>",
"         Pure sensory-motor deficit",
"        </p>",
"        <p>",
"         Hemiparesis, homolateral ataxia",
"        </p>",
"        Dysarthria/clumsy hand",
"       </td>",
"       <td>",
"        Small artery (lacunar) infarct",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Vertebrobasilar",
"       </td>",
"       <td>",
"        <p>",
"         Cranial nerve palsies",
"        </p>",
"        <p>",
"         Crossed sensory deficits",
"        </p>",
"        <p>",
"         Diplopia, dizziness, nausea, vomiting, dysarthria, dysphagia, hiccup",
"        </p>",
"        <p>",
"         Limb and gait ataxia",
"        </p>",
"        <p>",
"         Motory deficit",
"        </p>",
"        <p>",
"         Coma",
"        </p>",
"        Bilateral signs suggest basilar artery disease",
"       </td>",
"       <td>",
"        Embolic = atherothrombotic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Internal carotid artery",
"       </td>",
"       <td>",
"        Progressive or stuttering onset of MCA syndrome, occasionally ACA syndrome as well if insufficient collateral flow",
"       </td>",
"       <td>",
"        Atherothrombotic &gt; embolic",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_15_27900=[""].join("\n");
var outline_f27_15_27900=null;
var title_f27_15_27901="Brachytherapy esophagus CA selection criteria";
var content_f27_15_27901=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F73664%7EONC%2F80000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F73664%7EONC%2F80000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selection criteria for definitive and palliative brachytherapy for esophageal cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Definitive treatment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Good candidates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Unifocal thoracic esophageal cancer &le;10 cm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            No extraesophageal extension",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            No nodal disease or metastatic disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Poor candidates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tumor &gt;10 cm in length",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Extraesophageal extension",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Regional lymphadenopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tumor involving GE junction or cardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Contraindications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Esophageal fistula",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cervical esophageal location",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Stenosis that cannot be bypassed",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Palliative treatment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thoracic esophageal lesions with distant metastases",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Unresectable local disease progression",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Recurrence after definitive EBRT",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GE: gastroesophageal; EBRT: external beam radiation therapy.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Gaspar LE, Nag S, Herskovic A, et al. American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer. Int J Radiat Oncol Biol Phys 1997; 38:127.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Schema for definitive and palliative treatment for esophageal cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Suggested scheme for definitive treatment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            External beam radiotherapy (EBRT)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            45 to 50 Gy in 1.8 to 2.0 Gy fractions, five times aweek with concurrent chemotherapy followed by brachytherapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Brachytherapy after EBRT and not concurrent with chemotherapy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            HDR: total dose of 10 Gy, 5 Gy fractions,&nbsp;one fraction per week starting&nbsp;two to three&nbsp;weeks following completion of EBRT",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            LDR: total dose of 20 Gy single course, 0.4 to 1.0 Gy per hour starting&nbsp;two to three&nbsp;weeks after completion of EBRT",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Suggested scheme for palliative treatment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Recurrence after EBRT or short life expectancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Brachytherapy* (HDR: 10 to 14 Gy in one to two fractions or LDR: 20 to 40 Gy in one to two fractions at 0.4 to 1.0 Gy per hour)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            No previous EBRT",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            EBRT 30 to 40 Gy in two to three&nbsp;Gy fractions followed by brachytherapy* (HDR: 10 to 14 Gy in one to two fractions or LDR: 20 to 25 Gy in a single course at 0.4 to 1.0 Gy per hour)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            No previous EBRT and life expectancy &gt;6 months",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Guidelines similar to those for definitive therapy above",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Gy: gray; HDR: high-dose rate; LDR: low-dose rate.",
"     <br>",
"      * All brachytherapy doses specified 1 cm from midsource/mid-dwell position. Applicator diameter of 6&nbsp;to 10 mm is recommended.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Gaspar LE, Nag S, Herskovic,A, et al. American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer. Int J Radiat Oncol Biol Phys 1997; 38:127.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_15_27901=[""].join("\n");
var outline_f27_15_27901=null;
var title_f27_15_27902="Spreading melanoma PI";
var content_f27_15_27902=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F75736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F75736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial spreading melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 206px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Assymetry and color variability are characteristic of superficial spreading melanomas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James C Shaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_15_27902=[""].join("\n");
var outline_f27_15_27902=null;
var title_f27_15_27903="Posterior neck muscles";
var content_f27_15_27903=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior neck muscles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 156px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The posterior neck muscles include the trapezius, splenius, semispinalis, and levator scapulae. The trapezius is the flat, triangular muscle that covers the posterior portion of the neck, shoulders, and thorax. It originates from the occiput, nuchal ligament, spinous processes of C7-T12, and the supraspinal ligaments. It inserts into the lateral clavicle, acromion, and scapular spine. The splenius and semispinalis capitis arise from the lower cervical and upper thoracic vertebrae and insert on the skull. The levator scapulae originates from the upper four cervical vertebrae and inserts onto the superomedial corner of the scapula.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_15_27903=[""].join("\n");
var outline_f27_15_27903=null;
